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Summary 
 
 
 
High-grade serous ovarian cancer (HGSOC) is the most commonly diagnosed (70%) 
and aggressive epithelial ovarian cancer (OvCa) subtype; only 30% of the patients 
diagnosed with advanced stage disease live beyond 5 years after initial diagnosis, 
making it the most lethal gynecologic cancer. In contrast to many other cancers, the 
prognosis for HGSOC is unchanged in recent decades, despite extensive translational 
and clinical research. To a large degree, this is linked to the fact that HGSOC 
pathogenesis has remained an enigma such that there is currently no clear consensus 
even about the exact cell-of-origin. Nonetheless, recent ‘omics’ technologies have 
started to shed new light on the molecular landscape of HGSOC, which may not only 
help to better understand its biology, but also to uncover new therapeutic strategies 
and stratify patients for treatment. In particular, the field of quantitative proteomics has 
reached a state that now enables system-wide analysis of protein expression in any 
biological system. Complemented by the study of protein-protein interactions, post-
translational modifications or protein dynamics, modern proteomic technologies are 
extremely versatile for the study of proteins in various settings, such as in the context 
of HGSOC biology.  
 
All three projects described in this thesis were conducted in a very productive 
interdisciplinary collaboration with the Ernst Lengyel ovarian cancer laboratory at the 
University of Chicago. 
 
In the first project, I aimed to characterize 30 frequently used ovarian cancer cell lines 
for their suitability to represent HGSOC at the proteomic level. It was shown recently 
that the most often used HGSOC cell lines do not resemble human HGSOC tissue at 
the global genomic level (12). Conversely, some rarely used cell lines were found to 
be more suitable to model HGSOC, at least based on their genomic make-up. 
However, it was still unknown to what extent these reported genomic features were 
reflected at the protein level. We hypothesized that a streamlined and in-depth 
proteomic workflow may refine the previously suggested cell line classification and 
define the proteomic HGSOC cell line landscape. By quantitatively analyzing > 10,000 
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proteins, we found for the first time that the ‘good’ HGSOC cell lines grouped into two 
distinct proteome classes. Integration of primary cells and tumor tissues further 
revealed that the grouping of the proteomes likely reflects a cell-of-origin based 
classification, an interesting observation in light of the previously hypothesized dualistic 
precursor model for HGSOC (13). This large inventory of proteins across cell lines 
additionally provides a useful resource for the OvCa community and can be accessed 
via the MaxQB database at http://maxqb.biochem.mpg.de/mxdb/project/list. 
 
In the second and principal project, I conducted a discovery proteomics based study 
with the goal to improve understanding of chemotherapy sensitivity in advanced stage 
HGSOC, the largest histologic subgroup of epithelial ovarian cancers (70%). Up to 80-
90% of patients with metastatic HGSOC develop a chemoresistant state despite a 
favorable initial response to conventional carboplatin/taxol chemotherapy (14), leading 
to the above-mentioned low 5-year survival rate of only 30%. However, a small number 
of patients with metastatic disease (17%) respond remarkably well to chemotherapy 
and remain free of relapse for more than a decade after primary treatment (15). The 
molecular details for these exceptional responses are still unknown despite the 
extensive genomic characterization of HGSOC (16, 17). In a first of a kind clinical 
proteomics study, we analyzed 25 HGSOC patient biobank samples from responders 
and non-responders to a depth of in total a 9,000 proteins. Integrating the clinical 
survival data into the analysis revealed that chemotherapy outcome is generally not 
apparent from the global proteome pattern. Instead, I found the expression of a single 
protein, cancer-testis antigen 45 (CT45), to be an independent prognostic indicator for 
long-term survival. We validated this finding in a larger patient cohort and subsequently 
showed an active function of CT45 in mediating chemotherapy sensitivity based on in 
vitro and in vivo models. Extending these findings, my work revealed mechanistic 
insights of the biology of CT45 mediated chemotherapy sensitivity. It interferes with 
protein phosphatase 4 (PP4) dependent signaling on chromatin during the DNA 
damage response (DDR). Furthermore, we found evidence of an additional axis of anti-
cancer immune response directed against CT45, involving T-cell mediated cytotoxicity 
and likely potentiating the effect on long-term survival. 
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In the third project of this thesis, I established a highly sensitive ‘micro-proteomic’ 
workflow, which enabled the analysis of as few as 5,000 laser-microdissected tumor 
cells from FFPE biobank material to an unprecedented depth of up to 5,000 proteins 
from single-run (4h) analysis. This made it possible to address important clinical 
questions directly related to HGSOC biology: How does the proteome change during 
HGSOC progression from early pre-neoplastic lesion to late metastasis? What is the 
contribution of the tumor microenvironment (TME) to ovarian cancer progression? For 
the first time, we analyzed the proteomic progression of HGSOC in eleven patients 
diagnosed with advanced stage disease. Interestingly, whereas our results did not 
reveal commonly observed metastatic changes in the tumor proteome, we identified a 
conserved stromal protein signature in the tumor microenvironment, which was linked 
to metastasis to the omentum. Follow-up experiments by my collaboration partners at 
the University of Chicago (Lengyel group) highlighted the importance of the identified 
stromal proteins in mediating the aggressive nature of metastatic HGSOC. These 
observations may open up new avenues for HGSOC treatment in future. 
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1 Introduction 
 
1.1 Ovarian cancer 
 
Ovarian cancer (OvCa) is an aggressive disease and the most lethal gynecologic 
malignancy: Only 46 % of patients survive five or more years, which accounts for 
14,180 deaths in the US annually (18) and 29,770 deaths in the European Union (19-
21). The high mortality is in part due to presentation at late stage (only 15% are 
diagnosed with loco-regional stage I/II disease). Furthermore, the response to the 
standard platinum-based chemotherapy has a limited durability, with 20% of patients 
chemo refractory and 30% chemo resistant, meaning they have recurrence in less than 
six months. Despite extensive biomedical research efforts in the past decades, 
uncertainties about the exact origin and pathogenesis of this disease remain, making 
OvCa one of the least understood cancers.  
Major histological subtypes for epithelial OvCa, which are associated with different 
prognosis and pathogenesis, include serous, endometrioid, clear-cell and mucinous 
cancers. For this thesis, the term ‘ovarian cancer’ is used as a synonym for ovarian, 
fallopian tube, and peritoneal cancer. 
 
1.1.1 Pathogenesis of high-grade serous ovarian cancer  
 
High-grade serous ovarian cancer (HGSOC) represents the most commonly 
diagnosed (70%) and aggressive subtype of epithelial OvCa with a 5-year survival rate 
of only 30% for metastatic, advanced stage disease (22). According to the 
classification of the International Federation of Gynecology and Obstetrics (FIGO), 
75% of patients are initially diagnosed with stage III or IV disease, highlighting the 
importance of research dedicated to early ovarian cancer detection and prevention 
(18). 
Traditionally, HGSOC was believed to originate exclusively in the ovaries as the 
ovaries are almost invariably transformed. There is experimental and pathological 
evidence for the ovarian surface epithelium (OSE) as a possible site of origin as OSE-
derived inclusion cysts can undergo tubal metaplasia and full transformation (23-25). 
Moreover, OSE is a multipotent epithelium that may give rise to HGSOC (23). 
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However, the recent paradigm-shifting discovery of a potential precursor lesion, serous 
tubal intraepithelial carcinoma (STIC), in the tubal fimbria of BRCA mutation carriers 
and HGSOC patients has questioned the traditional view of HGSOC origin from the 
OSE (14, 26-33). These studies revealed that the pre-neoplastic STIC lesions were 
associated with secretory cells, TP53 mutations and up-regulation of DNA damage 
markers (e.g. JH2AX) (34-36). Interestingly, somatic TP53 mutations in STICs and 
corresponding HGSOCs were found to be identical in 27 of 29 patients with ovarian 
cancer suggesting a clonal relationship between STICs and HGSOCs (37). Today, 
HGSOC is thought to 1) originate primarily in the secretory cells of the distal fallopian 
tube, 2) evolve to STIC, 3) fully transform to invasive fallopian tube cancer, and 4) 
regularly metastasize to ovarian and/or extra-ovarian tissues such as the omentum 
(Fig. 1). Consequently, HGSOC of the ovary may represent a first metastatic spread 
from the fallopian tube to the ovary. However, some HGSOCs develop without any 
detectable fallopian tube involvement, suggesting a different site of origin for these 
cancers, such as the OSE or another cell type in the ovary. It is noteworthy that both 
hypotheses are supported by animal models (38-41). While neither hypothesis on the 
cell of origin of OvCa has unequivocally been proven correct, it is generally accepted 
that the high prevalence of STICs (27) (70% for ovarian or peritoneal HGSOC), 
indicates that the majority of HGSOC may indeed originate in the fallopian tube. 
 
 
 
 
 
 
 
 
 
Figure 1: Model of high-grade serous ovarian cancer progression in the fallopian 
tube. Left: High-grade serous ovarian cancer (HGSOC) is thought to originate in the 
secretory cells of the fallopian tube (FTEC) and often metastasizes to omental tissue. 
Right: Different stages of HGSOC progression in the fallopian tube. 
Immunohistochemical staining of p53 mutant signatures reveals HGSOC initiation in 
STIC lesions. Tumor cell expansion leads to the development of invasive carcinoma. 
Adapted and modified from (1). 
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Due to ineffective screening methods, the majority of HGSOC cases (75%) is 
diagnosed with advanced stage disease when the tumor has already spread and 
metastasized to the peritoneal cavity. Interestingly, HGSOC disseminates primarily to 
the adipocyte-rich omentum, which the tumor can utilize as energy source for rapid 
growth in the peritoneal cavity (42). Following detachment from the primary tumor site 
such as the fallopian tube or ovary, which usually involves an epithelial-to-
mesenchymal transition (43), E-cadherin loss (44) and a more invasive phenotype 
(45), the tumor cells are thought to reach the mesothelium-lined omentum and 
peritoneum via passive transport through the peritoneal fluid (46). Tumor cell binding 
to the mesothelium, a single cell layer of mesothelial cells attached to a basement 
membrane, is orchestrated through binding via β1-integrins (47) as well as CD44 (48). 
Once bound, ovarian carcinoma cells can induce a cascade of proteolytic (49, 50) and 
pro-apoptotic (51) activities to invade deeper into the sub-mesothelial layers. Only little 
is known about what happens after successful ovarian carcinoma implantation. 
However, it has been speculated that the tumor induces proangiogenic signaling to 
build de-novo vasculature surrounding the site of metastasis (46). 
The tumor microenvironment (TME) plays a key role during all phases of tumorigenesis 
(52), influences chemotherapy response (53) and patient outcome (54, 55). Several 
cell types of the microenvironment interact with tumor cells and modulate the 
aggressiveness of their behavior. For cancers such as HGSOC, the TME cell types 
include cancer-associated fibroblasts (CAFs), tumor-associated macrophages 
(TAMs), endothelial cells, adipocytes, mesothelial cells as well as various immune cell 
types. Of note, HGSOC was one of the first reported examples for a positive correlation 
between prolonged patient survival and the number of intraepithelial tumor-infiltrating 
lymphocytes (TILs) (56). 
In light of the recent success in applying immune checkpoint inhibition strategies for 
cancer immunotherapy treatment of melanoma or non-small cell lung cancer (57), it is 
tempting to speculate that HGSOC might also be vulnerable to these combination 
treatments. However, a recent clinical phase II study of an immune checkpoint inhibitor 
against PD-L1, although not associated with safety issues, had minimal overall 
efficiency (58). Future studies are needed to dissect why only a small subset of patients 
showed complete and durable responses. Interestingly, in another study, patients with 
good neoadjuvant chemotherapy response had a lower number of intratumoral 
FOXP3+ regulatory T-cells (Tregs) (59), suggesting a functional link between these 
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cells and chemotherapy. Moreover, neoadjuvant chemotherapy increased the T-cell 
specific expression of PD-L1 indicating that immune checkpoint inhibition in 
combination with chemotherapy may offer a promising new therapeutic approach for 
HGSOC treatment.  
Tumor antigens such as ERBB2, TP53, CTAG1B, MSLN, NY-ESO-1, MAGE 
melanoma antigen family members or TERT (60) have already shown promise to elicit 
an immune response against HGSOC. Clearly, treating HGSOC with immunotherapy 
approaches is very promising and this thesis directly contributes to this concept 
(Results section 2.2).  
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1.1.2 The proteogenomic landscape of HGSOC 
 
Genetically, HGSOC is characterized by ubiquitous somatic TP53 mutations and 
genetic instability (16). In addition to TP53 mutational inactivation, there are only very 
few known additional recurrent mutations, including BRCA1, BRCA2, RB1, NF1, FAT3, 
CSMD3, GABRA6 and CDK12, as well as BRIP1 and PALB2 (61). Instead, there are 
widespread DNA copy number alterations (CNA), which together with the low number 
of recurrent mutations make HGSOC a ‘C class’ tumor (62) (Fig. 2).  This suggests an 
early breakdown of DNA repair pathways, ultimately leading to pronounced 
chromosomal instability. Interestingly, functional loss of TP53 is not sufficient to drive 
the full transformation from STIC to invasive fallopian tube cancer in animal models 
(63) indicating that additional, yet unidentified molecular events are crucial for this step 
in progression. (61). The most commonly observed chromosomal alterations lead to 
CCNE1 amplification (20%), NF1 loss (17%) and RB1 loss (15%). Based on genomic 
pathway analyses, it was suggested that roughly half of all HGSOC tumors are 
defective in homologous recombination (64).  
Owing to its high degree of structural chromosomal alterations and low mutational 
profile, HGSOC should represent an ideal cancer type for proteomic or proteogenomic 
approaches, since all proteins in the amplicons are investigated together (65). A very 
recent report from the CPTAC consortium investigated 169 HGSOC tissue samples at 
the proteomic level and related it to genomic information such as copy number 
alterations (5). A low overall correlation between mRNA and protein levels (Spearman 
r = 0.45) was reported and several copy number alterations with in trans effects on 
protein abundance (independent of the genomic locus) showed no changes of mRNA 
levels. This contradicts reports in other cancers such as colorectal (66) or breast 
cancer (67) and, assuming correct proteomic quantification, highlights the unique 
molecular landscape of HGSOC. The authors identified several genomic copy number 
alterations that directly translated to changes in protein abundance and used these 
findings to stratify patients into different survival groups. These proteogenomic 
alterations included fractions of chromosomes 2, 7, 20 and 22, which caused changes 
in abundance of more than 200 proteins (Fig. 2c).  Further analysis revealed that many 
of these proteins were involved in cell movement/adhesion and immune system related 
functions, indicating important biological roles of these processes during HGSOC 
progression.  
6 
 
 
 
 
 
 
 
 
 
  
a 
 
b 
 
c 
 
Figure 2: HGSOC is characterized by genomic copy number alterations rather 
than mutations. a. HGSOC is classified as a ‘C class’ tumor and features the 
highest number of recurrent copy number alterations across human cancers. ‘M 
class’ tumors (left) are dominated by mutations. For HGSOC, only few recurrent 
mutations have been identified (1). b. Overview of recurrent mutations and genomic 
alterations in HGSOC (1). c. Copy number alterations (CNA) associated with RNA 
abundance and protein abundance along the genome. Adapted from (5). 
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1.1.3 Prioritized HGSOC research goals 
 
1.1.3.1 The need for accurate cellular models 
 
The identification of accurate HGSOC models for preclinical investigations was 
declared as one of the key missions at the Ovarian Cancer Action’s international 
research meeting (Helene Harris Memorial Trust (HHMT)) in January 2015 (14). Since 
most pre-clinical research relies on cellular models for in vitro and in vivo studies, this 
raises the important question of how closely they resemble the tissue being studied. 
It has recently become apparent that a considerable amount of research in the past 
was based on cellular models that do not resemble HGSOC at the global genomic level 
(12). This was caused in part because no reliable genomic tools were available to 
distinguish between representative and poor cellular models, as well as to identify 
cross-contamination or an incorrect assignment of the underlying tissue of origin. With 
the development of “omics” tools that identify models which represent human disease, 
a variety of urgent, HGSOC related, questions, such as characterizing distinct HGSOC 
subtypes reflective of their cell-of-origins or understanding mechanisms of drug 
resistance and/or sensitivity at the molecular level, as well as tumor biology can be 
tackled. 
 
The concept of characterizing cell lines for pre-clinical research is not novel. 
Historically, first reports in the ovarian cancer field date back to the late 70s and 80s 
when individual, newly established OvCa cell lines were described according to 
morphology, histology, karyotype, and growth characteristics (68-74). This led to the 
assignments of the tissue of origin for many of the OvCa cell lines used today. 
However, due to a lack of standardized and validated methods for the systematic 
comparison of cell lines, the results of these investigations were often questionable. 
More advanced and large-scale analyses had to wait until the 21st century when major 
breakthroughs in ‘omics’ technologies had occurred. Since then, multiple studies have 
been published almost all focusing on genomic or transcriptomic-based methods (12, 
75-77). Most importantly, in conjunction with cell line data obtained from the Cancer 
Cell Line Encyclopedia (CCLE) consortium (78), a recent study evaluated a panel of 
47 ovarian cancer cell lines by means of copy number alterations, mutation frequency, 
and gene expression data (12). Surprisingly, the authors found that the most commonly 
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used cell lines did not resemble HGSOC at the genomic level. This study has also 
provided a rational for the use of a set of newly identified HGSOC cell lines. Based on 
these findings, three recent reports addressed functional properties of the ‘good’ 
HGSOC cell lines (79-81). Unexpectedly, these were less capable to form in vivo 
tumors than the previously used ones and displayed a larger functional heterogeneity 
in e.g. proliferation, migration, invasion and the expression of EMT markers.  
 
Before the subsequently described studies, it remained elusive to what extent the 
previously reported cell line features are represented at the protein level. The 
proteomic profiling of OvCa cell lines conducted in this thesis (Results section 2.1) 
complements and significantly expands the above-mentioned recent studies and 
findings. 
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1.1.3.2 Understanding chemotherapy efficacy 
 
 
HGSOC treatment involves first surgery, which often requires surgical debulking, 
followed by adjuvant chemotherapy with a combination of carboplatin and paclitaxel. 
Although most HGSOC patients initially respond well to first-line chemotherapy, 80-
90% of those diagnosed with advanced stage disease develop chemoresistant 
disease. This usually happens through several cycles of relapse which can be 
monitored by serum CA-125 levels (Fig. 3).  Much research has concentrated on 
understanding the multifaceted nature of chemoresistant HGSOC by using a variety of 
genomic and bioinformatic tools, however, so far only little has really translated into 
the clinic. Therefore, despite the tremendous amount of work by oncologists, clinicians 
and life-scientists all around the world, HGSOC mortality has only changed minimally 
in the last decades. Conversely, the molecular landscape of chemotherapy sensitive 
HGSOC has not yet been studied in great detail. A recent large-scale ovarian cancer 
study found that 17% of patients with advanced stage disease survived beyond 10 
years after initial diagnosis (15). This suggests the presence of yet unidentified, 
predisposing molecular features promoting chemotherapy sensitivity and long-term 
survival. It is of great clinical importance to understand these ‘exceptional responders’, 
as they may shed light on the problem of very widespread chemotherapy resistance. 
 
  
Figure 3: Treatment and disease course of HGSOC. 
Following initial response to carboplatin based chemotherapy, 
the majority of HGSOC patients develops a chemoresistant 
state over multiple treatment/relapse cycles as indicated by 
CA125 levels (in units per millilitre) over time (1). 
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1.1.3.3 Understanding disease progression   
 
To date, only little is known about the proteomic progression of HGSOC and the 
development of its complex microenvironment from early serous tubal intra-epithelial 
carcinoma (STIC) lesions in the fallopian tube to omental metastases. As outlined in 
the HHMT 2015 meeting (14), more sophisticated and integrated ‘omics’ approaches 
are urgently needed to dissect the multitude of molecular changes taking place in the 
tumor.  
 
There is a current lack of streamlined and robust proteomics methods to analyze ‘low-
input’ samples, such as those obtained from laser-capture microdissection (LCM), 
coupled to the unavailability of tumor tissue from multiple tumor sites. Therefore, the 
previous large-scale proteomic analysis of HGSOC was based on whole-tissue 
specimens predominantly obtained from invasive ovarian tumors (5). LCM approaches 
are superior to whole-tissue analysis in regard of the finely-resolved quantitative read-
out in the presence of cell type heterogeneity in the HGSOC environment. This 
scientific challenge could be addressed using improved sample processing workflows 
with the goal to analyze minute amounts of tissue. Together with well annotated 
biobanks this will allow further mechanistic studies at the proteomic level. These will 
not only address the degree and nature of proteomic alterations linked to disease 
progression, but might also reveal novel disease-relevant driver proteins. 
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1.2 The Proteome 
 
The central dogma of molecular biology states that genetic information is encoded in 
the form of DNA in the nucleus, which can be read and transcribed into transportable 
messenger RNA (mRNA) molecules and ultimately translated into functional proteins 
(82). Today this sequential flow of information can be analyzed in a very 
comprehensive and system-wide manner for genome and transcriptome analyses 
using next-generation sequencing approaches. Mass spectrometry (MS) based 
proteomics is the technology of choice to study the entirety and nature of all expressed 
proteins in the cell, the so called proteome (83). Whereas the genome encodes a 
defined number of genes (a20.000) (84, 85), the level of complexity increases 
substantially for the number of transcripts, which are dynamically expressed in different 
cell types and time points and which can be differentially spliced. The proteome is 
much more complex still, due to the existence of diverse protein modifications or 
protein processing (86). Furthermore, protein-protein interactions as well as spatio-
temporal protein dynamics add yet another level of protein complexity. Consequently, 
proteomics is a multidisciplinary research field comprised of a plethora of approaches 
and methodologies to analyze and characterize proteins under various biological or 
biomedical conditions. 
 
 
1.3 Mass spectrometry-based quantitative proteomics 
 
Over the last decades, mass spectrometry (MS) has evolved into the key technology 
for the study of proteins, the functional entities of most biological processes taking 
place inside and outside of the cell. Mostly due to very significant technological 
advances in MS itself, availability of powerful solutions for sample preparation, as well 
as sophisticated computational workflows to analyze gigabytes of raw data files, MS-
based proteomics in principle allows converting every protein-centric biological 
experiment into a systems biology approach. Historic milestones for the field of MS-
based proteomics include the development of the soft ionization techniques matrix-
assisted laser desorption / ionization (MALDI) (87, 88) and electrospray ionization 
(ESI) (89). In the latter technique, which shared the Chemistry Nobel Prize in 2002, 
kilovolt potentials between the end of the capillary column and the entrance of the 
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mass spectrometer generate a spray of charged droplets. Intact proteins or peptides 
are then directly ionized out of the liquid phase into the gas phase.  
Conceptually, there are two strategies for MS-based proteomics: In top-down 
proteomics, intact proteins are analyzed by the MS, which, due to the complexity of the 
mass spectra generated from individual intact proteins, involves extensive up-front 
protein purification. Top-down proteomics is therefore mainly used for recombinant 
protein characterization such as therapeutic antibodies, protein degradation products, 
and proteoforms, including the exact combination of post-translational modifications 
(PTMs) on them (90). Small proteins are more amenable to MS-analysis than large 
ones, due to better protein purification and fewer charge states, and top down may 
have advantages in this case. 
In bottom-up or ‘shotgun’ proteomics (Fig. 5), proteins are first digested to peptides by 
using sequence specific proteases such as trypsin and are then analyzed individually 
by the mass spectrometer. This is the method of choice for the study of proteins, 
protein complexes and entire cellular proteomes. An underlying reason for this is that 
MS of peptides is much more sensitive and easy than MS of intact proteins and lends 
itself to straightforward protein identification. Furthermore, many proteins such as 
insoluble or ‘sticky’ proteins are not be amenable to purification and analysis but can 
readily be analyzed at the peptide level by shotgun proteomics (91).  
Complex peptide mixtures require sufficient upfront chromatographic separation to 
ensure that as many peptide species as possible can be subjected to mass 
spectrometric analysis. The combination of liquid chromatography (LC) coupled ‘on-
line’ to ESI mass spectrometry has emerged as a very powerful platform to analyze 
complex samples (92). In LC-MS, chromatographic separation of peptides is based on 
their different strengths of hydrophobic interaction with a stationary phase, typically 
C18-silica phase. Peptide elution then occurs in a time dependent manner by an 
increasing concentration of an organic solvent such as acetonitrile. Eluting peptide 
species are then ionized via ESI and directly transferred to the vacuum of the mass 
spectrometer. The mass spectrometer continuously scans the peptide mass range, 
recording the masses and intensities of the eluting peptides. For peptide identification, 
tandem MS (or MS/MS) is employed, in which specific peptides are selected, isolated 
and fragmented by collision with neutral gas molecules such as nitrogen, argon or 
helium. A pre-defined number of the most intense peptides per MS1 scan (also termed 
survey or full scan) is selected and subsequently fragmented by collision-induced 
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dissociation (CID) or higher-energy collisional-dissociation (HCD). This strategy is 
called data-dependent acquisition and produces alternating cycles of full scans and 
fragmentation scans throughout the entire chromatographic retention time. CID or HCD 
fragmentation primarily break peptide bonds, resulting in b-ion (N-terminal part) or y-
ions (C-terminal part). In current bottom up proteomics, hybrid Orbitrap systems have 
become very popular and are used exclusively in this thesis. They typically include a 
selection quadrupole, which is coupled to a collision cell and a ‘C-trap’ for injection of 
the ions into the Orbitrap analyzer itself (93). In a typical shotgun proteomics 
experiment, hundreds of thousands of tandem mass spectra are recorded in this way. 
Correctly assigning them to their calculated spectra obtained from in silico digestion of 
the corresponding peptide sequence is a challenging task in the computational 
downstream analysis. MaxQuant is a widely used software package for the analysis of 
shotgun proteomics data developed by our group  (94). Peptides (MS1 features) are 
identified by first assigning them at parts-per-billion (ppb) mass accuracy to compatible 
peptides retrieved from a proteome reference file, and secondly by using the 
probability-based Andromeda search engine (95) to stringently match the observed 
fragment ions (MS/MS information) of each peptide to the theoretical fragment ions. A 
scoring function then identifies the best database hit among all submitted comparisons 
(Fig. 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Peptide identification in tandem mass spectrometry. Measured tandem 
mass spectra (left) and theoretical mass spectra retrieved from the in silico digestion 
of a reference proteome (right) are matched to each other for the probability score 
based peptide identification process. Adapted and modified (91). 
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The resulting peptide spectral matches (PSM) are finally assembled back into proteins. 
Due to the inherent fact that not all identified tryptic peptides are unique to one protein, 
the concept of protein groups is widely used in the field of shotgun proteomics. In order 
to deal with this ‘protein inference’ problem, proteins are assigned to the same protein 
group if there are only shared peptides among the proteins within one group. This 
usually involves splice variants from the same genomic locus or proteins sharing 
similar domains. 
 
 
 
 
 
 
Figure 5: A representative shotgun proteomics workflow. 
Following homogenization and lysis of cells or tissues, extracted proteins are digested 
with sequence specific enzymes such as trypsin and separated via high performance 
liquid chromatography (HPLC). Electrospray-ionized peptides are then analyzed by the 
mass spectrometer in data-dependent mode. A pre-defined number of the most intense 
peptides per full-scan are then subjected to fragmentation via higher-energy collisional 
dissociation (HCD). The resulting fragment ions contain peptide sequence information 
and are then used to search a reference database to identify the measured peptides. 
Peptides are then assembled into proteins using bioinformatic tools (Maxquant), based 
on their published sequences. Finally, downstream bioinformatic analyses include 
descriptive and inferential statistics for data interpretation. Adapted (8).  
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Mass spectrometry itself is not inherently a quantitative methodology. This is due to 
the fact that different analytes can strongly vary in their physico-chemical properties 
such as size, charge or hydrophobicity, which can ultimately lead to different mass 
spectrometric signals (4). Consequently, relative quantitative information can only be 
retrieved by comparing identical peptide species across samples. Peptide signals from 
different experimental conditions are compared to each other without any a priori 
information about the absolute protein concentration in the sample. To this end, various 
strategies have been developed over the years, each of them having unique strengths 
and weaknesses. They can conceptually be divided into label-free or stable isotope 
labeling approaches and the most commonly used approaches summarized in Figure 
6.  
For stable isotope labeling, specific mass shifts are introduced according to the heavy 
and light stable isotope labels employed. This can be achieved either metabolically, 
chemically or enzymatically during protein digestion. Quantitative information is 
extracted by comparing the intensities of the light to the corresponding heavy peptides. 
In metabolic labeling such as stable isotope labeling with amino acids in cell culture 
(SILAC) (96), heavy isotopes are introduced at the earliest possible experimental time 
point through growth media or food containing the heavy isotopes.   
Figure 6: Labeling strategies for quantitative proteomics and their accuracy. 
Different colors (blue and yellow) represent different experimental conditions. 
Horizontal lines show when the samples are combined. Dashed lines indicate stages 
of potential experimental variation. Adapted from (2-4). 
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Consequently, metabolic labeling is by far the most accurate method as variation 
caused by different sample handling can be neglected. In SILAC, a combination of 
heavy arginines and lysines with tryptic digestion is usually used in order to generate 
peptide species that contain at minimum one heavy amino acid (except for the last, C-
terminal peptide). This is crucial as non-labeled peptides are not distinguishable from 
the light sample. Therefore, SILAC strictly depends on successful label incorporation, 
which can substantially vary between different cell lines and might require several 
rounds of cell divisions. Primary cells or clinical samples such as tumor tissues can 
generally not be labeled with SILAC amino acids. To address this limitation, multiple 
labeled cell lines can be combined and used as a surrogate reference termed super-
SILAC mix (97). These cell lines should ideally closely resemble the tissue being 
studied in order to provide a reference to as many endogenous proteins as possible. 
However, as cell lines may not fully reflect the entire proteomic composition of tissues, 
e.g. due to the presence of multiple cell types in the tissue microenvironment, or tissue-
specific extracellular matrix proteins, super-SILAC quantification – despite it accurate 
and robust quantification - inevitably suffers from less quantitative depth compared to 
label-free approaches. Furthermore, the presence of different label states increases 
the MS1 level complexity. 
 
In chemical labeling approaches such as for example isobaric Tag for Relative and 
Absolute Quantitation (ITRAQ) (98) or tandem mass tags (TMT) (99), isobaric tags are 
introduced chemically by the covalent binding to primary amines on the peptides. Due 
to the identical masses of the used isobaric tags, which is achieved by balancing 
groups, peptides derived from samples labeled with different isobaric reagents are 
indistinguishable at the MS1 level. This is advantageous because, in contrast to 
metabolic labeling, the MS1 level complexity does not increase. Upon fragmentation, 
distinct reporter ion species are then generated, which provide relative peptide 
quantification. Current versions of TMT allow analyzing up to ten samples at once in 
the same mass spectrometric run (TMT 10-plex) (100). This is a very versatile 
approach for the comparison of a large number of samples, for example in discovery 
based clinical proteomics projects that aim at screening large patient cohorts over a 
short time period. Disadvantages include more complex fragmentation spectra, 
chemical side reactions and mainly the co-fragmentation of peptides with similar 
elution profiles, which inherently result in an underestimation of the actual 
 
17 
 
protein/peptide abundance ratios (‘ratio compression’ (101)), unless specialized 
methods are used (85). 
 
The method used exclusively in this thesis is label-free quantification (LFQ). Here, the 
intensities of identical peptide species from multiple mass spectrometric runs are 
directly compared to each other without any isotope labeling. Consequently, LFQ can 
principally be applied to any type and number of biological samples of interest. As 
illustrated in Fig. 7a, LFQ can be further subdivided into spectral counting or intensity 
based approaches (102). Due to higher quantitative accuracy, intensity-based 
approaches such as the MaxLFQ algorithm (103) of the MaxQuant software (94), are 
superior to spectral counting approaches as these simply correlate the number of 
peptide spectral matches for a given protein to its abundance (102). Spectral counting 
can be especially problematic for the quantification of small or low abundance proteins 
that may not provide enough data points (spectral counts) for precise quantification 
(Fig. 7b). 
Due to the completely separate sample handling in label-free quantification, 
experimental variability can theoretically be introduced at all stages in the proteomic 
workflow, potentially reducing the quantitative accuracy of LFQ workflows. However, 
advanced software has now been developed, which is capable of dealing with technical 
variations introduced during sample processing or MS measurement (103). This 
makes label-free quantification a very attractive and cost-effective alternative to label-
based approaches (although at the cost of increased replicates). Post-processing of 
proteomic raw files - apart from peak picking or noise reduction - generally includes 
normalization algorithms to adapt retention times and MS intensities (10, 103). In the 
context of studies that aim at comparing a large number of samples at great proteomic 
depth, large dynamic range and reasonably high quantification accuracy, intensity-
based LFQ has gained strong momentum in recent years. In particular, MaxLFQ, which 
is a part of the MaxQuant bioinformatic suite, incorporates very sophisticated re-
normalization algorithms and the maximum number of pairwise comparisons (103) and 
has been used throughout this study. Remarkably, MaxLFQ enabled the time-resolved 
quantification of the in vivo insulin signaling pathway covering >10,000 phosphorylation 
sites without any sample pre-fractionation (104). The LFQ workflow was highly 
reproducible and, as experimentally assessed, only marginally contributed to the total 
sample variability. In fact, biological differences between tissues or variations in LC-
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MS measurements caused higher variability. In this way, the study accurately 
quantified phosphorylation changes on timescales of less than 1 min and from fold 
changes as small as 2-fold.  
In summary, intensity-based LFQ workflows are now cost-effective, reproducible, 
streamlined, and universally applicable. The high level of quantitative accuracy and 
precision, which can be achieved today, has made LFQ a true and valid alternative to 
label-based approaches. Apart from relative quantification, the summed LFQ values of 
the peptides identifying each protein can also be used as a rough proxy for the absolute 
amount of protein.   
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Figure 7: Label-free quantification strategies and their accuracies.  
a. The two types of label-free quantification strategies are spectral counting 
and peptide intensity-based quantification. Quantification based on spectral 
counting (middle panel) compares the number of MS2 scans recorded for 
each sample in order to estimate relative peptide/protein abundances. Right 
panel: peptide intensity-based quantification relies on the comparison of 
peak intensities along the peak retention time. b. Intensity-based 
quantification approaches (e.g. the MaxLFQ algorithm) are more accurate 
than spectral counting approaches. Log ratios of E.coli (orange)/human 
(blue) 3:1 vs 1:1 samples are plotted against the estimated absolute protein 
abundance (summed peptide intensities (log10) of the 1:1 sample). Note 
that quantification ratios are less accurate for spectral counting compared 
to MaxLFQ as determined by the larger ratio scattering in the lower intensity 
(y-axis) region. Adapted and modified from (10). 
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1.4 Clinical cancer proteomics 
 
The first mass spectrometric clinical test was recently approved by the federal drug 
administration (FDA) in the United States, detecting a large number of pathogenic 
yeast and bacteria strains (105, 106). The simultaneous and timely identification of 
almost 200 different strains with a single device provides a significant advance in the 
field as conventional methods require culturing of microorganisms, which can take 
several days and may be problematic for severe infections where the correct clinical 
treatment is time-sensitive. This example clearly shows that current proteomic 
technology has the capacity to improve or even replace current clinical standard tests. 
For diseases such as cancer, this may open the door for proteomics-based 
personalized healthcare to guide patient diagnosis, treatment and clinical care.  
 
 
1.4.1 Cancer proteomics: A brief history 
 
 
First attempts to profile protein expression in a disease context such as cancer already 
date back to more than half a century ago when Fine and Creyssel reported in 1959 
abnormal serum levels of globulin among patients with myeloma and 
macroglobulinemia (107). This observation was based on starch gel electrophoresis 
(108), a technique that – although revolutionary at the time - allowed the detection of 
only a few protein bands. More complex proteome analyses became feasible with the 
development of isoelectric focusing and polyacrylamide gels in the 1960s, which 
subsequently led to the development of two-dimensional polyacrylamide gel 
electrophoresis (2D PAGE). Because hundreds of protein spots could be visualized 
simultaneously, the era of 2D PAGE can be seen as the beginning of protein-centric 
systems biology. 2D PAGE was then extensively applied to a variety of cancer 
diseases. For example, one study reported the identification of acute lymphoblastic 
leukemia cell subgroups based on the analysis of 413 protein spots, which also led to 
the discovery of putative markers for specific B or T cell lineages (109). However, 
despite its wide application, 2D PAGE has remained a cumbersome methodology for 
the detection and identification of low abundant proteins due to the limited dynamic 
range of detection and unreliable reproducibility. In addition, protein identification via 
‘Edman degradation’ was laborious and no longer adequate for the ever increasing 
number of detectable protein bands or spots. These unsurmountable hurdles strongly 
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increased the interest for alternative analytical methods such as mass spectrometry; 
however, its application had to wait for major technological breakthroughs in the field, 
namely the development of the soft ionization techniques MALDI and ESI techniques 
for peptide or protein ionization. Early applications of MS for protein combined 2D 
PAGE to first separate proteins by their molecular mass and isoelectric point and 
secondly to identify them via specific peptide mass maps obtained by the mass 
spectrometer (110). This was a paradigm-shifting development due to the rapid, 
sensitive and systematic nature of protein identification. That said, gel-based protein 
separation eventually was superseded by more direct approaches. In particular, ESI 
MS in combination with sample pre-fractionation and isotopic labeling has replaced 
that technology and has been used extensively for the large-scale analysis of proteins 
derived from biological samples such as cell lines, tissues or body fluids for many years 
(111).  
Today, MS-based proteomics is coming ever closer to its goal of detecting all 
expressed proteins of complex samples such as cancer cell lines. This is due to great 
technological improvements of the current generation of mass spectrometers, as well 
as refined sample preparation and computational workflows (112). For the field of 
cancer proteomics, this has opened up a new era of systems biology to decipher 
signaling pathways, identify novel protein signatures related to tumor initiation and 
progression, or to discover new biomarker candidates. However, despite the great 
level of excitement and enthusiasm that current technologies provide, pre-mature 
claims from the early 2000s have affected the reputation of the cancer proteomics field. 
In 2002, a study was published that reported the unambiguous detection of early 
ovarian cancer based on unidentified proteomic patterns obtained by surface-
enhanced laser desorption and ionization (SELDI) (113). This diagnostic test was 
reported to have an unprecedented diagnostic sensitivity (100%) and specificity (95%), 
which consequently gained great attention in the scientific and non-scientific media. 
Shortly after publication, doubts about effectiveness of the test accumulated (114) and 
it turned out that the obtained results were not reproducible due to artifacts from 
different sample processing (115, 116). Notably, even noise regions were sufficient to 
distinguish OvCa patients from normal individuals in the test samples, suggesting that 
systematic differences in sample handling strongly contributed to these results. The 
lessons from this study should guide the current development of cancer proteomic 
approaches, caution researchers with respect to biomarker claims and motivate them 
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to rigorously avoid previous pitfalls. For example, the use of biologically meaningful 
data such as protein expression levels provides stronger scientific rationale for the 
stratification of patients than the mere presence or absence of dubious unassigned 
mass spectrometric peaks. Furthermore, to put the potential biomarkers into a 
biological perspective, modern proteomic technologies allow the unambiguous and 
system-wide analysis of protein-protein interactions (117) or signaling networks (118), 
aiding the study of protein function on the molecular level. Integrating these additional 
approaches may lead to more promising new cancer discoveries in the future.  
 
In light of the improved proteome coverage, reduced biases and increased quantitative 
precision of modern MS-based proteomics technologies (92), the integration of whole-
genome or transcriptome sequencing data is currently one of the most important goals 
for the field of cancer proteomics. This could allow to address alterations in the flow of 
genetic information from the genome to the proteome (119). Based on the efforts of 
‘The Cancer Genome Atlas’ (TCGA) project, which sequenced, characterized and 
catalogued cancer-specific alterations for several human cancer types (120), the 
National Cancer Institute launched the ‘Clinical Proteomic Tumor Analysis Consortium’ 
(CPTAC) to systematically identify disease-relevant proteins and their underlying 
biological pathways. For example, CPTAC’s proteogenomic analyses of colorectal 
cancer revealed novel proteomic tumor subtypes associated with clinical outcome, 
similar to their studies in breast (67) and ovarian cancer (5). Interestingly, protein levels 
in tumor tissues could not be reliably predicted based on DNA or RNA-bases methods 
alone, emphasizing the urgent need to expand proteogenomic efforts.  
 
1.4.2 Cancer tissue proteomics  
 
Clinical cancer proteomics can be subdivided by the sample of interest - generally into 
tissue or body fluid analysis. Cancer tissue proteomics, as also conducted in this 
thesis, usually aims at the global, ideally proteome-wide, quantification of proteins 
expressed in the sample of interest to systematically address proteomic changes 
between e.g. healthy and diseased states. In particular, studies tailored to 
retrospectively analyze the proteome under certain clinical conditions, such as in the 
context of a drug response, are among the most prominent applications of cancer 
tissue proteomics. These approaches provide a historical snapshot of the protein 
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repertoire in the diseased tissue, which can be combined with knowledge about 
subsequent patient outcome events. This combination of reliable clinical data with 
proteomics information, could be a powerful tool to uncover new drug targets or 
disease-specific biomarkers. For example, in a recent lymphoma study conducted by 
our laboratory, a combination of tissue proteomics and machine-learning based 
classification reliably segregated patients with diffuse large B-cell lymphoma according 
to the cell-of-origin (121). Interestingly, this also revealed that a cell line derived 
signature can be used to stratify patients. 
 
As most cancer tissue specimens are archived in the form of formalin-fixed and 
paraffin-embedded (FFPE) material, we have developed techniques to reverse 
formalin crosslinking of proteins to ensure deep and quantitative proteomic profiling to 
a depth of up to 10,000 proteins (122, 123). This allowed the systematic dissection of 
the proteomic composition of biobank-derived tumor cells in comparison to matched 
normal tissues. We found that cell-surface and nuclear proteins showed the strongest 
expression differences, suggesting de-regulated signaling pathways in the cancer 
cells. Furthermore, proteomic differences between primary and metastatic colorectal 
cancer were of minor nature indicating that no extensive proteome remodeling is 
required for the metastatic spread to distant organs (124). Interestingly, this 
observation was also made in breast cancer recently (125).  
The utility of FFPE material for proteomic analyses may not drastically depend on 
storage time as even 28 years old samples have already been used successfully (126). 
Moreover, post-translational modifications such as phosphorylation and N-
glycosylation can also be analyzed in FFPE material (127). 
 
With respect to sample collection and processing, cancer tissue proteomics can be 
performed based on whole-tissue samples or homogeneous cell populations isolated 
after careful microscopic inspection of the area of interest via laser-capture 
microdissection (LCM) (128). This is especially advantageous for the analysis of 
distinct cell types present in the heterogeneous tumor tissue environment such as 
cancer cells, fibroblasts, immune cells or endothelial cells. Indeed, LCM has been 
widely applied to identify new biomarker candidates in a variety of diseases such as 
prostate (129), breast (130) and ovarian cancer (131).   
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Due to low sample quantities, LCM workflows are inherently more challenging and 
require optimized sample processing to minimize any potential sample loss. This can 
be aided either by using filter devices (123) or MS compatible compounds for tissue 
lysis and protease digestion such as trifluoroethanol (132), which is fully volatile and 
thus enables simple buffer exchange via vacuum centrifugation without any additional 
sample loss. In this way, as few as 1.000 microdissected cells have been analyzed 
already in 2011, although only to a depth of a few hundred proteins (132). Clearly 
further technological improvements in mass resolution, accuracy and sensitivity are 
needed to substantially increase the proteome coverage of these ‘micro-proteomic’ 
approaches.  
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1.4.3 Biomarker discovery 
 
1.4.3.1 Types and technology 
 
 
 
According to the National Cancer Institute, a biomarker is defined as:  
 
“A biological molecule found in blood, other body fluids, or tissues that is a sign of a 
normal or abnormal process, or of a condition or disease. It may be used to see how 
well the body responds to a treatment for a disease or condition “.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 8: Common strategies for biomarker discovery.  
Green boxes indicate the involvement of mass spectrometry. The 
two marked green boxes indicate methodologies that were used in 
this thesis (Results sections 2.2 and 2.3). 
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In respect to personalized medicine and the 
development of highly effective anticancer 
drugs, biomarkers can be grouped into 
prognostic, predictive or pharmacodynamic 
types (Fig. 9) (7). 
Prognostic biomarkers such as the gene 
expression based Mamma Print (Agendia), 
Oncotype DX (Genomic Health) or the H/I 
test (AviaraDx), are used to predict the 
clinical outcomes of breast cancer patients 
and to stratify these patients according to 
their likelihood of benefiting from a particular therapeutic intervention. Prognostic 
biomarker studies therefore usually aim at analyzing treatment naive tissue or body 
fluid specimens collected during the initial surgical procedure, usually shortly after 
diagnosis. In contrast, a predictive biomarker may indicate the probability of success 
for a specific treatment. A classic example of a predictive biomarker is the genomic 
amplification of the ERBB2 gene in breast cancer which indicates the clinical efficacy 
of the ERBB2 blocking antibody trastuzumab (Herceptin). Furthermore, leukemia 
patients carrying the PML–RARA translocation respond remarkably well to all-trans 
retinoic acid (ATRA) therapy. The third group of ‘pharmacodynamic biomarkers’ is 
used to monitor treatment outcome. They are important to assess the optimal drug 
dose or to define the best route of administration. The identification of 
pharmacodynamic biomarkers is challenging for solid tumors due to the limited 
availability of tissues from multiple time points during the treatment course.  
 
Molecular biomarkers include DNA or RNA molecules, as well as proteins and 
metabolites. Consequently, various analytical platforms and strategies have been 
developed over the years for biomarker discovery (see Fig. 8).  As proteins represent 
the functional molecular machineries of the human body and are actively involved in 
disease onset, progression and/or resolution, they are principally well suited as 
molecular biomarkers to diagnose and monitor patients or to guide treatment and 
assess therapeutic outcomes (133). However, the discovery of new protein biomarkers 
is much more challenging than that of DNA or RNA-based ones. This is due to the 
comparative immaturity of MS-based proteomics and to the large dynamic range of 
Figure 9: Biomarker types. Adapted 
and modified from (7). 
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protein concentrations found in tissues and body fluids. In human plasma for example, 
protein concentrations are distributed over more than 10 orders of magnitude (134), 
an overwhelmingly large span compared to the dynamic range of detection of roughly 
6 orders of magnitude for a typical state-of-the-art shotgun proteomics measurement 
(92). Multiple strategies have attempted to overcome the dynamic range problem such 
as antibody-based depletion of the most abundant plasma proteins or extensive 
sample pre-fractionation. However, these methods usually come at the cost of 
reproducibility and throughput, two very important aspects in the design of a clinical 
proteomics study. This has prompted our group to develop a highly reproducible single-
run plasma proteomics workflow, employing  short 20 min gradients, which is capable 
of robustly quantifying hundreds of proteins, among them more than 40 FDA-approved 
biomarkers (135). Once MS-based proteomics develops more powerful and reliable 
workflows to characterize the plasma proteome in greater depth, it may uncover novel 
biomarkers or protein patterns in an unbiased fashion. 
The classical approaches for the discovery of protein biomarkers are immunoaffinity-
based, as there is currently no PCR equivalent available for proteins to amplify signals 
of low abundant analytes. Depending on the assay, they can detect protein biomarkers 
in the low nanogram/milliliter range from blood samples (136). However, by their nature 
they are ‘biased’ in the sense that biomarker candidates have to be selected a priori. 
 
1.4.3.2 Biomarker study design 
 
 
Great care has to be taken in designing and performing discovery proteomics based 
biomarker studies, as large datasets inevitably produce a high number of false-positive 
results without suitable statistical validation. These wrong ‘hits’ may be eliminated by 
proper design of verification and validation studies. A recent search of SciFinder 
Scholar™ resulted in roughly 20,000 ‘hits’ for the terms protein or peptide biomarker 
(137). However, this stands in stark contrast to the actual number of roughly one FDA 
approved biomarker per year since 1998 (136). Although the long and laborious route 
from the discovery phase to the clinical application is one reason for the low number 
of new biomarker tests, it is also apparent that flaws during primary study design or 
realization inevitably prevent the initial discovery of meaningful candidates.    
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Figure 10 summarizes the different phases of a typical biomarker study. In this thesis, 
we applied discovery-based clinical proteomics to two ovarian cancer projects, partly 
following such an outline (Results sections 2.2 and 2.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The definition of a distinct clinical problem or need is the starting point of any 
hypothesis-driven discovery proteomics study. The research question should be as 
simple as possible to simplify later data interpretation. A well-defined homogenous 
patient cohort should be selected according to clinico-pathological characteristics such 
as disease subtype, stage or medication as well as socio-demographical background 
like gender, age and body mass index. The size of the discovery cohort has to be 
chosen with respect to the expected inter-patient variability as well as assay variability. 
Typical numbers for discovery proteomics based studies are in the range of 10-50 
patients, however, this may strongly vary depending on the clinical question, sample 
type and analytical platform as well as available resources. Moreover, analytical 
strategies are usually defined based on the exact clinical question and sample type of 
interest. As an example from this thesis (Results section 2.3), a highly sensitive single-
run mass spectrometric workflow needed to be developed and adapted, which was 
Figure 10: Phases of biomarker study design (6). 
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capable of analyzing low-input samples (a 5.000 – 25.000 cancer cells) derived from 
laser-capture microdissection. If sufficient material is available, pre-fractionation steps 
or PTM enrichment strategies can also be applied to tissue or body fluid samples prior 
to MS analysis (123, 138, 139).  
The selection of the appropriate sample source is a very critical aspect of the study 
design. For body fluid analyses, samples can generally be categorized according to 
their proximity to the tissue of interest (6). Proximal fluids such as cerebrospinal 
fluid (CSF) or ascites are ideal sources for disease-specific biomarkers due to likely 
high local analyte concentrations (136), however, their availability is usually limited due 
to the invasive nature of collection.  The second category is comprised of non-invasive 
body fluids such as urine or plasma, which are available in large quantities. However, 
disease-specific biomarkers present in these samples may be difficult to detect due to 
strong dilution effects in addition to the large dynamic range in plasma. With respect 
to sample collection, care has to be taken regarding any pre-analytical variability 
introduced by different sample handling or storage conditions (140). The use of 
approved standard protocols for sample collection and handling reduces variability 
(141). 
Downstream data analysis should incorporate stringent statistical testing to identify 
significant ‘true’ hits in the dataset. Especially for large-scale ‘omics’ datasets, 
Bonferroni correction, Benjamini-Hochberg or permutation-based false-discovery 
rates, need to be applied in addition to the primary statistical tests to account for 
multiple-hypothesis testing. The outcome is usually a list of biomarker candidates, 
which need to be further verified in a larger and independent patient cohort. In this 
context, antibody-based methods such as tissue microarrays (TMA) or ELISA are 
frequently used to screen large patient cohorts in a candidate-driven, targeted manner. 
Furthermore, targeted, quantitative MS such as multiple reaction monitoring (MRN) in 
combination with isotope-labeled standards can be applied for biomarker verification, 
with the promise of high accuracy, sensitivity, and reproducibility (142).  
Finally, for clinical approval, ‘validation studies’ may need to be performed in which 
thousands of samples are analyzed to assess clinical performance (i.e. sensitivity and 
specificity) of the biomarker test. 
In summary, the proper design of biomarker discovery studies is extremely challenging 
and does not follow a ‘one-fits-all’ rule. Instead, each phase has to be adapted to the 
end goal addressing a precise clinical need. 
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1.4.4 Cancer antigen discovery 
 
The immune system is extremely efficient in recognizing tumor-related antigens 
presented on human leukocyte antigens (HLA) complexes, which can ultimately result 
in T-cell mediated tumor rejection and long-term protection. This has led to the design 
of highly effective immunotherapies to treat diverse of human cancers (57).  
 
Generally, cancer immunotherapy comprises a variety of strategies to activate the 
patient’s immune system against the diseased, neoplastic tissue. Among them, 
checkpoint inhibition strategies, which aim at breaking the tumor’s intrinsic ability to 
suppress tumor-directed T-cell activation, have recently shown remarkable clinical 
results in e.g. advanced melanoma (143) and an ever-expanding list of other 
neoplasms. This has prompted the field to uncover the identity and nature of the 
underlying tumor-derived antigens to develop more personalized cancer 
immunotherapies in form of e.g. cancer vaccines or adoptive T-cell transfers. The 
combination of these personalized approaches with checkpoint inhibition therapies 
and/or standard conventional therapies, such as chemotherapy, may unleash the full 
potential of cancer immunotherapy in the near future. 
 
Tumor antigens can be grouped into tumor associated antigens (TAAs), tumor-specific 
antigens (TSAs) and cancer germline/cancer-testis antigens (CTAs) (144). TAAs are 
often differentiation antigens or overexpressed oncogenes, for example Wilms tumor 
1 (WT1) (145) or Her2/neu (146). Due to the fact that TAAs are also expressed in 
normal tissues, their immunogenicity strongly depends on overexpression in the tumor 
to overcome immunological tolerance mechanisms (144). Given their frequent 
expression, cancer immunotherapy strategies targeting TAAs are principally applicable 
to a large number of patients. However, the immunoreactivity can be associated with 
severe side effects caused by the destruction of normal tissue (147).  
 
TSAs, in contrast, represent antigens with high tumoral specificity such as neo-
antigens derived from somatic non-synonymous mutations or chromosomal 
rearrangements, which are usually absent in the germline genome. The altered amino 
acid sequence can be presented on HLA complexes on the cell surface and finally be 
detected as foreign by T-cells. Therefore, the presence of TSAs usually correlates with 
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the mutational status of the tumor. Lung carcinomas, melanomas and colorectal 
carcinomas are prime examples for tumors with high mutational loads and presumably 
large neo-antigen repertoires (11, 148). One challenge of TSAs is that mutated 
antigens are rarely shared between patients, which limits the design of effective cancer 
vaccines applicable to a large number of patients. Nevertheless, patient-specific TSAs 
may be used in future to individually treat patients according to their available tumor 
antigen repertoire, an ultimate instance of personalized medicine. In particular, a 
combination of mass spectrometry, next generation sequencing (NextGenSeq) and 
bioinformatics was used recently to discover novel mutated neo-antigens that, when 
administered as vaccines, provided therapeutic protection in a mouse model (149). 
This provides a proof of principle that a personalized immunotherapy approach 
targeting patient-specific neo-epitopes might also work in a clinical context.   
 
The last group of antigens is comprised of cancer germline/cancer-testis antigens. Due 
to their frequent and tumor specific expression, CTAs have been increasingly 
recognized as attractive cancer immunotherapy targets. CTAs are normally expressed 
in immune-privileged organs such as testis, fetal ovaries, and trophoblasts (150). In 
cancer tissues, CTAs can be activated at an advanced disease stage due to 
demethylation of CpG islands in promotor regions. According to the genomic locus, 
CTAs are grouped into an X chromosome-coded class (CTA-X) and a non-X 
chromosome-coded class (non-CTA-X) (150). CTAs make up an estimated half of all 
tumor-specific antigens that elicit spontaneous T-cell responses in cancer patients 
(11). The CTA database (http://www.cta.lncc.br/) currently lists 158 CT antigen 
families. Among them, the MAGE-A gene family and NY-ESO-1 are the most 
prominent CTA-X members, which are currently tested as potential cancer vaccines in 
the clinic. Of particular note, NY-ESO-1-specific T-cells were successfully used for an 
adoptive T-cell transfer in myeloma patients with promising clinical responses in 16 of 
20 patients (151). To extend the list of expressed CTAs in various cancer types, much 
research has been dedicated to the discovery of frequently expressed CTAs and their 
underlying immunogenic HLA peptides. Based on RT-PCR data, CTAs are commonly 
expressed in lung cancer, hepatocellular carcinoma, bladder cancer, ovarian cancer, 
and melanoma (150). Taking advantage of to their known regulation by DNA 
methylation, a recent study employed a DNA de-methylation strategy to activate CTA 
expression with the goal of identifying CTA-derived HLA-I peptides by mass 
32 
 
spectrometry (152). This approach may furthermore represent a very attractive 
therapeutic approach for cancers with low CTA expression such as renal cancer, colon 
cancer, gastric cancer or leukemia/lymphoma. Indeed, treatment with 5-aza-2'-
deoxycytidine, a drug causing global DNA demethylation, activated NY-ESO-1 
expression, which in turn promoted T-cell mediated tumor cell killing (153). In addition, 
treatment with decitabine (5-aza-2'-deoxycytidine) was recently shown to be 
synergistic with immune checkpoint blockage therapy in a murine ovarian cancer 
mouse model (154), underlining the great potential of CTAs for immunotherapeutic 
interventions to treat cancer. 
 
 
 
 
 
 
 
 
Figure 11: Human tumor antigen classes.  
a. Tumor-specific antigens and their origins are shown. As a result of genomic 
mutations, mutant variants of peptides can be presented on HLA complexes on the cell 
surface. In addition, mutations can also enable HLA binding of non-binding peptides. 
Cancer-testis antigens are tumor-specific due to their non-physiological up-regulation 
via DNA demethylation in the tumor. Expression in germline cells does not lead to 
presentation due to the lack of HLA receptor molecules. b. Antigens with low tumor 
specificity and their origins are shown. Genes that are expressed tissue-specifically 
(e.g. melanocyte-specific) or at unnatural high levels (e.g. ERBB2) can also elicit anti-
tumor responses (11). 
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Historically, the first T-cell recognized cancer antigen, MAGEA1, was discovered in 
1991 using a genetic screening approach of a melanoma DNA library (155). In 1995 
the SEREX method (156) (serological analysis of recombinant cDNA expression 
libraries) was established, which used a recombinantly expressed cDNA tumor library 
to identify specific serum antibody epitopes. Multiple CTAs were identified this way, for 
example NY-ESO-1 (157) and SSX2 (158). However, today in the age of whole-
genome analysis and systems biology, new cancer-specific antigens are primarily 
identified by a combination of NextGenSeq approaches, such as whole-exome-
sequencing, and bioinformatic in silico predictions for HLA binding (159-161). This 
strategy has been widely applied for cancer antigen discovery, however, as 
intracellular processing and antigen immunogenicity is generally not taken into 
account, many reported peptide hits are irrelevant in vivo. Consequently, immense 
experimental follow-up work is needed to filter for ‘true’ and T-cell reactive candidates. 
For example, in a recent study only half (54%) of the a priori known antigens were also 
recovered within the top three hits from an in silico prediction of a large number of 
peptides (162), highlighting the necessity for alternative approaches that identify HLA 
peptides in a completely unbiased and more direct fashion.   
Mass spectrometry should in principle be a very powerful tool to directly measure and 
identify HLA peptides (HLAp) isolated from cell lines, tissue or plasma-derived HLA 
complexes (163-165). This approach is termed ‘MS-based immunopeptidomics’ and 
includes immunoaffinity purification of HLA complexes and subsequent isolation of the 
entirety of bound HLA peptides. These are then separated and analyzed by LC-MS. 
For HLA complex purification, pan-HLA class I and pan-HLA class II antibodies are 
used, however, allele-specific antibodies have also been reported in this context (166). 
Beginnings with just a few peptides more than 20 years ago (167), this today allows 
the simultaneous identification of thousands of HLA-I peptides in a single mass 
spectrometric run, without the use of peptide pre-fractionation. This has led to the 
identification of multiple cancer-related antigens in a large number of cancer diseases 
such as melanoma, glioblastoma, renal cell carcinoma, ovarian cancer, hepatocellular 
carcinoma and leukemia (163). Even neo-antigens resulting from somatic mutations 
can readily be detected by integrating NextGenSeq data of the analyzed sample (149). 
MS-based immunopeptidomics further allows discovering post-translationally modified 
HLAp, which might be exclusive to the tumor and therefore offer an additional level of 
immunogenic targets for immunotherapy. Validation approaches for the identified 
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HLAp include the design and measurement of synthetic versions of the candidate 
peptides, whose spectra should exactly match those of the experimentally observed 
ones. In addition, functional follow-up work is needed to test T-cell reactivity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 12: MS-based immunopeptidomics workflow for antigen 
discovery and personalized immunotherapy. 
Antigen discovery by MS-based immunopeptidomics for personalized cancer 
immunotherapy. Immunoaffinity-based HLA complex purification from cancer 
tissues or cell lines. Isolated HLA-binding peptides are measured by HPLC-
MS/MS, followed by database matching. In specialized laboratories this now 
allows to simultaneously identify thousands of HLA-I peptides in a single MS 
run. Selected candidate peptides are validated by obtaining mass spectra from 
synthetic peptide versions as well as through T-cell assays to determine HLA 
binding and immunogenicity. Downstream immunotherapeutic applications 
include the development of personalized immunotherapies such as peptide 
vaccines or adoptive T-cell transfers (9). 
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1.5 Aims of the thesis 
 
In this thesis, state-of-the-art MS-based proteomics methodologies were developed 
and applied to investigate high-grade serous ovarian cancer (HGSOC) at the 
proteomic level. I completed three projects addressing important clinical questions 
related to HGSOC. All three projects were conducted in an exceptionally productive 
and fruitful collaboration with the Ernst Lengyel ovarian cancer laboratory at the 
Department of Obstetrics and Gynecology, of the University of Chicago. 
The first project addresses an important question for any HGSOC-related pre-clinical 
investigation: which ovarian cancer cell lines are ‘good’ models to study HGSOC? We 
reasoned that an integrated and streamlined proteomic workflow applied to frequently 
employed ovarian cancer cell lines would offer a very attractive methodology to identify 
suitable cell line models by comparing their underlying proteomic profiles to those of 
the actual HGSOC tissues and to corresponding primary cells. Our single-run, label-
free workflow identified distinct HGSOC cell line proteomes and refined a previously 
reported genomics-based cell line classification.  
For the second project, I used the developed single-run workflow to retrospectively 
compare the proteomes of HGSOC patients with differential survival times following 
standard carboplatin/taxol chemotherapy. The in-depth analysis yielded a total of 9,000 
proteins obtained from FFPE biobank samples and highlighted the power of discovery-
based clinical proteomics to identify novel protein biomarker candidates linked to 
chemotherapy efficacy.  Complemented by a variety of techniques including interaction 
proteomics and immunopeptidomics, we further gained functional and mechanistic 
insights into the biology of chemotherapy sensitive HGSOC. The results are currently 
being evaluated for potential use in a clinical setting in the future.  
The third project of this thesis likewise focused on the analysis of FFPE biobank 
specimens and constitutes the first proteomic analysis of HGSOC progression. 
Towards this goal we developed and adapted a novel and highly sensitive and 
streamlined proteomic workflow to analyze as few as 5,000 tumor cells. This allowed 
us investigating the proteome of the tumor and its adjacent microenvironment in the 
context of HGSOC progression. Our results revealed novel insights into ovarian cancer 
biology and highlighted the importance of the tumor microenvironment for ovarian 
cancer progression. Current work addresses the potential clinical utility of our findings.  
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2 Results 
 
2.1 Manuscript 1: Deep proteomic profiling of ovarian cancer models 
 
2.1.1 Project aim and summary 
 
 
 
 
 
 
 
 
 
 
 
The large heterogeneity of ovarian cancer is reflected in the fact that the 
histopathological origin of the most frequently used OvCa cell lines is not completely 
clear (12). Research dedicated to the identification of bona-fide HGSOC cell lines has 
consequently gained strong interest in the OvCa community (22, 168). In a recent 
genomics-based study, HGSOC cell lines with high genetic similarity to HGSOC tumor 
tissues were identified, however, so far a proteomics-based classification comparing 
cell lines and tumors has not been undertaken. We therefore undertook such an 
integrated and streamlined MS-based proteomics approach, reasoning that it would 
represent a powerful technology for the identification of ‘good’ HGSOC cell lines.  
 
For the first time, we acquired quantitative proteomic data (>10.000 proteins) for 30 
ovarian cancer cell lines, primary cells and tumor tissues. This revealed a high 
proteomic similarity in terms of expressed proteins (77%). However, our data clearly 
showed large protein expression level differences for the analyzed cell lines indicating 
a pronounced quantitative proteome heterogeneity. This observation prompted us to 
investigate whether our data allowed the identification of distinct proteomic cell line 
subgroups.  
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Extending previous genomics-based findings (12), we identified two distinct HGSOC 
types of cell line proteomes, in addition to a group of clear-cell OvCa cell lines. The 
integration of immortalized ovarian surface epithelial cells (IOSE) and fallopian-tube 
epithelial cells (FTEC) further suggested a possible dual cell-of-origin based 
classification for the newly identified HGSOC cell line proteomes. Based on a novel 
67-protein signature that we derived, we were then able to validate our findings in two 
independent datasets, among them a recent study of 84 HGSOC tumor proteomes. 
This showed that patients with an IOSE-like profile had a worse prognosis than those 
with a FTEC-like profile and suggests a previously overlooked simple stratification 
according to the cell-of-origin.  
 
As a proof-of-concept, we additionally showed that our proteomic dataset can be used 
to select the most appropriate cell lines for various pre-clinical investigations. This 
delineated a strong up-regulation of several ‘vitamin A pathway’ proteins in a subgroup 
of cell lines with HGSOC-like genomic and proteomic features. For example, the 
transporter protein CRABP2, which promotes anti-oncogenic all-trans retinoic acid 
(ATRA) signaling (169), was highly expressed in these cells. We showed that our 
quantitative data correctly predicted the anticipated tumor-suppressive response to 
ATRA that we measured in our system.  
 
Our proteomic dataset has been made available for the OvCa community on a user-
friendly website: http://maxqb.biochem.mpg.de/mxdb/project/list. 
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2.1.2 Contribution 
 
Ernst Lengyel conceived the initial idea for the project and proposed it to Matthias 
Mann and myself in 2013. Matthias Mann, Ernst Lengyel (University of Chicago), Karen 
Watters (University of Chicago), and I incubated and developed this project. Matthias 
Mann and Ernst Lengyel supervised me during all phases of the project. My 
contribution included the conceptual study design, proteomic sample preparation, 
proteomic data acquisition, as well as data analysis and interpretation. Karen Watters 
conducted all functional ATRA experiments and validation experiments.  I designed 
the majority of the figures and tables in the publication and wrote the manuscript 
together with Karen Watters, Ernst Lengyel and Matthias Mann. 
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2.1.3 Publication 
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2.2 Manuscript 2 (in preparation): Proteomic characterization of 
chemotherapy sensitive ovarian cancer  
 
2.2.1 Project aim and summary 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment for HGSOC involves a surgical debulking procedure followed by 
neoadjuvant carboplatin/paclitaxel combination chemotherapy. Unfortunately, 80-90% 
of patients diagnosed with advanced stage disease develop a chemoresistant state 
independent of any favorable initial response. Conversely, 17% of patients with 
advanced stage disease show long-term survival beyond 10 years after initial 
diagnosis (15). To date, it is still unclear what distinguishes these long-term survivors 
from the majority of patients with poor clinical outcome. The strong survival differences 
between these patient subgroups suggest the existence of yet unidentified, 
predisposing molecular mechanisms that actively contribute to chemotherapy 
sensitivity and promote long-term protection from any tumor relapse. The objective of 
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this study was therefore to apply state-of-the-art discovery-based proteomics to clinical 
biobank (FFPE) specimens obtained from advanced-stage HGSOC patients to identify 
discriminating proteins linked to the above mentioned different chemotherapy 
outcomes. 
 
Our single-run proteomic workflow led to the quantification of in total a 9,000 proteins 
obtained from 25 biobank specimens; an unprecedented proteomic depth considering 
the absence of any sample pre-fractionation. Out of all quantitatively compared 
proteins, we identified a single differentially expressed protein that was highly up-
regulated in the majority of the long-term survivors. To our knowledge, this is the first 
time that MS-based proteomics unambiguously discovered a clear molecular marker 
for cancer treatment success, and interestingly it manifested not as a global pattern 
but as a unique, differentially expressed entity. The protein turned out to be unknown 
except having been picked up in a large group of differentially expressed mRNAs 
where it has been termed cancer-testis antigen 45, CT45 (170) and neither the 
literature nor its sequence associate it to any known molecular function. The finding 
that CT45 was differentially expressed was then confirmed in a larger patient cohort 
(a150 cases) using tissue microarrays (TMA). This revealed that platinum resistance 
commenced after 363 days when CT45 staining was weak to strong versus 153.5 days 
for patients with no detectable expression of CT45. 
 
Due to the tumor-specific expression of cancer-testis antigens and their recognized  
capacities to mount anti-cancer immune responses (150), we addressed if the 
favorable patient outcome was linked to T-cell mediated tumor rejection. We used an 
immunopeptidomics approach, which we applied to cell lines and tumor tissues to 
screen for CT45-derived HLA class I peptides. This indeed led to the first identification 
of CT45-derived HLA-I peptides. Our work further showed that these antigens are 
capable of activating patient-derived cytotoxic T-cells and to promote cancer cell killing 
in vitro. Based on this evidence, our results indeed suggested that the immune system 
may contribute to the favorable outcome of CT45+ patients. However, we were unable 
to ascertain a general correlation between the number of cytotoxic T-cells and CT45 
expression in our initial discovery cohort. This indicated a strong immune inhibitory 
microenvironment in omental HGSOC tissues, in line with a recent report (59).  
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As no clear biological function has been reported for CT45, we used an interaction 
proteomics approach in the hope of gaining functional insights through ‘guilt by 
association’. Indeed, we found that CT45 interacted with the DNA damage-linked 
protein phosphatase 4 (PP4) complex on chromatin and that this caused an inhibitory 
phenotype in the context of PP4-mediated DNA damage signaling. We further showed 
that ovarian cancer cells expressing CT45 were more susceptible to carboplatin-based 
chemotherapy in vitro and in vivo, ultimately leading to apoptosis. Based on our 
functional studies, I developed a model in which cells expressing CT45 run into stalled 
chromatin relaxation after DNA damage repair, resulting from inhibited PP4-mediated 
KAP1/TRIM28 de-phosphorylation. 
 
We conclude that CT45 may represent an ideal prognostic biomarker for 
chemotherapy sensitivity and long-term survival in HGSOC and possibly in other 
cancers. The identified HLA-I peptides represent promising candidate antigens for 
cancer immunotherapy approaches in the future or may help to stratify patients with 
differential responses to immune checkpoint blockage therapies. Patients with high 
tumoral levels of CT45 may represent ideal subjects for immune checkpoint therapies 
as T-cells would be exposed to strong antigens presented on the cancer cells. 
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2.2.2 Contribution 
 
Ernst Lengyel suggested the comparison of responders and non-responders to 
chemotherapy and proposed this to Matthias Mann and myself in 2012. Matthias Mann, 
Ernst Lengyel (University of Chicago), Marion Curtis (University of Chicago), and I 
initiated this project, which was a shared effort between both laboratories over a period 
of 4 years starting end of 2012. Matthias Mann and Ernst Lengyel supervised me 
during all phases of the project. My work started with an adaptation and optimization 
of the proteomic sample preparation for clinical FFPE material, which soon allowed to 
us measure relatively deep (6.000 - 8.000 proteins) biobank proteomes in single-run 
(4h) analysis. I acquired all proteomic measurements of the study, analyzed and 
interpreted the data and identified CT45 as a marker of chemotherapy sensitivity. My 
interactomics work suggested an important functional role in DNA damage signaling 
and my HLA immunopeptidomics results showed that it may be a cancer 
immunotherapy target. Together with Marion Curtis and Bradley Ashcroft from 
University of Chicago, I then worked on follow-up experiments to gain functional 
insights. Marion Curtis collected and processed all biobank specimens of the study, 
conducted all animal experiments and performed the comet assays and other 
functional assays. Jaikumar Duraiswamy performed all T-cell based experiments. I 
designed most of the figures in the publication and wrote the manuscript together with 
Marion Curtis (Univ. of Chicago).  Ernst Lengyel and Matthias Mann edited the 
manuscript. 
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2.2.3 Publication 
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ABSTRACT  
 
Most high-grade serous ovarian cancer (HGSOC) patients will develop resistance to platinum-
based chemotherapy but a subset (15%) will remain disease-free for over a decade. To discover 
drivers of long-term survival following chemotherapy, we analyzed the proteomes of 25 
platinum resistant and sensitive HGSOC patients to a depth of over 9,000 proteins. We 
identified cancer/testis antigen 45 (CT45) as an independent prognostic factor for prolonged 
disease-free survival. Immunopeptidomics discovered several CT45 derived HLA class I 
peptides capable of activating patient-derived cytotoxic T cells. Interaction proteomics 
identified a direct interaction with members of the protein phosphatase 4 (PP4) complex linking 
CT45 to the DNA damage response. CT45 mediates chemosensitivity by impeding PP4-
dependent KAP-1 dephosphorylation following DNA damage leaving the chromatin in an open 
conformation and making it susceptible to carboplatin toxicity. Thus, CT45 is a novel regulator 
of chemosensitivity and is a potential target for immunotherapy. 
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INTRODUCTION 
 
HGSOC accounts for the majority of ovarian cancer fatalities (~70%) with the high 
mortality rate mainly driven by late diagnosis and frequently acquired resistance to 
chemotherapy (14). However, one in six patients remains disease-free for more than ten years 
after initial diagnosis with advanced stage disease (III or IV) treated with tumor debulking 
surgery following by chemotherapy treatment (15). This suggests the presence of tumor-
intrinsic, pre-disposing features that influence chemotherapy outcome and promote long-term 
survival in this subset of patients. The molecular mechanisms which explain why some patients 
are long-term survivors have not been illuminated.  
Cancer is predominantly studied at the genetic level, but proteomics has long been a 
promising complementary technology to gain insight into this disease at the protein level. 
Currently, there are few if any examples where this technology has identified clinically relevant 
biomarkers of the disease (136, 171). However, proteomics technology has improved 
tremendously in recent years and advances in proteomic sample preparation and computational 
workflows now enable very deep and quantitative profiling of cellular systems, including 
formalin-fixed and paraffin-embedded (FFPE) biobank material, to a depth and quantitative 
accuracy that could not be achieved previously (67, 123, 172). We therefore reasoned that a 
system-wide quantitative proteomics approach using state-of-the-art mass-spectrometry 
applied to clinical biobank specimens would offer a promising strategy to uncover driver 
proteins responsible for chemotherapy response and improved survival.  
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RESULTS 
 
Identification of CT45 by shotgun proteomics 
We performed quantitative proteomics on FFPE tumor samples isolated from 25 
chemotherapy-naïve patients with advanced stage HGSOC (Fig. 1a, Extended Data Fig.1, 
Supplementary Tables 1 and 2). Since patients with advanced stage disease generally have 
the worst prognosis (15), we selected metastatic tumors from the omentum for proteomic 
analysis. We first assessed global proteomic differences between chemoresistant (N=11, 
median DFS = 190 days) and chemosensitive (N=14, median DFS=1160 days) patients in our 
cohort by adapting a recently described and highly sensitive label-free proteomic workflow 
capable of accurately quantifying a large portion of the cellular proteome (103, 173).  We 
stringently identified and quantified more than 9,000 proteins from low µg input archival 
samples in single-run measurements in the MaxQuant environment (94, 103) (1% FDR at 
protein and peptide levels; Extended Data, Fig. 1b). The dynamic range of protein signals 
spanned more than six orders of magnitude (Extended Data Fig. 1c). Pearson R values between 
all specimens were consistently above 0.77 (mean 0.88) and the correlation was 0.95 between 
independently prepared tissue of the same tumor (Extended Data Fig. 1d). Based on the 
quantitative levels of 8,190 proteins after data filtering (Methods, Extended Data Fig. 1b), we 
observed few overall proteome changes across patients. However, the comparison of 
chemosensitive and chemoresistant patients identified cancer/testis antigen 45 (CT45), as 
significantly higher expressed in chemosensitive patients (FDR < 5%, Fig. 1b). Furthermore, 
CT45 protein levels strongly correlated with disease-free survival time (Extended Data Fig. 2a). 
CT45 is comprised of 10 distinct but highly similar genes, which make them nearly identical at 
the protein level (amino acid identity >98%, Extended Data Fig. 2b). Immunohistochemistry 
for CT45 confirmed the relative expression of CT45 in serial sections of the tumors used in the 
proteomic cohort and showed localization to the nucleus and in some cases to the nucleolus 
(Fig. 1c). 
To validate the proteomic findings in a larger patient cohort, we stained tissue microarrays 
(TMA) to analyze CT45 expression in over 200 cases of primary and metastatic ovarian cancer 
(Extended Data Fig. 3a). CT45 protein levels were assessed by a gynecologic pathologist 
blinded to patient outcomes. CT45 was only rarely expressed in cases of endometrioid, clear 
cell, or mucinous ovarian cancer subtypes compared to serous papillary - in line with a previous 
study of mRNA expression (174) - and the protein was expressed at identical levels between 
primary and metastatic tumors from the same HGSOC patients. Consistent with our discovery 
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cohort, CT45 expression correlated with chemosensitivity in 124 patients with advanced stage 
HGSOC (FIGO 2014 stage IIIb or higher) (P = 0.005, Extended Data Fig. 3a). Furthermore, 
patients with high CT45 expression (staining 1+) had prolonged disease-free survival compared 
to patients with no expression of CT45 (P = 0.02, 363 days versus 153.5 disease free days; Fig. 
1d) and there was a trend towards longer overall survival (P = 0.09, Extended Data Fig. 3b). 
Thus, CT45 expression is an independent prognostic indicator for advanced stage HGSOC. 
 
CT45 is an independent prognostic indicator 
  
To validate the proteomic findings in a larger patient cohort, we stained tissue microarrays 
(TMA) to analyze CT45 expression in over 200 cases of primary and metastatic ovarian cancer 
(Extended Data Fig. 3). CT45 protein levels were quantified by a gynecologic pathologist who 
was blinded to the patients’ outcomes. CT45 expression was not as common in endometrioid, 
clear cell, mucinous ovarian cancer subtypes compared to serous papillary, in line with large-
scale mRNA expression data (174). There was no significant difference in protein expression 
between primary and metastatic tumours from the same HGSOC patients (P = 0.61). However, 
consistent with our discovery cohort, CT45 expression correlated with chemosensitivity in 124 
patients with advanced stage disease (FIGO IIIb or higher) (Extended Data Fig. 3). Kaplan-
Meier survival analysis revealed that advanced stage (FIGO IIIb or higher) HGSOC patients 
with high CT45 expression had a lower risk of recurrence with median days to platinum 
resistance of 363 days (staining 1+) versus 153.5 days for patients with no expression of CT45 
(P = 0.02, Fig. 1e). A trend towards longer overall survival was also evident (P = 0.09, Fig. 1f). 
We further validated our proteomic findings using a larger and independent public dataset 
generated by The Cancer Genome Atlas (TCGA) consortium (64). Using RNA-Seq data of 305 
HGSOC cases, we calculated CT45 expression from the accumulated expression of the detected 
6 gene family members (CT45A1-A6). Grouping patients into a CT45 high group (top 25%, 
N=76) and CT45 low group (lower 75%, N=229) resulted in a significantly longer overall 
survival for the CT45 high group (P = 0.01, Fig. 1g). Thus CT45 expression is an independent 
prognostic indicator for advanced stage HGSOC. 
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CT45 is a native tumor antigen 
 
Despite previous reports on CT45 expression in several tumor types (175-178), its role 
as a tumor antigen has not been elucidated. To investigate whether CT45-specific peptides are 
bound and presented on human leukocyte antigen (HLA) class I complexes on cancer cell lines, 
we used an approach coupling immunopeptidomics to mass spectrometry(163) with a cell line 
(59M) expressing high endogenous levels of CT45 (Extended Data Fig. 4a and 4b). Of 6,413 
identified HLA-I peptides (Extended Data Fig. 4c, Supplementary Table 3), five derived 
from CT45: AVDPETVFK, GVQGPTAVR, GVQGPTAVRK, VQGPTAVRK, QGPTAVRK; 
all of which matched the binding motifs of the A-03:01 and A-11:01 HLA-I receptor (Extended 
Data Fig. 4d, 4e, and 4f).  We further confirmed the identity of these peptides using synthetic 
versions and tandem mass spectrometry (Extended Data Fig. 4g). In-silico HLA epitope 
prediction revealed weak and strong binding affinity of AVDPETVFK to A-03:01 or A-11:01, 
respectively, and low or no binding affinity for the remaining four peptides (Fig. 2a).  
CT45 expression is regulated by DNA methylation (174) and patients treated with 
demethylating agents show an altered immune response that correlates with upregulation of 
cancer/testis antigens as well as genes involved in immunomodulatory pathways (179, 180). 
Treatment with 5-aza-2'-deoxycytidine (DAC) strongly activated CT45 expression in 
SKOV3ip1 ovarian cancer cells (Fig. 2b, Extended Data Fig. 5a) along with the CT antigens 
NY-ESO-1, MAGEA4 and SSX2, in line with recent publications (179, 180). Using the same 
immunopeptidomics strategy, we identified three additional, but sequence related CT45 
peptides matching to the measured peptide motifs of the alleles A-03:01 and/or A-68:01 (Fig. 
2c, Extended Data Fig. 5b, 5c, and 5d, Supplementary Table 3).  
To address if the identified epitopes function as targets for CD8+ T cells, we stimulated patient 
derived A-11:01 CD8+ T cells collected from a CT45 positive tumor with the two CT45 
peptides with the best binding affinity predictions (AVDPETVFK and GVQGPTAVRK). Both 
CT45 peptides, but not a control peptide, induced T cell activation as assessed by Ki67 and 
intracellular IFNγ staining of CD8+ T cells (Fig. 2d). Similar results were obtained using A-
03:01 CD8+ T cells using three peptides identified after DAC treatment (Extended Data Fig. 
5e).  The A-11:01 CD8+ T cells reacted with one of two CT45 tetramers (A-11) containing the 
peptide, AVDPETVFK, which had the highest predicted affinity for A-11:01, while A-03:01 
CD8+ T cells reacted with the tetramer (A-03) containing the GVQPTAVRK peptide (Fig. 2e). 
Co-culture of the CT45+ 59M cell line with peptide stimulated A-11:01 CD8+ tumor-
infiltrating lymphocytes (TIL) targeting two different CT45 peptides lysed the cancer cells in a 
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dose-dependent manner (Fig. 2f). These data demonstrate that CT45 is an endogenously 
processed and presented antigen recognized and targeted by patient-derived CD8+ T cells. 
 
CT45 is a functional mediator of chemosensitivity  
In addition to DAC’s ability to modulate the immune response, it also shows synergism 
with platinum agents in ovarian cancer therapy (181, 182). DAC sensitized SKOV3ip1 ovarian 
cancer cells to carboplatin (Extended Data Fig. 6a) and intriguingly, proteomic analysis on 
DAC treated cells revealed that CT45 was among the top ten DAC induced proteins (Fig. 2b).  
Overexpression of CT45 in an ovarian cancer cell line reduced the number of colonies in a 
colony formation assay (Fig. 3a) but did not affect proliferation or the cell cycle (Extended 
Data Fig. 6c and 6d). Addition of carboplatin reduced proliferation and colony formation in 
CT45 expressing cells (Extended Data Fig. 6c and Fig. 3a). Similar effects were observed in 
a second serous ovarian cancer cell line, OVKATE (Extended Data Fig. 6b and 6e). Treatment 
with carboplatin significantly reduced growth of CT45 expressing subcutaneous tumors in an 
immunodeficient mouse as compared to the untreated CT45+ tumors while having no effect on 
the vector control cell line (Fig. 3b). CT45 expression also significantly reduced overall tumor 
growth as compared to the vector control (Fig. 3b). This data reveals a functional link between 
CT45 expression and carboplatin chemosensitivity and highlights the potential tumor 
suppressive capacities of CT45 in ovarian cancer. 
To understand the mechanism of CT45-mediated chemosensitivity, we mined a recent 
quantitative human interactome study published by our laboratory (117). Interestingly, we 
found that CT45 interacts with several members of the evolutionarily conserved protein 
phosphatase 4 (PP4) complex. The PP4 interaction was confirmed in two ovarian cancer cell 
lines (OVCAR-5 and COV318) expressing Flag or V5-tagged CT45, respectively. The 
regulatory subunits PP4R3α, PP4R3β, and PP4R2 as well as the catalytic subunit, PP4C, of PP4 
were all highly significantly enriched in CT45 immunoprecipitates (p < 0.001; Fig. 3c and 3d, 
Extended Data Fig. 6f) pointing to their specific and direct interaction with CT45. Since PP4 
deficiency impedes the DNA damage response (DDR) (183-187) and causes hypersensitivity 
to platinum compounds (188), we next investigated if CT45 expression influenced the level of 
DNA damage in ovarian cancer cells following treatment with carboplatin. Indeed, CT45-
expressing cancer cells showed increased levels of the DNA damage marker γH2AX and 
cleaved caspase-3 after carboplatin exposure (Fig. 3e). In addition, more DNA damage was 
present in CT45-expressing cells as demonstrated by longer tail moments in a comet assay (Fig. 
3f). 
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CT45 promotes chromatin relaxation mediated by KAP1 phosphorylation 
PP4 plays an important role in the DNA damage response by dephosphorylating several 
critical proteins including 53BP1 (186), γH2AX (183, 189), RPA2 (184), and KAP-1/TRIM28 
(190, 191). Using a candidate based approach we found that carboplatin treatment induced 
phosphorylation of KAP-1 at the ATM target site Ser824 (192). Phosphorylation was increased 
in CT45-expressing cells as compared to vector control cells following DNA damage (Fig. 4a). 
Consistent with these results, phosphorylated KAP-1 was pan-nuclear, peaking at day 3 
following carboplatin treatment in both cell lines (Fig. 4b). In CT45-expressing cells p-KAP-1 
peaked at a higher level and remained elevated on day 5 and day 7, while the p-KAP-1 signal 
dissipated to baseline levels by day 7 in control cells. We observed similar trends for γH2AX. 
KAP-1 is a building block of heterochromatin important for chromatin condensation (193) and 
to understand whether CT45 is also associated with chromatin, we analyzed both ectopically 
(OVCAR5-CT45) and endogenously (59M) CT45 expressing cells using a biochemical 
chromatin segregation assay(194). CT45 was strongly chromatin-enriched and associated with 
nuclease resistant heterochromatin, similar to its PP4 interaction partners, as well as the known 
heterochromatin linked proteins HDAC2 and KAP-1 (Fig. 4c and Extended Data Fig. 7a).  
One possibility for how CT45 may inhibit KAP-1 dephosphorylation is by altering KAP-1 
retention on the chromatin (195), but we did not find that either CT45 or carboplatin altered the 
chromatin enrichment of KAP-1 or PP4 (Extended Data Fig. 7b). 
 Furthermore, chromatin-immunoprecipitation coupled to mass spectrometry (ChIP-
MS)(196) confirmed an association of CT45 with heterochromatin as indicated by the co-
enrichment of KAP1 and HDAC2 in addition to the PP4 complex (Fig. 4d). Pathway analysis 
of the CT45 interactome revealed a strong enrichment of heterochromatic and DDR linked 
proteins (Fig. 4e). Reciprocal ChIP-MS using KAP-1 as a bait showed a clear enrichment of 
CT45, independently confirming its association with chromatin (Extended Data Fig. 7d and 
7e). The interaction of CT45 with heterochromatin-associated PP4 was not affected by 
carboplatin (Extended Data Fig. 7c). 
Since KAP-1 phosphorylation at S824 induces global chromatin decondensation 
following DNA damage (191, 192, 194), we next asked if the KAP-1 Ser-824 phosphorylation 
differences caused changes in chromatin structure. Following carboplatin treatment, cells 
expressing CT45 had larger nuclei on day 5 suggesting an increased level of relaxed chromatin 
(Fig. 4f). Structural chromatin changes were interrogated using a micrococcal nuclease 
(MNase) assay (197) at several time points following carboplatin exposure. After five days, 
carboplatin treatment induced global chromatin relaxation in both vector control and the CT45 
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overexpressing cell line. Strikingly, CT45 induced a higher proportion of nuclease-accessible 
chromatin compared to vector control cells (Fig. 4g and 4h) indicating that the chromatin is 
more accessible to platinum-induced chromatin damage. Furthermore, whereas the control cells 
completely restored chromatin compaction at day 7, chromatin in CT45 expressing cells 
remained in a relaxed conformation suggesting that CT45 impedes the KAP-1 mediated 
restoration of chromatin compaction through its binding to PP4 during recovery from DNA 
damage (Fig 4i). 
 
DISCUSSION 
Until recently, proteomic technology was not amenable to in-depth proteome analysis 
from FFPE tissue without extensive sample pre-fractionation, which requires relatively large 
sample amounts and measurement times. Using a high sensitivity, single-run workflow on 
minute amounts of FFPE tissue, we are now able to quantify over 9,000 proteins, which was 
crucial in the identification of CT45 as an independent prognostic factor for patients with 
advanced stage HGSOC. The ability to successfully use minute amounts of starting material 
from biobank samples as demonstrated here provides validation for the application of MS-based 
proteomics to a variety of important clinical questions and in particular to the long elusive 
identification of clinically relevant cancer biomarkers. 
Mutational load correlates with clinical response to CTLA-4 blockade in melanoma 
(198) and to PD-1 inhibition in colorectal cancers with mismatch-repair deficiencies (199). 
Therefore, most immunotherapy approaches have focused on cancers with a high mutational 
load and the presence of mutant antigens. Notably, ovarian cancer patients treated with immune 
checkpoint inhibitors have not experienced the impressive response rates evident in some other 
cancers (200).  This has been attributed to the low mutational burden present in ovarian tumors 
which are characterized by copy number alterations (62, 201). In our discovery cohort several 
patients showed long term survival following treatment with surgery and chemotherapy. Two 
of these patients are positive for the HLA class I alleles A-03:01 or A-11:01 which bind the 
CT45 derived peptides we discovered using immunopeptidomics (Fig. 2). We hypothesize that 
CT45 may serve as a non-mutant tumor rejection antigen that provides long-term protection to 
patients through activation of cytotoxic T cells which inhibit cancer growth. Based on our 
studies we could envision a treatment approach where CT45 expression is activated on tumor 
cells (e.g. by DAC) and targeted by T cells engineered to recognize the CT45 peptide:HLA-I 
complex.  
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Using interaction proteomics, we found that CT45 directly interacts with the 
evolutionarily conserved protein phosphatase 4 complex, mediating sensitivity to the DNA 
damaging agent carboplatin by impeding dephosphorylation of KAP-1. Phosphorylated KAP-
1 provides a global signal to transiently relax chromatin in order for DNA damage repair to 
occur (193, 202). Our data suggest that CT45 prevents chromatin associated PP4 from 
dephosphorylating KAP-1 and thereby suspends chromatin in a relaxed state (Fig. 4i). Over 
time this leads to further accumulation of platinum induced DNA damage as more of the 
chromatin is exposed and ultimately result in cell death.  KAP-1 was originally described as a 
transcriptional corepressor (203) and was shown to assist in the inactivation of p53 through an 
interaction with MDM2 leading to repression of p53 transcriptional activity (204). Since most 
HGSOC tumors have mutant p53 it is unknown what if any affect CT45 may have on the 
transcriptional activity of p53 mediated by prolonged KAP-1 phosphorylation.  
Overall, our data suggest a model (Fig. 4i) whereby CT45 functions as both a cell 
intrinsic mediator of chemosensitivity by impeding KAP-1 mediated chromatin condensation 
during recovery from DNA damage and as an antigen for CD8+ T cells. Both these findings 
may be clinically relevant. We propose that CT45 expression could be activated in tumors 
lacking CT45 by treating with demethylating agents to improve efficacy of chemotherapy both 
during first line therapy and with recurrent disease. Furthermore, immunotherapy targeting 
CT45 either alone or in combination with platinum-based chemotherapy could be an effective 
strategy for the treatment of advanced stage ovarian cancer. 
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Figure 1. Proteomics identifies CT45 expression to predict long-term survival in HGSOC 
a, Summary of the shotgun proteomics workflow applied to FFPE biobank specimens from 
ovarian cancer patients. Following tissue lysis and homogenization, purified proteins were 
digested and analyzed in single-run HPLC-MS using a Q Exactive mass spectrometer. Data 
were analyzed and quantified in MaxQuant(94, 103). b, Volcano plot of chemotherapy resistant 
versus sensitive patient proteomes. Expression fold changes are plotted against the t-test p-
value. Dashed lines indicate the significance threshold (FDR < 0.05, s0 = 2). CT45 is highlighted 
in green. c, Immunohistochemistry for CT45 and corresponding H&E staining in serial sections 
of tumor from 3 representative patients. d, Kaplan-Meier survival analysis based on CT45 
staining scores from ovarian cancer TMAs for disease-free survival. Advanced stage HGSOC 
patients comparing a staining score of 0 (N=82) versus 1+ (N=42).  
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Figure 2. CT45 is a native tumor antigen 
a, Predicted binding affinities (NetMHC4.0) for HLA class I peptides of CT45 with a length of 
8-11 amino acids. Affinities are plotted on the y-axis as % rank-1. Weak affinity cut-off: % rank 
< 2, high affinity cut-off: % rank < 0.5. Peptides identified by MS are highlighted in green. 
b, Volcano plot of the proteomic comparison between 5-aza-2'-deoxycytidine (DAC) treated 
and control SKOV3ip1 ovarian cancer cells. Protein fold change (t-test difference, log2) is 
plotted against the t-test p-value (–log10). Significance thresholds are indicated by dashes lines 
(FDR < 0.01). Cancer-testis antigens including CT45 are highlighted. c, HLA-I peptide 
intensity ratio from immunopeptidomics of DAC treated versus control SKOV3iP1 ovarian 
cancer cells, plotted against the ranked peptide ratio. CT45 peptides are highlighted in green. 
d, Staining for Ki-67 and IFN-γ of CD8+ T cells (A-11:01) after stimulation with two CT45 
peptides (AVDPETVFK and GVQGPTAVRK) or one HIV negative control peptide analyzed 
with flow cytometry. e, Tetramer staining of A-11:01 or A-03:01 CD8+ T cells with two CT45 
tetramers (AVDPETVFK and GVQGPTAVRK) and one HIV negative control tetramer 
analyzed with flow cytometry. f, Lysis of HLA-A11:01 positive 59M cell line by CD8+ effector 
T cells (A-11:01) at indicated effector:target ratios using a chromium release assay. Data are 
means r s.d. from two independent experiments. 
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Figure 3. CT45 mediates chemotherapy sensitivity  
a, Clonogenic survival assay of the ovarian cancer cell line OVCAR5 stably overexpressing 
CT45 (green) or control vector (purple) after carboplatin (5µM) treatment. Dots represent mean 
values from three independent experiments. Error bars show s.e.m. for each group. 
Representative images are shown above bars. b, Growth of OVCAR5-V5 (control plasmid) and 
OVCAR5-V5-CT45 tumors (N=5-8) over time during treatment with carboplatin (20mg/kg). 
Data are means r s.e.m. for each group. c, Interaction proteomics screen in OVCAR5 cells 
stably overexpressing FLAG-tagged CT45.  Protein enrichment (t-test difference) was 
calculated over the corresponding control cell line (FLAG tag alone) and plotted against the t-
test p-value (-log10). Dashed lines indicate significance thresholds. The bait protein CT45 
(green) and members of the PP4 complex (blue) are highlighted. Results represent 3 replicates 
per experiment group P < 0.01. d, Western blot of immunoprecipitated V5-tagged CT45 
protein. The co-enriched members of the protein phosphatase 4 complex, PP4R3α, PP4R3β and 
PP4C, are shown. e, Western blot of cleaved caspase-3, γH2AX, and CT45 following treatment 
with carboplatin (5µM) and paclitaxel (1.5nM). Day 5. f, Tail moment following carboplatin 
treatment at day 5 using a comet assay. Data are means + s.e.m. of 4 independent replicates 
(right panel). Representative images of comet assays are shown. OVCAR5 cells were treated 
with 5µM carboplatin and COV318 were treated with 2µM carboplatin. 
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Figure 4. CT45 interferes with chromatin dynamics after DNA damage 
a, Western blot analysis of OVCAR5 and OVKATE cell line pairs treated with carboplatin 
(5µM). Day 3. b, Immunofluorescence staining of KAP1-S824 (red) γH2AX (green) and DAPI 
(blue) in OVCAR5-V5 and OVCAR5-V5-CT45 cell line pair with or without carboplatin 
treatment (5µM) at day 3, 5, and 7. Data are means + s.e.m. of 5 independent replicates (right 
panel). Representative cells are shown left. c, CT45 positive 59M cells were collected and 
processed for a chromatin segregation assay as detailed in the Methods. PP4 complex members, 
KAP1, and HDAC2 were detected by western blot. d, Volcano plot of chromatin-
immunoprecipitation mass spectrometry (ChIP-MS) results for the V5-tag in OVCAR5-V5-
CT45 vs. OVCAR5-V5 cell line. Fold enrichment of V5-tagged CT45 over control cell line 
72 
 
(V5 tag alone) is plotted against the t-test p-value (-log10). Dashed lines indicate significance 
thresholds (FDR < 0.01, s0 = 2). e, Pathway enrichment analysis of proteins significantly co-
enriched with CT45 (right side of volcano plot in panel d). Most significant pathways are ranked 
by enrichment false-discovery rate. f, Fold change in nuclear sizes of OVCAR5-V5-CT45 and 
OVCAR5-V5 cells at day 5 with carboplatin (5µM) treatment normalized to untreated cells. 
Representative DAPI images are shown in upper panel. Bar plots represent nuclear sizes from 
5 independent experiments. Scale bar=10µM. Data are means r s.e.m. 
g, h OVCAR5-V5-CT45 and OVCAR5-V5 cells were collected and processed for the 
micrococcal nuclease (Mnase) assay as described in the Methods. Results are shown for 
untreated control samples at day 3 and day 3, 5 and 7 with carboplatin (5µM) treatment. DNA 
size profiles are illustrated in h. i, Proposed model of CT45 mediating chemosensitivity and 
long-term survival in metastatic HGSOC. 
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Extended Data Figure 1. Patient characteristics of proteomic cohort and proteomic depth 
per specimen. a, Clinico-pathologic parameters for the resistant and sensitive patients analyzed 
by proteomics. b, Proteomic depth per patient. Samples were measured as technical duplicate. c, 
Dynamic range of protein abundance of all quantified proteins. d, Correlation matrix of all measured 
samples based on Pearson correlation values. The proteomic comparison of independently 
prepared tissue of the same tumor is highlighted.  
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Extended Data Figure 2. CT45 gene homology and staining validation. a, Correlation analysis 
of disease-free survival time versus CT45 protein expression (log2) for 25 HGSOC patients. 
Patients highlighted in green were alive at the time of analysis. b, Amino acid alignment of the 10 
members of the CT45 gene family. Color shows level of conservation with red being 100% and 
blue being 0%.  
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Extended Data Figure 3. Patient characteristics of tissue microarray validation cohort.  
a, Clinico-pathologic parameters for patients with advanced stage serous papillary ovarian cancer 
included in the TMA validation cohort. Tumors were stained for CT45 and the staining was scored 
0-3. b, Kaplan-Meier survival analysis for overall survival based on CT45 staining scores from 
ovarian cancer TMAs. Advanced stage HGSOC patients comparing a staining score of 0 (N=82) 
versus 1+ (N=42) are compared.  
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Extended Data Figure 4. HLA-I peptidomics reveals presentation of CT45-derived 
peptides. a, Western blot of CT45 protein expression in 8 ovarian cancer cell lines. b, Schematic 
of immuno-peptidomics strategy to identify HLA-I binding peptides. HLA-I receptors with peptide 
complexes are pulled down with an antibody specific for HLA-I. Peptides are eluted from the HLA 
complex and identified by mass spectrometry. c, Histogram of the identified peptide lengths from 
the 59M cell line (length 8-11 amino acids) consistent with peptides that bind to HLA-I receptors. 
d, CT45A1 protein sequence. Identified HLA-I peptides are highlighted in red. e, Identified 
consensus clusters based on the GibbsCluster -1.0 tool for all identified 9-mer peptides (4,017) f, 
Binding motifs. HLA-I consensus binding motifs for the two largest clusters in e. The A11:01 motif 
is similar to A3:01. g, Comparison of MS/MS scans from experimentally identified HLA-I peptides 
(upper panel) and synthetic versions of the same peptides (lower panel). Y (red) and b-ions (blue) 
are shown.  
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Extended Data Figure 5. CT45-derived peptides are presented after DAC treatment. 
a, Western blot of CT45 protein expression in SKOV3ip1 (HLA-A*03:01, 68:01) following DAC 
treatment. 59M serves as positive control. b, Histogram of the identified peptide lengths from the 
DAC treated SKOV3ip1 cell line. c, Identified consensus clusters based on the GibbsCluster tool 
for all identified 9-mer peptides (5,146). d, HLA-I consensus binding motifs for the two largest 
clusters identified in c. The A68:01 motif is similar to A3:01. e, Stimulation of CD8+ tumor infiltrating 
HLA-A*03:01+ T cells isolated from ascites with CT45-derived peptides. Staining for Ki-67 and IFN-
γ of CD8+ T cells (A-03:01) after stimulation with 3 CT45 peptides (EGVQGPTAVR, GVQGPTAVR, 
and VAVDPETVFKR) or an EBV positive control or HIV negative control peptide analyzed with flow 
cytometry.  
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Extended Data Figure 6. CT45 sensitizes cancer cells to carboplatin. a, MTT of SKOV3ip1 
cells with or without 500nM DAC treated with increasing doses of carboplatin. Cells were pretreated 
with 500nM DAC for 72hr then cultured for 4 days and treated with carboplatin on day 7. The MTT 
was performed after 72hr with carboplatin treatment. b, Western blot of CT45 expression in ovarian 
cancer cell lines transduced with a CT45A5 lentivirus. c, Proliferation of OVCAR5 control (V5) or 
CT45 expressing cells with increasing concentrations of carboplatin. d, Cell cycle analysis of 
OVCAR5 control (V5) or CT45 expressing cells stained with propidium iodide. e, Clonogenic 
survival assay of the ovarian cancer cell line OVKATE stably overexpressing CT45 (green) or 
control (purple). Dots represent mean values from three independent experiments. Error bars show 
s.e.m. for each group. f, Interaction proteomics screen in the ovarian cancer cell line COV318 
stably over-expressing V5- tagged CT45. Protein enrichment (t-test difference) is calculated over 
the corresponding control cell line (V5 tag alone) and plotted against the t-test p-value (-log10). 
Dashed lines indicate significance thresholds (p < 0.005, s0 = 3). The bait protein CT45 (green) and 
members of the protein phosphatase 4 complex (blue) are highlighted. Results represent 3 
replicates per experiment group.  
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Extended Data Figure 7. CT45 is chromatin-bound independent of DNA damage. a, Chromatin 
fractionation of the OVCAR5-V5-CT45 cell line. b, Chromatin fractionation of the OVCAR5-V5-
CT45 cell line carboplatin c, ChIP-MS results targeting V5-tagged CT45 in the OVCAR5-V5-CT45 
cell line ± carboplatin. Fold enrichment is calculated over an IgG control antibody. The bait protein 
CT45 (green) and members of the protein phosphatase 4 complex (blue) are highlighted. Results 
represent 3 replicates per experiment group. d, e, ChIP-MS results targeting KAP1 in the OVCAR5 
cell line pair (d), and the 59M cell line (e). Protein enrichment (t-test difference) is calculated over 
the corresponding control (V5 control cell line for d or an IgG control antibody for e, and plotted 
against the t-test p-value (-log10).  
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METHODS 
Cell lines and reagents 
SKOV3ip1 (from Dr. Gordon Mills, M.D. Anderson Cancer Center, Houston, TX), OVCAR5 
(UCSF) and COV318 (from Dr. Gottfried Koneczny, UCLA) were cultured in DMEM, 10% 
FBS. 59M (ECACC) was cultured in DMEM, 10% FBS supplemented with 10µg/ml bovine 
insulin (Sigma, MO). OVKATE (from Dr. Gottfried Koneczny, UCLA) were cultured in 
RPMI-1640, 10% FBS. All cell lines were tested for mycoplasma and authenticated using a 
commercial service (CellCheck, IDEXX Bioresearch). Growth factor reduced Matrigel was 
from BD Biosciences (Rockville, MD). pLX304 (205) was a gift from Dr. David Root 
(Addgene plasmid #25890). pLX304-CT45A5 was acquired from DNASU Plasmid Repository 
(206-208) (clone HsCD00446210). 3xFLAG-CT45A1 was synthesized (Eurofins) and cloned 
into pcDNA3.1 (Invitrogen).  The Ki-CT45-2 antibody (used for WB and IMF) was a kind gift 
of Hans-Jürgen Heidebrecht. W6/32 monoclonal antibodies were purified from the growth 
medium of HB95 cells that were grown in CELLine CL-350 flask (Wilson Wolf Manufacturing 
Corporation, Minnesota) using Protein-A Sepharose (Invitrogen, CA). Antibodies acquired 
from Cell Signaling Technology were: γH2AX (9718, rabbit), Cleaved Caspase-3 (9661), anti-
rabbit IgG-HRP (#7074), and anti-mouse IgG-HRP (#7076), normal rabbit IgG (#2729). 
Antibodies acquired from Bethyl laboratories were: PP4C (A300-835A), PP4R3β (A300-
842A), KAP1 (A300-274A), pS824-KAP1 (A300-767A). Other antibodies used were: actin 
(Sigma, #A5441), anti-CT45A antibody (Sigma, SAB1301842), γH2AX (mouse, Thermo 
Scientific, #MA1-2022), and V5 (Life Technologies, #MA5-15253), PP4R2 (Atlas antibodies, 
HPA034695), PP4R3α (Atlas antibodies, HPA002568).  HLA-I types of cell lines were 
determined using high-resolution genotyping (Center for Human Genetics and Laboratory 
Medicine, Martinsried). 
 
FFPE tissue preparation for MS analysis 
Tumors were collected from patients undergoing primary debulking surgery by a gynecologic 
oncologist at the University of Chicago Hospital, Department of Obstetrics and Gynecology, 
Section of Gynecologic Oncology. Informed consent was obtained before surgery and the study 
was approved by the IRB of the University of Chicago. FFPE biobank specimens (5 serial 
sections, 10uM thick) were first deparaffinized as previously described (123). Areas containing 
70% or more tumor were macrodissected from the slide using a scalpel blade. Lysis was then 
carried out in 4% SDS, 10 mM Hepes pH 8.0 at 99°C for 60 min and by 15 min sonication 
(level 5, Bioruptor, Diagenode). Proteins in the cleared lysate (16,000 g, 10 min) were reduced 
with 10 mM DTT for 30 min and alkylated with 55 mM iodoacetamide for an additional 30 
min. 100 ug of proteins were purified from SDS by acetone precipitation and the protein pellet 
resolved in 100 μl 6 M urea/2 M thiourea (in 10 mM Hepes pH 8.0). LysC digestion was carried 
out with 1 μg of LysC for 3 h at room temperature. After adding 4 volumes of 50 mM 
ammonium bicarbonate buffer, 1 μg trypsin was added for tryptic digestion overnight. The next 
day, digestion was stopped by adding 1% TFA. Peptides were finally desalted on C18 StageTips 
and kept at -20°C until MS analysis. The majority of samples were injected twice for MS 
analysis. 
 
Liquid Chromatography (LC)-MS analysis of FFPE samples 
For LC-MS analysis, a Q Exactive(209) (Thermo Fisher Scientific) mass spectrometer was used 
coupled on-line to an EASY-nLC 1000 HPLC system (Thermo Fisher Scientific). Desalted 
peptides were separated on in- house packed C18 columns (75 μm inner diameter, 50 cm length, 
1.9 μm particles, Dr. Maisch GmbH, Germany) in a 250-min gradient from 2% to 60% in buffer 
B (80% acetonitrile, 0.5% formic acid) at 200 nl/min. Mass spectra were acquired in data-
dependent mode. Briefly, each survey scan (range 300 to 1,650 m/z, resolution of 70,000 at m/z 
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200, maximum injection time 20 ms, ion target value of 3E6) was followed by high-energy 
collisional dissociation based fragmentation (HCD) of the 5 most abundant isotope patterns 
with a charge ≥ 2 (normalized collision energy of 25, an isolation window of 2.2 m/z, resolution 
of 17,500, maximum injection time 120 ms, ion target value of 1E5). Dynamic exclusion of 
sequenced peptides was set to 45 s. All data was acquired using Xcalibur software (Thermo 
Scientific). 
 
Data analysis of proteomic raw files 
MS raw files were processed with the MaxQuant software (94) (version 1.5.3.15). The 
integrated Andromeda search engine (95) was used for peptide and protein identification at an 
FDR of less than 1%. The human UniProtKB database (August 2015) was used as forward 
database and the automatically generated reverse database for the decoy search. ‘Trypsin’ was 
set as the enzyme specificity. We required a minimum number of 7 amino acids for the peptide 
identification process. Proteins that could not be discriminated by unique peptides were 
assigned to the same protein group (94). Label-free protein quantification was performed using 
the MaxLFQ (103) algorithm (MaxQuant environment). Briefly, quantification was based on 
extracted high-resolution 3D peptide features in mass-to-charge, retention time and intensity 
space. Only common peptides were used for pair-wise ratio calculations. Protein ratios were 
then determined based on median peptide ratios. We required a minimum peptide ratio count 
of 1 to report a quantitative read-out and averaged the results from duplicate measurements of 
the same sample. The ‘Match Between Runs’ feature of MaxQuant was enabled to transfer 
peptide identifications across runs based on high mass accuracy and normalized retention times. 
Prior to data analysis, proteins, which were found as reverse hits or only identified by site-
modification, were filtered out.  
 
Tissue microarray 
Tissue microarrays (TMAs) were deparaffinized and rehydrated through xylenes and serial 
dilutions of EtOH to deionized water.  They were incubated in antigen retrieval buffer (Tris-
EDTA, pH 9, S2367, DAKO) and heated in steamer at over 97 ˚C for 20 minutes.  Tissue 
sections were incubated in a humidity chamber with CT45A antibody (1:200, Sigma, 
SAB1301842) for 1h at room temperature. The antigen-antibody binding was detected by Bond 
Polymer Refine Detection (DS9800, Leica Microsystems). Tissue sections were briefly 
immersed in hematoxylin for counterstaining and were covered with cover glasses. The stained 
TMAs were scored by an expert pathologist on a scale from 0-3. Data acquisition and analysis 
were blinded. Tumors were collected from patients undergoing primary debulking surgery by 
a gynecologic oncologist at the University of Chicago Hospital, Department of Obstetrics and 
Gynecology, Section of Gynecologic Oncology. Informed consent was obtained before surgery 
and the study was approved by the IRB of the University of Chicago. 
 
 
HLA-I peptidomics 
SKOV3ip1 cells were treated with 500nM 5-aza-2'-deoxycytidine (DAC) (Sigma, MO) for 3 
days with DAC refreshed every 24 hours. After treatment cells were cultured an additional 4 
days without DAC and collected for HLA-I purification at day 7. 59M cells were cultured under 
normal conditions prior to collection. HLA peptide purification, mass spectrometric analysis 
and data analysis were performed as previously described (163). We used the GibbsCluster-1.0 
Server tool (210) to perform Gibbs clustering analysis of all identified 9-mer HLA-I peptides 
as input using the default settings for 1-6 clusters. We compared the resulting motifs to the 
known and predicted motifs of the HLA-I alleles using the MHC motif viewer (211). Binding 
motifs were plotted using the Seq2Logo tool (212). The NetMHC 4.0 algorithm (213) was used 
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to model binding affinity of the identified peptides using default affinity thresholds for peptide 
binding (% rank 0.5 for strong binders and 2 for weak binders). 
 
T cell peptide stimulation 
Tumors and ascites were collected from ovarian cancer patients undergoing primary debulking 
surgery at the University of Chicago. TILs were thawed and resuspended in RPMI, 10% FCS 
(or human serum). Cells were adjusted to 2x106/ml in 24-well plates and cultured for 7-10 days 
in the presence or absence of 1Pg/ml peptide. After 3 days, 6IU/ml of rhIL-2 was added to the 
culture. Flow cytometric analysis of cultured cells was performed. 
 
Intracellular cytokine staining: In vitro expanded TILs were restimulated at the end of culture 
with the relevant peptide (100 ng/ml) in the presence of Brefeldin A (BD Biosciences) for about 
5-6 hours at 37qC in a 5% CO2 incubator. The cells were washed once with FACS buffer and 
stained with surface makers (anti-CD3, -CD8, live/dead stain) for 30 min on ice. Then the cells 
were fixed and permeabilization with the Cytofix/Cytoperm kit (BD Biosciences), and stained 
for cytokines using either anti-IFN-J antibody. After washing, the cells were analyzed on a flow 
cytometer.  
 
Tetramer staining: In vitro expanded TILs were stained with PE-labeled MHC Class I 
tetramers along with surface staining antibodies (anti-CD3,-CD8, live/dead stain) for 1 hour on 
ice. MHC class-I tetramers carrying CT45 antigen (GVQGPTAVRK AVDPETVFK) or HIV 
peptides (RLRPGGKKK or QVPLRPMTYK) were used. After washing, the cells were 
analyzed on a flow cytometer.  
 
51Cr release assays: The 59M tumor cell line (target cells) was labeled with 100 PCi 51Cr at 
37qC for 1 hour. Target cells were than washed three times in PBS, resuspended in culture 
medium at 1x105 viable cells/ml and 100 Pl was added per well of a 96-well U-bottom plate. 
In vitro expanded TILs (effector cells) were washed twice in culture medium and added to 
targets at the given ratios. Plates were shortly centrifuged to settle cells, and incubated at 37qC 
in a 5% CO2 incubator for 5 hours after which time the supernatants were harvested, transferred 
to small tubes and counted using a Liquid Scintillation Counter. Spontaneous 51Cr release was 
evaluated in target cells incubated with medium alone. Maximal 51Cr release was measured in 
target cells incubated with zap solution at a final concentration of 1% (v/v). Percent specific 
lysis was calculated as (experimental - spontaneous lysis/maximal - spontaneous lysis) times 
100. 
 
Clonogenic survival assay 
Cells were treated with different carboplatin concentrations for 48-72 hours. 2000 cells per 6-
well were then plated for 7-9 days in drug-free medium. Grown colonies were fixed and stained 
with 1% formaldehyde, 1% methanol and 0.05% Crystal Violet for 20 min. Colony numbers 
were then counted with the ColonyArea ImageJ plugin and plotted as percent of control on a 
logarithmic scale. 
 
Western blot analysis 
Cells were treated with indicated drugs for 3 days and then media was changed. On indicated 
day of collection, both adherent and non-adherent cells were collected in RIPA buffer (25mM 
Tris-HCl pH 7.6, 150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) 
supplemented with protease inhibitor cocktail (Thermo Scientific) and phosphatase inhibitor 
cocktail (Sigma). Lysates were incubated for 30 min on ice, sonicated and cleared by 
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centrifugation (15min, 14 000 rpm, 4°C). The quantity of protein was determined by BCA 
reagent (Pierce). The extracts were analyzed by SDS-PAGE on a 4-20% gradient gel (Bio-Rad). 
 
Comet assay 
Cells were treated with carboplatin for 3 days and then incubated an additional 2 days without 
drug. The comet assay was performed on day 5 as previously described(214). Briefly, 2.5e4 
cells/ condition were resuspended in 70uL 0.5% low melting point agarose (LMPA) at 37C and 
plated on a glass slide precoated with 1% agarose in PBS. Samples were allowed to solidify at 
4C for 20 minutes with a square cover glass. The cover class was gently removed and a second 
70uL layer of 0.5% LMPA was applied and again allowed to solidify. The cover glass was 
removed and the slides immersed in Comet Lysis solution (2.5M NaCl, 100mM EDTA, 10mM 
Tris, 0.015% Triton X-100, pH 10) for one hour at 4C and from this point forward protected 
from light. After lysis, the slides were equilibrated for 20 minutes in Comet Electrophoresis 
Buffer (0.3N NaOH, 1mM EDTA, pH 10) at 4C, and then run at 25V for 20 minutes. Then they 
were incubated at room temp in Comet Neutralization Buffer (0.4M Tris, pH 7.5) for five 
minutes twice, then in ddH2O for three minutes, stained with a 1:10,000 dilution of SYBR Gold 
in ddH2O, and finally mounted with a glass cover slip for imaging. Images were taken at 10X 
using a Zeiss AxioObserver A.1. At least 100 cells were quantified/ sample using the software 
OpenComet (215). Data shown is the mean + s.e.m. of 4 biological repeats. 
 
Mouse experiments 
Five million OVCAR5-V5 or OVCAR5-V5-CT45 cells suspended in a 1:2 solution of serum-
free media to growth-factor reduced matrigel were injected subcutaneously into the right and 
left flanks respectively, of 8 weeks old female athymic nude mice. After 5 days, treatment was 
administered through the tail vein 1 time/week at 20mg/kg. Sterile water served as the control 
treatment. Tumor growth was measured every 2-3 days using calipers until the tumor neared 1 
cm3 and was measured daily. Once the tumor reached 1 cm3 the mouse was sacrificed. 4 mice 
were removed from the study early due to ulcerations of the skin. All experiments were 
approved by the Institutional Animal Care and Use Committee of the University of Chicago. 
 
Affinity Purification and Mass Spectrometry 
Affinity purification coupled to mass spectrometry (AP-MS) was performed as previously 
described (216). For immunoprecipitation of cell lines ectopically expressing N-terminally 
tagged CT45A1 (3xFLAG tag) or C-terminally tagged CT45A5 (V5 tag), 30 ul of ANTI-FLAG 
M2 Affinity Gel (Sigma) or ANTI-V5 Affinity Gel (Sigma, CLONE V5-10), respectively, was 
used and incubated with 1 mg of total lysate overnight at 4°C. After three washing steps in 
washing buffer (150mM NaCl, 50mM Tris (pH 7.5), 5% glycerol, 0.05% IGPAL-CA-630) and  
three washing steps in a buffer containing 150mM NaCl, 50mM Tris (pH 7.5), 5% glycerol, 
elution was carried out by a partial on-bead digest. Peptides were finally desalted with C18 
StageTips prior to MS analysis. 
 
Chromatin experiments 
For chromatin immunoprecipitation coupled to mass spectrometry (ChIP-MS), freshly 
harvested cells were crosslinked with 1% formaldehyde for 10 min in PBS. Cells were lysed in 
IP Buffer (50 mM Tris-HCl (pH 8), 100 mM NaCl, 5mM EDTA (pH 8), 0.3% SDS, 1.7% 
Triton-X-100, supplemented with EDTA-free protease inhibitor cocktail (Roche) and 
phosphatase inhibitor cocktail (Roche)) and chromatin sonicated to an average size of 200-400 
bp. 1 mg of total cell lysate was incubated with 3 µg of respective antibody overnight at 4°C 
under constant rotation.  The next day, 30 µl of protein G-coupled agarose beads (Cell signaling 
technology) were added and incubated for 3h at 4°C under constant rotation. Antibody-bait 
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complexes were then washed three times with low salt wash buffer (50 mM HEPES pH 7,5, 
140 mM NaCl, 1% Triton), once with high salt wash buffer (50 mM HEPES pH 7,5, 500 mM 
NaCl, 1% Triton) and twice with TBS. Elution was carried out by a partial on-bead digest as 
recently described(216). Peptides were finally desalted with C18 StageTips prior to MS 
analysis.  
 
Chromatin fractionation was performed as described previously(194). Soluble proteins and 
proteins bound to open or compacted chromatin were separated by stepwise increasing the salt 
and nuclease (MNase) treatment. 1E7 cells were washed with PBS and 1 ml low salt buffer 
(LSB:10 mM HEPES [pH 7.4], 25 mM KCl, 10 mM NaCl, 1mM MgCl2, 0.1 mM EDTA). 
Pelleted cells were then resuspended in six times the packed cell volume (PCV) of LSB 
supplemented with protease and phosphatase inhibitor cocktail (Roche).  After snap freezing in 
liquid nitrogen, samples were quickly thawed and immediately centrifuged (10 min at 10,000 
rpm). The pellet was resuspended in a volume of high-salt buffer (HSB: 50 mM Tris-HCl [pH 
8.0], 5% [v/v] glycerol, 1 mM EDTA, 10 mM MgCl2, 400 mM KCl, supplemented with 
protease and phosphatase inhibitor cocktail), equal to 0.25 V of LSB. After centrifugation at 
10,000 rpm (supernatant = nucleoplasmic fraction), the pellet was resuspended in a volume 
nuclease buffer containing 10 U/ml MNase (NEB) and incubated at 37°C for 10 min and 
centrifuged for 5 min at 10,000 rpm (supernatant = chromatin fraction 1). The pellet was then 
resuspended in the same volume of nuclease buffer containing 100 U/ml MNase and incubated 
another 45 min at 37°C before an equal V of solubilization buffer (nuclease buffer + 2% [v/v] 
NP-40, 2% [v/v] Triton X-100, 600 mM NaCl) was added. After brief vortexing, samples were 
centrifuged (5 min, 10,000 rpm) and the supernatant collected (chromatin fraction 2). Finally, 
the pellet was resuspended in a volume of solubilization buffer and an equal V of denaturing 
buffer (50 mM Tris [pH 6.8], 1% [v/v] SDS, 100 mM DTT, 10% glycerol), briefly sonicated, 
boiled for 5 min, and centrifuged for 5 min at 10,000 rpm (supernatant = chromatin fraction 3).  
 
 
Chromatin relaxation was assayed using the micrococcal nuclease (MNase) assay as previously 
described (197), with a few modifications.  Briefly, nuclei from 1E6 cells were extracted with 
300 µl ice-cold lysis buffer (10 mM Tris-HCl (pH 7.5), 10 mM NaCl, 3 mM MgCl2 and 0.4% 
IGPAL-CA-630) on ice for 5 min. After centrifugation (2,000g for 5 min at 4°C), nuclei were 
washed two times in lysis buffer and one time in 500 µl digestion buffer (0.32M sucrose, 50mM 
Tris-HCl (pH7.5), 4mM MgCl2, 1mM CaCl2). Nuclei were then digested in digestion buffer 
with 50 gel units MNase (NEB) for 9 min at 27°C in a final volume of 100 µl. The reaction was 
stopped by adding a final concentration of 1% SDS and 15mM EGTA. Genomic DNA was 
purified and separated by gel electrophoresis (1.2% agarose). 
 
Immunofluorescence 
Cells were treated with 0 or 5 µM carboplatin on glass chamber slides. After 72hr, media was 
changed. At designated timepoints, slides were fixed for 10min at room temperature with 4% 
paraformaldehyde, cells were washed and permeabilized with PBS/0.1% Triton-X for 15min 
and then blocked for 1hr in blocking buffer (PBS/0.1%Triton-X/0.05% BSA/0.05% goat 
serum). Cells were washed three times and then were then incubated with primary antibody 
overnight diluted in blocking buffer at 4°C. Following three washes, cells were incubated with 
secondary antibody (diluted in blocking buffer) for 1hr at room temperature and then with 
Hoechst 33342 for 2min. Slides were mounted with ProLong Gold Antifade. Slides were 
imaged using a Zeiss LSM 510 microscope. Image analysis was performed using CellProfiler 
(217). A minimum of 100 cells/sample were analyzed. Data shown is the mean + s.e.m. of 4-5 
biological repeats. 
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Statistical analysis 
All statistical and bioinformatics analyses were done using the freely available software Perseus 
(218) (MaxQuant environment), R framework, Stata Version 14 (Stata Corp., College Station, 
TX) or GraphPad Prism (GraphPad). For pairwise proteomic comparisons, we used a 2-sided 
t-test statistic including a permutation-based false discovery rate (FDR) of 1% (5% for Fig. 1b 
after filtering for at least 10 out of 25 valid values) and an s0 value (219) of 2. Missing values 
were imputed based on a normal distribution (width = 0.15; downshift = 1.8). For analysis of 
clinicopathological data, comparisons between groups were performed using chi-squared or 
Fisher’s exact tests for categorical variables and Wilcoxon rank-sum tests for continuous 
variables. Overall survival and disease-free survival was compared between groups using the 
log-rank test. The association between CT45 levels and disease-free days was assessed using 
Pearson correlation. Pathway enrichment analysis (Fig. 4e) was performed based on a Fisher 
exact test with a Benjamini-Hochberg FDR cutoff of 0.02. GOBP, CORUM and Uniprot 
Keyword annotations were used for the analysis. 
Sample sizes were determined based on previous experience with the individual experiment 
except for animal studies where power calculations were used. With the exception of the tissue 
microarray analysis, no randomization or blinding was done for data acquisition or assessment 
of outcome. The mean and the standard error of the mean (s.e.m) indicating variance are 
reported for all graphs. For experiments making one comparison, data was analyzed using a 
two-tailed Mann Whitney U test to account for non-normal distribution of the data. For 
experiments with more than one comparison, One-Way ANOVA with Tukey’s multiple 
comparisons post-test was used. Before applying ANOVA, we first tested whether the variation 
was similar among the groups using the Bartlett’s test. Where the standard deviations were 
significantly different, a log2 transformation was applied to the data before analysis. Differences 
were considered significant if p< 0.05. 
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2.3 Manuscript 3 (in preparation): Compartment-resolved proteomics of 
ovarian cancer progression 
 
2.3.1 Project aim and summary 
 
 
 
 
 
 
HGSOC has been characterized at the genomic, transcriptomic and proteomic level 
(5, 16, 17). This has usually meant analyzing whole tumor tissues taken primarily from 
the ovaries, which are almost inevitably transformed. However, due to the large variety 
of different cell types present in the tumor microenvironment, as well as due to 
contributions from the extracellular matrix, data obtained from whole-tissue analyses 
inherently result in a mixture of different cell type specific read outs, which may limit 
data interpretation or at worst lead to incorrect conclusions. Consequently, whole-
tissue analysis usually requires further orthogonal validation to ensure the validity of 
the identified features. Not surprisingly, known HGSOC subtypes, namely 
‘differentiated’, ‘immunoreactive’, ‘proliferative’, and ‘mesenchymal’ (220, 221), are 
strongly linked to features representing the complex HGSOC microenvironment. 
However, given the availability of efficient and streamlined approaches tailored to 
analyze only the cell type of interest, more accurate results may be obtained than that 
of classical whole-tissue analyses. Laser-capture microdissection (LCM) allows 
isolating distinct cell types present in the tissue of interest, which increases the sample 
homogeneity and accuracy of the analytical read-out. We therefore wished to employ 
LCM coupled to state-of-the-art proteomic analysis to study the compartment-resolved 
proteomic composition and progression of HGSOC at high quantitative resolution.  
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In total, we collected 107 archival (FFPE) biobank samples obtained from 11 patients 
diagnosed with late stage HGSOC. This for the first time allowed to study the proteomic 
progression from early neoplastic STIC lesions (see introduction 1.1.1), through 
primary invasive fallopian tube and ovarian cancer, to omental metastasis, at a depth 
of in total a 7.000 proteins. Surprisingly, we found no shared metastatic proteome 
changes in the tumor compartments. There was a remarkably high proteomic 
correlation between primary and metastatic tumors from the same patients, similar to 
previous observations in studies of colorectal (124) and luminal breast cancer (125). 
However, by additionally analyzing the proteomic changes in the adjacent tumor 
microenvironment (stromal compartment), we identified a highly conserved stromal 
signature of HGSOC metastasis to the omentum. We validated our findings by a 
candidate-driven follow-up approach, which provided new functional insights into the 
complex metabolic and epigenetic interplay between HGSOC and its associated 
microenvironment. Of particular note, Nicotinamide N-Methyltransferase (NNMT), a 
metabolic enzyme that is associated with reduced S-adenosyl methionine (SAM) levels 
in cancer cells (222) and with loss of repressive H3K27me3 chromatin marks in 
differentiating human embryonic stem cells (223), was highly and ubiquitously 
expressed in the stroma of all omental metastasis specimens. This was further 
confirmed in a larger patient cohort by using tissue microarray analysis (TMA) 
encompassing over 200 matched primary (fallopian tube or ovary) and metastatic 
omental sites. NNMT expression in primary tumor sites was less frequent (35%), 
however, these patients showed significantly lower disease-free and overall survival 
time compared to the NNMT stromal negative group. Further functional experiments 
revealed an important role of NNMT in HGSOC progression as a metabolic regulator 
for cancer-associated fibroblasts. Interestingly, NNMT abrogation leads to a reversal 
of the CAF phenotype in vitro and was associated with less pronounced tumorigenicity 
in an orthotopic mouse model. We plan future pre-clinical work to address whether 
selective inhibition of the enzymatic activity of NNMT could be used in a clinical setup, 
for example in combination with standard chemotherapy. 
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2.3.2 Contribution 
 
Ernst Lengyel proposed to investigate the ovarian cancer microenvironment by 
proteomics to Matthias Mann and myself in October 2012. Matthias Mann, Ernst 
Lengyel (University of Chicago), Mark Eckert (University of Chicago), and I initiated 
this project. I developed and optimized a highly sensitive and streamlined sample 
preparation method for the analysis of low input samples (few thousand laser-
microdissected tumor cells) obtained from FFPE biobank material. I then acquired all 
proteomic measurements of the study, analyzed and interpreted the data. This 
identified a conserved stromal protein signature of OvCa metastasis to the omentum. 
Mark Eckert (Univ. of Chicago) collected all tissue samples and worked on the follow-
up experiments. I designed all proteomics related figures and tables, and wrote the 
manuscript together with Mark Eckert, Ernst Lengyel and Matthias Mann. 
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2.3.3 Publication 
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ABSTRACT 
 
 
High grade serous carcinoma (HGSC) has a poor prognosis primarily due to its early 
dissemination throughout the abdominal cavity. Although genomic and proteomic approaches 
have provided snapshots of the proteogenomics of ovarian cancer (OvCa) (224, 225), a 
systematic examination of both the tumor and stromal compartments is critical to understanding 
OvCa metastasis. We therefore developed a label-free proteomic workflow to analyze as few 
as 5,000 microdissected cells from each compartment. The tumor proteome was stable during 
the progression from in situ lesions to metastatic disease; however, the stroma was 
characterized by a highly conserved proteomic signature associated with metastasis. This 
signature prominently included the methyltransferase enzyme nicotinamide N-
methyltransferase (NNMT). Functionally, stromal NNMT expression was necessary and 
sufficient for multiple functional aspects of the cancer associated fibroblast (CAF) phenotype, 
including the expression of CAF markers and the secretion of cytokines and oncogenic 
extracellular matrix. Stromal NNMT supported OvCa migration, proliferation, and in vivo 
growth and metastasis. Mechanistically, expression of NNMT in CAFs led to a depletion of S-
adenosyl methionine (SAM) and a reduction in histone methylation associated with gene 
expression changes in the tumor stroma. This work supports the use of ultra-low input 
proteomics to identify candidate drivers of disease phenotypes and reveals that NNMT is a 
central, metabolic regulator of CAF differentiation and cancer progression in the stroma. 
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INTRODUCTION 
 
 
While almost all serous OvCa harbor TP53 mutations (37), other recurrent mutations 
are rare and serous cancers are generally characterized by chromosomal instability (224, 226). 
HGSC has a relatively high proportion of stroma, but little is known about how interactions 
between the cancer cells and the surrounding extracellular microenvironment regulate tumor 
growth. Several reports describe the proteome of human ovarian cancer (173, 225, 227, 228) 
but none have differentiated between proteins in the stroma and the epithelial components of 
the tumor. Given that the stroma has a tumor-supporting role and co-evolves with the epithelial 
compartment during progression and metastasis (229-232), we set out to evaluate the proteome 
of both compartments in a systematic fashion. We reasoned that developments in mass 
spectrometry (MS)-based proteomics (172), particularly in ultra-high sensitivity analysis (233), 
could be combined with microdissection technology to obtain a more accurate and finely-
resolved picture of cancer progression. 
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RESULTS 
 
To elucidate the proteomic changes underlying OvCa progression in both the tumor and 
stroma, we identified a cohort of 11 patients which supplied access to HGSC tissue representing 
serous tubal in situ carcinoma (STIC), invasive fallopian tube (FT) lesions, invasive ovarian 
(Ov) lesions, and omental (Om) metastases (Supplementary Table S1; Fig. 1a). All tissues 
were collected prospectively during initial debulking surgery and all patients were 
chemotherapy naïve. For each patient and every anatomic site, both tumor and stromal 
compartments were microdissected and proteins extracted using an optimized high sensitivity, 
label-free proteomic workflow for low-input samples. We applied an MS1-based quantification 
method that enables quantification even when many of the peptide signals are insufficient for 
fragmentation (Methods). In total, we obtained 7,515 unique protein quantifications from 107 
analyzed samples, both tumor and benign, at a protein and peptide false-discovery rate (FDR) 
of less than 1% (94). A median of 5,080 and 4,511 proteins were quantified per tumor or stromal 
sample, respectively, and at similar dynamic ranges (Supplementary Table S2, Fig. 1b, and 
Extended Data Fig. 1a). Independently microdissected and processed specimens had excellent 
reproducibility (Pearson r = 0.986) (Extended Data Fig. 1b) and unsupervised hierarchical 
clustering robustly segregated tumor and stromal proteomes (Extended Data Fig. 1c). Tumor 
compartments were enriched for known markers of HGSC (e.g., PAX8, EPCAM, mucin-16, 
and folate receptor alpha) while stromal compartments were characterized by expression of 
ECM components and activated fibroblast markers (e.g., collagens, fibronectin (FN1), smooth 
muscle actin (SMA), and myosins) (Supplementary Table S2, Fig. 1c and Extended Data 
Fig. 1d). Pathway enrichment analyses revealed an over-representation of pathways involved 
in DNA replication and epithelial differentiation in the tumor compartment (Extended Data 
Fig. 2a) while the stromal compartment was dominated by extracellular matrix and 
transforming-growth factor beta (TGF-β) signaling pathways (Extended Data Fig. 2b).  
 
We hypothesized that proteins differentially expressed between anatomic sites would 
reveal functional effectors in both tumor and stromal cells associated with disease progression 
and metastasis. However, unsupervised hierarchical clustering of tumor compartments revealed 
no conserved proteomic signatures that correlated with anatomic sites, and only one protein 
(FABP4; upregulated in omental metastases and expressed at the tumor-stromal interface) was 
differentially expressed in any anatomic site to the depth of our analysis (FDR < 0.01, Fig. 1d 
and Extended Data Fig. 3a-c). Indeed, the tumor compartment was characterized by patient-
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specific protein signatures (ANOVA FDR < 0.01, Extended Data Fig. 3a, c) that likely reflect 
the molecular heterogeneity of HGSC between different patients (224, 225). In contrast, 
clustering of stromal samples led to a clear grouping of all omental samples, suggesting a 
conserved stromal response associated with metastasis across all patients (Supplementary 
Table S3 and Extended Data Fig. 3c). Moreover, a comparison between the four anatomic 
sites (STIC, FT, OV, and OM) identified 128 proteins significantly differentially expressed in 
these stromal compartments (Extended Data Fig. 3a). Interestingly, the omental metastasis 
group contributed most to this list of significant proteins. To identify the drivers with the 
strongest expression differences between primary and metastatic stroma, we compared all 
primary (FT or OV) and metastatic (OM) stromal sites in a pairwise fashion. This resulted in a 
set of 60 proteins which were universally up- or downregulated in all omental metastases (FDR 
< 0.01, Fig. 1d).  
The stromal signature consisted of 21 up- and 39 downregulated proteins, including 
FAP, LOX, TNC, and VCAN, which are proteins known to have tumor-supporting roles in the 
stroma (Fig. 1e and Extended Data Fig. 3d). Downregulated proteins included negative 
regulators of TGFβ such as LTBP4 (234) and SDPR (235). The 21 upregulated proteins that 
make up the stromal signature were all highly enriched in the mesenchymal TCGA subtype 
(Extended Data Fig. 3e) (5). Other proteins, such as ENPP1, PYCR1, and COPZ2, had no 
previously described roles in the tumor stroma or the biology of cancer associated fibroblasts 
(CAFs). Due to its biochemical activity and roles in epigenetic regulation, upregulation of 
nicotinamide N-methyltransferase (NNMT) in the omental stroma was an interesting target. 
NNMT transfers a reactive methyl group from S-adenosyl methionine (SAM) to nicotinamide 
(NA) to generate S-adenosyl homocysteine (SAH) and the metabolically inert product 1-methyl 
nicotinamide (1-MNA) (Fig. 2a). This activity generates a methyl sink in the form of 1-MNA, 
that leads to a depletion of SAM and a reduction in the global methylation potential of the cell 
(222, 236). NNMT-mediated SAM depletion leads to an attenuation of histone and protein 
methylation in cancer cells, adipocytes, and embryonic stem cells (222, 223, 237-239). 
NNMT was universally elevated in the metastatic stroma of OvCa patients, as assessed 
by proteomics and IHC (Fig. 2b-c and Extended Data Fig. 4a), and was significantly increased 
in transformed omental tissue compared to benign omental stroma (Fig. 2c and Extended Data 
Fig. 4b). A TMA encompassing over 200 matched primary (FT or Ov) and metastatic OvCa 
samples confirmed that NNMT protein expression was primarily localized in the stroma of both 
omental and peritoneal metastases (Fig. 2c-d). Tumor expression of NNMT did not vary 
significantly by anatomic site (Extended Data Fig. 4c). In both syngeneic (240) and 
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autochthonous (241) mouse models of HGSC, NNMT was highly expressed in the stroma of 
omental metastases (Extended Data Fig. 4d). High stromal NNMT was also observed in breast 
and colon cancer stroma, suggesting that stromal NNMT expression may be a general feature 
of CAFs in multiple cancer types (Extended Data Fig. 4e). 
CAFs are differentiated from normal fibroblasts by expression of CAF markers, 
secretion of oncogenic ECM components, production of pro-tumorigenic cytokines, 
cytoskeletal rearrangements associated with SMA expression, and increased ability to contract 
collagenous matrices (230). Knockdown of NNMT in OvCa CAFs led to a reversion of cell 
morphology to one that more closely resembled normal omental fibroblasts (NOFs) (Fig. 2e 
and Extended Data Fig. 5a-c). Knockdown or overexpression of NNMT led to significant 
perturbation of its activity, as assessed by 1-MNA production using MS (Fig. 2f). CAF markers, 
including SMA and fibronectin, were decreased upon NNMT knockdown and increased with 
its overexpression (Fig. 2g and Extended Data Fig. 5c-e). Analysis of TMAs also revealed 
that high stromal NNMT expression correlated with increased fibronectin levels (Extended 
Data Fig. 5f). Functionally, NNMT knockdown attenuated CAF collagen contractility (Fig. 
2h) and globally affected CAF gene expression (Supplementary Table S4 and Extended Data 
Fig. 5g). In particular, gene set enrichment analysis (GSEA) demonstrated a robust and 
significant enrichment of genes upregulated in the proteomic signature of metastasis and the 
TCGA mesenchymal subtype, including COMP, FN1, and COL11A1 (Fig. 2i and Extended 
Data Fig. 5h).  
Because NNMT regulated multiple aspects of the CAF phenotype and significantly 
altered expression of numerous genes, we hypothesized that high stromal NNMT expression 
drives gene expression through hypomethylation of DNA, RNA, or histones via attenuation of 
the SAM/SAH ratio (i.e., methylation potential of the cell) (222). Indeed, methylation potential 
was directly regulated by NNMT expression, as assessed by mass spectrometry. NNMT 
knockdown increased the SAM/SAH ratio more than 2.5-fold, while NNMT overexpression 
led to a greater than 5-fold decrease (Fig. 3a). Since global DNA methylation was not 
significantly increased upon NNMT knockdown (Extended Data Fig. 6a), we hypothesized 
that NNMT-mediated histone hypomethylation drove the CAF phenotype. 
Histone H3 lysine methylation and acetylation are tightly coupled to transcriptional 
activity (242-244). To understand how the observed alterations in methylation potential impact 
histone methylation, we performed targeted proteomics of histone H3, using a multi-reaction 
monitoring approach to quantify relative levels of histone methylation (243). NNMT 
knockdown led to an increase in histone methylation at residues associated with transcriptional 
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regulation (243, 244), including a significant increase in H3K4 and H3K27 trimethylation 
(me3; Fig. 3b). Immunoblotting confirmed that H3K27 trimethylation was perturbed upon 
knockdown or overexpression of NNMT (Fig. 3c and Extended Data Fig. 6b). Cartilage 
oligomeric matrix protein (COMP), an extracellular matrix protein (232), was the most 
upregulated protein in all metastatic stroma samples of the omentum when compared to the 
corresponding primary sites (FT and OV) (Fig. 1d and Extended Data Fig. 3c). COMP is 
highly expressed in the stroma of omental metastases (Fig. 3d) and tightly regulated by NNMT 
expression (Fig. 3e). We therefore investigated histone methylation (H3K27me3) at the COMP 
promoter as a proof-of-concept. Indeed, knockdown of NNMT led to a significant increase in 
H3K27me3 occupancy at the COMP promotor, as assessed by chromatin immunoprecipitation 
(Fig. 3f-g). Treatment of CAFs expressing shNNMT with the EZH2 histone methyltransferase 
inhibitor, DZNep, or the general histone methyltransferase inhibitor, 3DZA, was sufficient to 
revert the CAF phenotype by restoring expression of CAF markers and promoting collagen 
contractility (Fig. 3g-I and Extended Data Fig. 6c) (230). 
Functionally, CAFs support and accelerate tumor growth, progression, and metastasis 
(230, 245, 246). Stromal NNMT regulates the expression of several pro-tumorigenic cytokines 
(Supplementary Table S4) including IL-8, CXCL10, and CCL5 (Extended Data Fig. 7a). 
Overexpression of NNMT in normal fibroblasts promoted cancer cell proliferation in response 
to conditioned media; conversely knockdown of NNMT in CAFs attenuated cancer cell 
proliferation (Fig. 4a). Extending these findings, knockdown of NNMT in CAFs inhibited 
cancer cell chemotaxis (Fig. 4b). To understand if stromal NNMT activity is required for tumor 
progression in vivo, we co-injected HGSC cells expressing luciferase with CAFs expressing 
shCtrl or shNNMT constructs. Knockdown of NNMT specifically in the stromal compartment 
reduced in vivo proliferation and overall tumor burden (Fig. 4c). To determine if NNMT is 
sufficient to promote ovarian cancer progression, we utilized an orthotopic model in which ID8 
mouse ovarian cancer cells are co-cultured with conditioned media from fibroblasts expressing 
control or NNMT overexpression constructs for 48 hours before intraperitoneal injection (Fig. 
4d). Tumor seeding of the omentum was significantly increased when ID8 cells were pre-
treated with conditioned media from fibroblasts overexpressing NNMT (Fig. 4d). 
Although NNMT was primarily expressed in the stroma of omental metastases, a subset 
of patients had high stromal expression of NNMT in primary sites (37%; ovary and fallopian 
tube) (Fig. 2e). The TMA used to validate stromal NNMT expression was also used to evaluate 
the prognostic role of NNMT in chemo-naïve,  high grade serous cancer (247). We found that 
elevated stromal NNMT at primary sites was associated with a significantly worse recurrence-
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free (median survival of 349 versus 598 days) and overall survival (737 versus 1489 days; 
Supplementary Table S5, Fig. 4e, and Extended Data Fig. 7b). In contrast, expression of 
NNMT in the tumor compartment was not predictive of survival or recurrence (Extended Data 
Fig. 7c-d). High stromal NNMT expression was significantly associated with platinum 
resistance in our patient cohort (Supplementary Table S5). 
 
 
DISCUSSION 
 
In summary, by using laser-capture microdissection combined with an optimized high-
sensitivity proteomic pipeline we demonstrated the quantification of up to 5,000 unique proteins 
from as few as 5,000 cancer cells. This approach enabled compartment-resolved proteomic 
analysis of both tumor and stromal compartments across the HGSC progression series from 
STIC to metastatic tumors and revealed a metastatic stromal signature. Our results emphasize 
the molecular heterogeneity of ovarian cancer while also revealing that tumor proteomes within 
individual patients are comparatively stable during progression. In a recent genomic study of a 
subset of the patient cohort described here, we observed similar genomic alterations across all 
anatomic sites, including STIC, within each patient (248). Of note, we did not observe a 
proteomic signature that differentiated STIC from advanced cancers, suggesting STIC already 
possess the molecular aberrations at both the genomic and proteomic levels associated with a 
fully developed cancer. Despite the marked genetic and proteomic heterogeneity of epithelial 
OvCa across patients, the stromal proteome was remarkably uniform and characterized by high 
NNMT expression. 
NNMT metabolically reprograms the epigenome of the stroma to promote OvCa 
progression in a manner that co-opts NNMT-dependent processes that occur during embryonic 
stem cell priming (223), metabolic syndrome (237), and tumor cell aggressiveness (Fig 4f) 
(222). The specificity of the observed methylation patterns, marked by H3K27 and H3K4 
hypomethylation, is likely due to differences in the affinity of different methyltransferase 
enzymes for SAM (222, 249, 250). Although CAF gene expression can be regulated by 
chromatin modifiers and DNA methylation (251, 252), metabolically-defined histone 
methylation plays a central role in defining the pro-tumorigenic role of the stroma. Inhibition 
of NNMT activity by knockdown led to a reversion of the CAF phenotype, suggesting stromal 
methyltransferase activities can be targeted to normalize the tumor stroma. This study suggests 
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that epigenetic targets in the stroma may play key roles in the response to inhibitors targeting 
regulators of the epigenome undergoing clinical testing. 
 
 
 
 
 
 
 
 
 
 
Fig.1: Compartment-resolved proteomics of ovarian cancer progression reveal a stromal 
signature of HGSC metastasis. (a) Tumor and stromal compartments were microdissected from an 
ovarian cancer progression series (serous tubal intraepithelial carcinoma, STIC; invasive fallopian tube, 
FT; ovarian lesions, Ov; and omental metastases, Om) and label-free, quantitative shotgun proteomics 
performed to identify proteins differentially expressed in tumor and stromal compartments across all 
anatomic sites. (b) Number of unique proteins quantified by MaxLFQ in each anatomic compartment. 
(c) Ranking of proteins by expression in tumor compartment versus stromal compartment identifies 
established markers characterizing tumor (green) and stromal (purple) components of the tumor. (d) 
Volcano plots comparing omental metastases to primary sites (FT and Ov) in tumor (left) and stromal 
(right) compartments. Significantly differentially expressed proteins are highlighted in green (tumor) or 
purple (stroma), n = 11 patients. (e) Heatmap of proteins upregulated in omental stromal signature of 
metastasis (bottom axis) across all patients (rows) and anatomic sites (STIC, FT, Ov, and Om). Warmer 
colors are higher expression. Missing values are grey; missing samples are white. 
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Fig. 2: NNMT is upregulated in the stroma of HGSC metastases and regulates the CAF phenotype. 
(a) NNMT catalyzes the transfer of a reactive methyl group from S-adenosyl-L-methionine (SAM) to 
nicotinamide (NA), generating S-adenosyl-L-homocysteine (SAH) and the metabolically inert product 
1-methylnicotinamide (1-MNA), thus depleting intracellular SAM and reducing methylation potential. 
(b) Stromal NNMT expression from quantitative proteomic analyses reveals significant upregulation in 
omental metastases, n = 11 patients. (c) Representative NNMT immunohistochemistry (IHC) confirms 
elevated expression of NNMT in omental and peritoneal (Periton) metastases and stromal specificity. 
NNMT is not expressed in the benign omentum. (d) Stromal NNMT expression is elevated in omental 
(Om) and peritoneal metastases compared to ovarian sites. (e) Morphology of CAFs expressing 
indicated constructs (green; GFP). (f) Production of 1-MNA as assessed with HPLC-MS is attenuated 
upon knockdown and enhanced upon overexpression of NNMT, n = 3 biological replicates. (g) 
Knockdown of NNMT in CAFs attenuates expression of CAF markers (fibronectin, Fn1; smooth muscle 
actin, SMA), while NNMT overexpression in normal fibroblasts increases expression of the markers. 
(h) Knockdown of NNMT in CAFs reduces collagen contractility; overexpression in normal fibroblasts 
(3T3) increases contractility, n = 3 biological replicates. (i) Gene set enrichment analysis reveals that 
genes regulated by NNMT in CAFs are enriched for components of the stromal signature of metastasis. 
All error bars are standard error of mean (SEM). *p < 0.05; ***p < 0.001.  
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Fig. 3: NNMT regulates histone methylation to drive the CAF phenotype. (a) HPLC-MS relative 
quantification of SAM and SAH levels of CAFs (left) and normal fibroblasts (right; 3T3, 293T, and 
normal omental fibroblasts) expressing the indicated constructs, n = 3 biological replicates. (b) 
Quantitative proteomics of histone H3 methylation in CAFs expressing shCtrl or shNNMT constructs 
following immunoprecipitation. me1=mono-methylation; me2=dimethylation; me3=trimethylation. 
Significantly altered histone marks are highlighted in red. n = 3 technical replicates. (c) Immunoblotting 
of H3K27me3 in fibroblasts overexpressing NNMT (top) or CAFs transfected with the indicated 
siRNAs. (d) Representative immunohistochemistry of COMP in an omental metastasis. T=tumor; 
S=stroma. (e) qRT-PCR analysis of COMP expression in CAFs expressing the indicated constructs, n 
= 3 biological replicates. (f) Schematic of H3K27me3 peaks (maroon) and primers targeting COMP 
promoter region (red) in relation to COMP transcriptional start site. Relative H3K27me3 enrichment as 
determined with qPCR in CAFs expressing shCtrl or shNNMT constructs, n = 2 biological replicates. 
(g) Immunoblot and (h) qRT-PCR of CAF markers after treatment with the EZH2 histone 
methyltransferase inhibitor DZNep, n = 3 biological replicates. (i) Collagen contractility of CAFs 
expressing shNNMT construct treated with DZNep, n = 3 biological replicates. All error bars are SEM. 
*p < 0.05; **p < 0.01; ***p < 0.001.   
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Fig. 4: Stromal NNMT supports HGSC progression and is associated with a poor prognosis. (a) 
Proliferation (doubling time) of HeyA8 and TYKnu OvCa cells following treatment with the indicated 
conditioned media (CM). Proliferation rate increases (doubling time decreases) with NNMT 
overexpression and decreases (doubling time increases) upon knockdown, n = 3 biological replicates. 
(b) Representative images (left) and quantification (right) of chemotaxis of the indicated OvCa cells in 
response to conditioned media from CAFs expressing the shCtrl or shNNMT constructs, n = 3 biological 
replicates. (c) In vivo proliferation and total tumor burden of luciferase-labeled HeyA8 cells co-injected 
with CAFs expressing shCtrl or shNNMT constructs. 9 tumors per group. (d) Schematic of experimental 
design (top). Representative images and quantification of omental adhesion of luciferase/GFP-labeled 
ID8 mouse OvCa cells treated with conditioned media from fibroblasts expressing the indicated 
constructs, n = 7 mice per group. (e) A TMA assembled from 92 patients with chemonaïve HGSC and 
matched primary and metastatic tumors was stained for NNMT. Representative images of ovarian 
tumors expressing low (top) or high (bottom) levels of stromal NNMT (left). Kaplan-Meier overall 
survival curves for patients with low (black) or high (red) stromal expression of NNMT in ovarian sites 
(right). (f) Stromal NNMT drives ovarian cancer progression by metabolic regulation of histone 
methylation which causes epigenetic and transcriptional changes in the stroma that promote OvCa 
proliferation, migration, and metastasis. All error bars are SEM. *p < 0.05.  
102 
 
 
Extended Data Fig. 1: Quantitative proteomics of low-input samples. (a) MaxLFQ label-free 
quantitation values and dynamic range are similar across all anatomic sites and in both tumor (left) and 
stroma (right) samples. (b) Example of experimental replicates of microdissection, protein extraction, 
and quantitative proteomics with Pearson correlation of >0.95. (c) Unsupervised hierarchical clustering 
of all proteomic samples leads to clustering of tumor and stromal samples characterized by proteomic 
signatures associated with the indicated pathways. (d) One-dimensional principal component analysis 
of all tumor and stromal samples. Component 1 accounts for 23.5% of the total data variation. 
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Extended Data Fig. 2: Gene network analysis of HGSC progression proteomics. Gene network 
analysis of (a) all tumor compartments and (b) all stromal compartments in the progression series (Fig. 
1a). Pathways in more than one network are filled with more than one color.  Size of circles correlates 
with number of genes in the pathway; pathways will shared genes are connected with lines.  
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Extended Data Fig. 3: HGSC progression is characterized by patient-specific signatures in the 
tumor compartment and site-specific signatures in the stroma. (a) Left and right panels show 
proportions of all proteins that are significantly different by patient (purple) or anatomic site (blue). 
1,474 proteins are differentially expressed in the tumor compartment between patients while only 30 
stromal proteins are significantly different between patients. In respect to the compartment 
(tumor/stroma, blue) one protein is different in the tumor compartment (FABP4) while 128 proteins are 
differentially expressed in the stroma. (b) Boxplot of FABP4 expression in tumor (left) and stromal 
(right) compartments during progression. (c) Unsupervised hierarchical clustering of tumor (left) and 
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stroma (right) proteins reveals patient-specific clustering in the tumor compartment while the stromal 
samples cluster by anatomic site. For example, all STIC samples (green) across all patients cluster 
together. (d) Unsupervised hierarchical clustering of differentially expressed stromal proteins (Fig. 1d) 
reveal anatomic site-specific clusters, including a core signature of 21 proteins consistently upregulated 
in the stroma of omental metastases (box). (e) Expression of 21 protein signature in the TCGA subtypes 
reveals enhanced expression in mesenchymal subtype.  
 
  
106 
 
 
 
Extended Data Fig. 4: NNMT is highly expressed in the stroma of ovarian cancers. (a) 
Representative IHC of NNMT in omental metastases from individual patients reveals strong expression 
restricted to the stromal compartment. (b) Quantitative proteomics of the stroma of omental metastases 
(n = 11 patients) and normal omental tissue (nOm; n = 6 patients) find significantly elevated expression 
of NNMT in the metastatic stroma. (c) Quantification of tumoral NNMT staining in TMA analysis. (d) 
Representative IHC of NNMT in the stroma of metastases in an autochthonous model of ovarian cancer 
(top, PAX8:TP53
mut
;PTEN
-/-
;BRCA1
mut
) and a syngeneic model (bottom, ID8 intraperitoneal 
xenograft). (e) NNMT is expressed in the stroma of breast and colon cancers. ***p < 0.001. 
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Extended Data Fig. 5: NNMT promotes acquisition and maintenance of the CAF phenotype. (a) 
qRT-PCR for NNMT in CAFs expressing the indicated constructs, n = 3 biological replicates. (b) 
Immunofluorescence analysis of smooth-muscle actin (SMA) reveals attenuation of SMA stress fibers 
upon knockdown of NNMT in CAFs. (c) Representative brightfield images of normal omental 
fibroblasts and primary CAFs expressing shCtrl and shNNMT constructs reveal a reversion of CAF 
morphology to more closely resemble normal omental fibroblasts upon knockdown of NNMT. (d) 
Relative mRNA (n = 3 biological replicates) and (e) protein expression of fibronectin and SMA in CAFs 
expressing the indicated constructs. (f) Elevated stromal fibronectin is associated with NNMT 
expression. (g) Volcano plot of genes significantly regulated by NNMT upon knockdown in CAFs. 
Significantly differentially expressed genes are highlighted in red. Over-represented KEGG pathways 
are highlighted. (h) GSEA analysis of genes regulated by knockdown of NNMT in the TCGA 
mesenchymal signature. Error bars are 95% confidence intervals.  
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Extended Data Fig. 6: NNMT does not regulate DNA methylation and a general methyltransferase 
inhibitor is sufficient to induce expression of CAF markers. (a) Quantification of 5-methylcytosine 
(5-mC) in genomic DNA extracted from CAFs expressing the indicated constructs, n = 3 biological 
replicates. (b) Treatment of CAFs expressing and shNNMT construct with the general methyltransferase 
inhibitor 3-DZA reduces H3K27 trimethylation and increases SMA expression. Error bars are SEM; ns 
= not significant.  
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Extended Data Fig. 7: NNMT regulates pro-tumorigenic cytokines and is associated with a poor 
clinical outcome. (a) Representative images and quantification of a cytokine array of CAFs expressing 
the indicated constructs. Genes downregulated upon knockdown of NNMT are highlighted in blue, those 
increased in red. 100% relative to shCtrl is highlighted with dashed grey line (n = 2 technical duplicates). 
(b) Kaplan-Meier curve of recurrence-free survival of patients with low (black) or high (red) stromal 
NNMT expression in primary sites. NNMT expression in the tumor compartment at primary sites was 
not associated with (c) overall or (d) recurrence-free survival. Error bars are SEM.  
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METHODS. 
 
Patient samples. 
All patients included in the study underwent primary debulking surgery at the University of 
Chicago and were diagnosed with metastatic HGSOC (Supplementary Table S1). All human 
tissue samples were collected with informed consent under University of Chicago Institutional 
Review Board-approved protocols and in accordance with the Declaration of Helsinki. 
 
Laser-capture microdissection. 
Samples were prepared as previously described (248). Formalin-fixed, paraffin-embedded 
(FFPE) specimens were sectioned with a microtome (10 μm sections) and mounted on Leica 
PEN-membrane MembraneSlides (2 µm). Slides were deparaffinized with xylene and 
rehydrated through graded alcohols and water. Sections were stained with Mayer’s hematoxylin 
(Sigma) and dehydrated through graded alcohols and xylene. Tumor and stromal tissues were 
dissected with a Leica LMD 6500 laser microdissection system and tumor and stromal samples 
collected in 0.5 ml tubes. Depending on the FFPE specimen, an area of 1-5×106 Pm2 was 
collected (approximately 5-25,000 cells, as derived from dissected area × slide thickness / 
average mammalian cell volume of 2,000 Pm3, BNID 100434). 
 
FFPE tissue preparation for MS analysis. 
FFPE tissue lysis was adapted from previously described methods (132). Microdissected tissue 
was collected by pipetting 50 Pl of lysis buffer (50% 2,2,2-trifluoroethanol (TFE) and 5 mM 
dithiothreitol in 25 mM NH4HCO3 buffer) and centrifuged for 5 min at maximum speed to 
collect all remaining tissue. Samples were boiled at 95°C for 30 min and briefly centrifuged 
every 5-10 min. Subsequently, samples were sonicated for 10 min (level 5, Bioruptor Plus, 
Diagenode). After centrifugation for 10 min at maximum speed, supernatants were transferred 
to new tubes and alkylated with 20 mM iodoacetamide for 30 min in the dark. Samples were 
vacuum-concentrated for 30 min at 45°C (until approximately 10 Pl buffer remained). 40 Pl of 
fresh digestion buffer (10% TFE and trypsin in 50 mM NH4HCO3) was added in a trypsin 
(Promega) to total protein ratio of approximately 1:50. Digestion was carried out at 37°C 
overnight and digestion stopped by addition of 1% TFA. Samples were vacuum-evaporated to 
a volume of 5-10 Pl and resuspended in 100 Pl 0.2% TFA and 2% acetonitrile prior to desalting 
with C18 StageTips. Samples were stored at -20°C until MS analysis. 
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Liquid chromatography (LC)-mass spectrometry (MS) analysis. 
Quadrupole Orbitrap mass spectrometers (209, 253) (Q Exactive and Q Exactive HF, Thermo 
Fisher Scientific) coupled to an EASY-nLC 1000 HPLC system (Thermo Fisher Scientific) via 
a nano-electrospray source were operated in data dependent mode for LC-MS analysis of 
peptides. LC columns (75 μm inner diameter, 50 cm length) were packed in-house with C18 
particles (1.9 μm, Dr. Maisch GmbH, Germany). Peptides were separated with a 250 min HPLC 
gradient from 2% to 60% in buffer B (80% acetonitrile, 0.5% formic acid) at a flow-rate of 200 
nl/min. We employed a resolution of 70,000 at m/z 200 (60,000 for Q Exactive HF) for survey 
scans. The scan range was set to 300 to 1,650 m/z. Up to the 3 most abundant MS1 features 
(charge ≥ 2) were selected for high-energy collisional dissociation fragmentation at a resolution 
of 17,500 at m/z 200 (15,000 for Q Exactive HF). Dynamic exclusion of sequenced peptides 
was set to 45 s. Ion injection times and ion target values were set to 20 ms and 3×106 for the 
survey scans and 220 ms and 1×105 for the MS/MS scans, respectively. Data was acquired 
using Xcalibur software (Thermo Scientific). 
 
Data analysis of proteomic raw files. 
MS raw files were processed with MaxQuant (94) (version 1.5.3.15). The Andromeda search 
engine(95) of MaxQuant was used for peptide and protein identification. Andromeda is a 
probability-based search engine that employs a target-decoy approach to identify peptides and 
proteins at a false-discovery rate (FDR) of less than 1%. The UniProtKB database release 
(August 2015) was used as the forward database. MaxQuant automatically generated a reverse 
decoy database based on the provided forward database. Proteins which could not be 
distinguished based on the identified peptides were grouped into protein groups (94). The 
MaxLFQ(103) algorithm was used for label-free proteome quantification. MaxLFQ is a peptide 
intensity-based algorithm that makes use of high-resolution 3D peptide features in mass-to-
charge, retention time and intensity space.  
 
For each protein, peptide ratios were calculated in a pairwise manner and combined with protein 
ratios by calculating the median of all peptide ratios. Only the exact same peptide species was 
considered for each pairwise calculation. A least-squares analysis was then used to reconstruct 
the relative protein abundance across samples, which preserves the total summed intensity for 
a protein over all samples. A minimum of one ratio count for each pairwise comparison was 
required. The “Match Between Runs” feature of MaxQuant was enabled to match high-
resolution MS1 features between runs.  
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Proteomic bioinformatic analyses. 
All statistical and bioinformatics analyses were done using Perseus (218) (MaxQuant 
environment) or R framework. For pairwise proteomic comparisons, we used a 2-sided t-test 
statistic including a permutation-based FDR of 1% and an s0 value (219) of 2. Missing values 
were imputed based on a normal distribution (width = 0.15; downshift = 1.8). For pathway 
enrichment analyses, we used the Cytoscape plugin ClueGO. Enriched Gene Ontology 
annotations (GOMF) for the top 100 tumor or stromal proteins were calculated over the entire 
protein list and corrected by applying a Benjamini-Hochberg FDR of 5%.  
 
Tissue immunohistochemistry & immunofluorescence. 
FFPE tissue specimens were cut at 10 µm, deparaffinized in xylene, and rehydrated through 
graded ethanols. Following heat-mediated, sodium citrate antigen retrieval (10 mM sodium 
citrate, 0.05% Tween 20, pH 6), slides were stained with anti-NNMT (Santa Cruz G-4; 1:200) 
or anti-COMP (Thermo Fisher Scientific MA1-20221; 1:100) antibodies and processed with 
the VECTASTAIN Elite ABC HRP kit and DAB Substrate Kit (Vector Laboratories). Slides 
were counterstained with hematoxylin and dehydrated through graded alcohols and xylene. For 
immunofluorescence, slides were stained with fluorescently-labeled secondary antibodies 
(1:500; Thermo Fisher) and Hoechst 33258 (1:200; Molecular Probes). Confocal microscopy 
was performed with a Zeiss LSM510 and images processed with Image J 1.50j. 
 
Tissue microarray analysis. 
Assembly and construction of the tissue microarray have been previously described(254). 
NNMT immunohistochemical reactivity was scored without knowledge of clinical outcome by 
two experienced pathologists (S.M. and R.L.). Each sample was scored based on the percentage 
of positive cells in each compartment (0, no staining; 1, <30%; 2, 30–50%; 3, ≥50%); staining 
intensity was similar across all samples. Expression was considered “low” if the staining 
intensity was 0 or 1 and “high” if 2 or 3. Analysis was limited to the ovarian compartment of 
chemotherapy naïve patients with high grade serous pathology (n=97 patients; Supplementary 
Table S5). Kaplan-Meier survival curves and statistical analyses of overall and progression-
free survival were performed with GraphPad Prism 7 using the Mantel-Cox (log-rank) test. 
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Isolation of primary cells. 
CAFs were isolated from transformed omental tissue of patients with HGSOC. Normal omental 
fibroblasts (NOFs) were isolated from omental tissue from female patients undergoing surgery 
for benign conditions. CAFs and NOFs were isolated and validated as previously 
described(255). Tissues were thoroughly rinsed with PBS before mincing and digestion (12-18 
hr) with collagenase (3 mg/ml) and hyaluronidase (0.5 mg/ml) in 10% fetal bovine serum (FBS) 
in DMEM. Primary NOFs or CAFs adhered to tissue culture plastic within 24 hr. 
 
Cell lines. 
HeyA8 (Gordon Mills, MD Anderson, Houston, TX), 3T3 (American Type Culture Collection), 
293T (Lucy Godley, University of Chicago, Chicago, IL), and primary and immortalized CAF 
cells were cultured in DMEM supplemented with 10% FBS, MEM vitamins, MEM non-
essential amino acids, penicillin, and streptomycin. TYKnu cells (Gottfried Koneczny, 
University of California, Los Angeles) were cultured in MEM Alpha supplemented with 10% 
FBS, MEM vitamins, and MEM non-essential amino acids. ID8 cells were grown in DMEM 
supplemented with 4% FBS, Insulin-Transferrin-Selenium (5mg/ml; Gibco). All cells were 
cultured at 37 oC in a humidified incubator at 5% CO2. For experiments, CAFs and fibroblasts 
(3T3 and 293T cells) were grown in 10 µM methionine media. For some experiments, cells 
were treated with 1 µM DZNep or 1 µM 3DZA or vehicle (DMSO) control for 72 hr. All cells 
lines were Mycoplasma-negative and authenticated (IDEXX Bioresearch short tandem repeat 
marker profiling). 
 
Plasmids and expression. 
Short hairpin RNA (shRNA) oligonucleotides were designed using the shRNA Designer from 
BiOSETTIA (using accession number NM_006169) and cloned into the pLV-hU6-CMV-
Green backbone using the manufacturer’s protocol (Supplementary Table S7). CAFs were 
infected with non-targeting shCtrl or shNNMT constructs; 3T3 normal fibroblasts were infected 
with pLenti6 empty vector control or pLX304-NNMT overexpression vector (HsCD00442343; 
DNasu.org). CAFs were immortalized with pBABE-neo-hTERT (1774; Addgene). To produce 
lentivirus, 293T cells were seeded at 1 × 106 cells per 6 cm dish in DMEM supplemented with 
10% FBS. After 18 hr, cells were transfected with 1 µg expression vector, 0.9 µg pCMV-dR8.2 
packaging vector (8455; Addgene), and 0.1 µg pCMV-VSV-G expression vector (8454; 
Addgene) using Lipofectamine 2000. Viral supernatant was harvested at 48 and 72 hr post-
transfection, filtered through a 0.8 µm filter, and added to recipient cells with 4 µg/ml polybrene 
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for 8-12 hr before selection with puromycin (2 µg/ml) or blasticidin (1 µg/ml). For transient 
transfections, cells were seeded in a 6-well dish and transfected with 5 nmoles siRNA pools 
(GE Dharmacon) using Lipofectamine 2000 (Thermo Fisher) in OptiMEM Reduced Serum 
Media (Thermo Fisher).   
 
Targeted LC-MS/MS metabolomics. 
Cells were scraped into ice-cold PBS and isolated by centrifugation at 1,400 rcf at 4°C. Cell 
pellets were resuspended in 300 μl of an 80:20 mixture of MeOH/H2O. Internal deuterated 
standards, 10 nmol d3-serine, were added to the extraction solution for sample normalization. 
The mixture was sonicated (Fisher Scientific FB-505) for 5 s followed by a 10 min 
centrifugation at 16,000 rcf. The supernatant was collected and dried under N2 gas. The dried 
metabolites were resuspended in 30 µl of an 80:20 mixture of MeOH/H2O. Resuspended 
metabolites were separated by hydrophilic interaction chromatography with a Luna-NH2 
column (5 μm, 100 Å, 50 × 4.6 mm, Phenomenex). Mobile phase A was composed of 100% 
CH3CN, and mobile phase B was composed of 95:5 (v/v) H2O:CH3CN. For positive mode 
analysis, mobile phase A and B were supplemented with 0.1% formic acid. The gradient started 
with 0% B for 5 min and increased linearly to 100% B over 15 min with a flow rate of 0.4 
ml/min, followed by an isocratic gradient of 100% B for 10 min at 0.4 ml/min. Then, the column 
was equilibrated with 0% B for 5 min at 0.4 ml/min. Targeted MS/MS analysis was performed 
on an Agilent triple quadrupole LC-MS/MS instrument (Agilent Technologies 6460 QQQ). The 
capillary voltage was set to 4.0 kV. The drying gas temperature was 350 oC, the drying gas flow 
rate was 10 L/min, and the nebulizer pressure was 45 psi. The mass spectrometer was run in 
MRM mode. The following MS transitions were used to measure the indicated metabolites: NA 
(m/z 123.05 → 80.05), 1-MNA (m/z 137 → 94), SAM (m/z 399 → 250), SAH (m/z 385 → 136), 
and d3-Serine (m/z 109.07 → 63.1). Relative metabolite abundance was quantified by 
integrated peak area for the given MRM-transition. Data presented are representative of three 
independent biological experiments each containing three technical replicates for a given 
condition. 
 
Immunoblots and cytokine array. 
Cells were lysed in SDS lysis buffer containing 4% SDS and 10 mM HEPES, pH 8.5. Proteins 
were separated by SDS-PAGE on a 4-20% gel and transferred to a nitrocellulose membrane. 
The membrane was blocked with 5% non-fat dry milk (NFDM) in Tris-buffered saline with 
Tween 20 (TBST) for 30 min at RT and probed overnight with primary antibodies in 2% bovine 
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serum albumin in TBST at 4oC (Supplementary Table S6). After washing with TBST, the 
membrane was incubated with secondary antibodies (Thermo Fisher Scientific) conjugated to 
horseradish peroxidase at 1:5,000 dilution in 5% NFDM/TBST for 1 hr at RT. Proteins were 
visualized using Clarity Western ECL Substrate (Bio-Rad) or SuperSignal West Femto 
Substrate (Fisher Scientific). For the cytokine array, cells were seeded at 3×106 cells per 15 cm 
plate and grown for 72 hr in growth media. Conditioned media was collected, filtered through 
a 0.22 µm filter, and processed with the Proteome Profiler Human Cytokine Array Kit, Panel 
A (R&D Systems) following the manufacturer’s recommendations. Images were quantified 
using ImageJ. Full-length immunoblots are available in Supplementary Data.  
 
RT-qPCR. 
Total RNA was isolated and treated with DNase using RNeasy Mini Kit (Qiagen) according to 
the manufacturer’s protocol. Reverse transcription of 2 µg total RNA was carried out using the 
High Capacity cDNA Reverse Transcription Kit (ThermoFisher Scientific). qPCR was 
performed with TaqMan probes and TaqMan Fast Advanced Master Mix or custom primers 
(IDT) and Fast SYBR Green Master Mix on an Applied Biosystems StepOnePlus Real-Time 
PCR System and analyzed using the 2-ΔΔCt method (Supplementary Table S7).  
 
Collagen contractility assay. 
Indicated cells were trypsinized and diluted to 2×105 cells/ml in growth media. 400 µl of diluted 
cells were mixed with 200 µl of rat tail collagen (5 mg/ml; BD Biosciences) and neutralized 
with 5 µl 1 N NaOH and transferred to a 24-well plate. After 20 min of incubation, collagen 
gel was freed from the edges with a pipette tip and 600 µl of media added to the well. Collagen 
gels were incubated at 37 oC for 24 hr before fixation (4% paraformaldehyde) and staining with 
Eosin-Y (Sigma) before imaging to quantify collagen gel area with ImageJ 1.50j.  
 
Proliferation assays. 
Ovarian cancer cells were seeded at 1,000 cells per well in a 96-well plate and allowed to adhere 
for 24 hr before addition of conditioned media (72 hr) from the indicated cells. After 24 hr and 
48 hr, nuclei were visualized by addition of Hoechst 33258 (1:5000) and wells fluorescently 
imaged with a Zeiss Axiovert Observer.A1 to extract cell number and doubling time. Images 
were analyzed with ImageJ 1.50j. 
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Migration assays. 
40,000 cells in serum-free media were added to the top chamber of an 8.0 µm PET cell culture 
insert (Falcon) with conditioned media (72 hr) from indicated cells in the bottom reservoir. 
After 12 (HeyA8) or 18 (TYK-nu) hr cells were fixed with 4% PFA in PBS, representative 
fluorescent images collected with a Zeiss Axiovert Observer.A1, stained with 0.1% crystal 
violet, washed extensively with PBS, and dried. Crystal violet was released with 10% acetic 
acid and the absorbency measured at 520 nm to quantify relative migration.  
 
Gene expression analysis. 
RNA was collected from CAFs expressing shCtrl or shNNMT constructs (RNeasy Mini Kit, 
Qiagen) and 100 ng of total RNA analyzed on Illumina HumanHT-12 v4 Expression BeadChips 
(two biological replicates per group). cDNA labeling and hybridization were performed at the 
University of Chicago Functional Genomics core facility using protocols as suggested by the 
manufacturer. Data was processed with Illumina GenomeStudio GSGX 1.9.0 and in R 
(http://www.r-project.org) with the limma Bioconductor package and p values adjusted using 
Benjamini-Hochberg correction for multiple testing. All analyses were performed at the probe 
level. Annotation of significant (corrected p > 0.05) genes with KEGG pathways was performed 
with ConsensusPathDB-human (Release 32). Gene set enrichment analysis was performed with 
GSEA v2.2.0.  
 
DNA methylation quantification. 
Genomic DNA was extracted from indicated cells using the Wizard Genomic DNA Purification 
Kit (Promega). DNA methylation (5-methylcytosine) was quantified with the MethylFlash 
Global DNA Methylation (5-mC) ELISA colorimetric kit (Epigentek) and read with a 
Molecular Devices SpectraMax i3 plate reader per manufacturer’s protocol. 
 
Histone modification proteomics. 
Nuclei were isolated using gentle detergent treatment (0.3% NP-40 in NIB-250 buffer) of cells 
and centrifugation at 0.6 rcf and washed with NIB-250 buffer. Histones were acid-extracted 
and derivatized with propionic anhydride both prior to and following trypsin. Propionylated 
histone peptides were resuspended in 50µL water with 1% TFA and 3µL were injected in 3 
technical replicates on nanoLC/triple quadrupole MS which consisted of a Dionex UltiMate 
3000 coupled to a ThermoFisher Scientific TSQ Quantum triple quadrupole mass spectrometer. 
Buffer A was 100% LC-MS grade water with 0.1% formic acid and buffer B was 100% ACN. 
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The propionylated peptides were loaded onto an in-house packed C18 trapping column (4 cm 
× 150 µm; Magic AQ C18, 3µm, 200 Å -Michrom) for 10 min at a flow-rate of 2.5 µL/min in 
0.1% TFA loading buffer. The peptides were separated by a gradient from 1 to 35% buffer B 
from 5 to 45 min. The analytical column was a 10 cm × 75 µm PicoChip (1PCH7515-105H253-
NV New Objective) consisting of the same C18 material as the trapping column. The triple 
quadrupole settings were as follows: collision gas pressure of 1.5 mTorr; Q1 peak width of 0.7 
(FWHM); cycle time of 3 s; skimmer offset of 10 V; electrospray voltage of 2.5kV. SRM mass 
spectrometer transitions were developed as described previously (256). Data were analyzed 
using Skyline software (v3.5; MacCoss Lab, University of Washington) with Savitzky–Golay 
smoothing of peaks. Automatic peak assignment and retention times were checked manually. 
 
Chromatin immunoprecipitation. 
For chromatin immunoprecipitation (ChIP), freshly harvested cells were crosslinked with 1% 
formaldehyde for 10 min in PBS. Cells were lysed in IP Buffer (50 mM Tris-HCl (pH 8), 100 
mM NaCl, 5mM EDTA (pH 8), 0.3% SDS, 1.7% Triton-X-100, supplemented with EDTA-free 
protease inhibitor cocktail (Roche) and phosphatase inhibitor cocktail (Roche)) and chromatin 
sonicated (Biorupter Plus, Diagenode) to an average size of 200-400 bp. 1 mg of total cell lysate 
was incubated with 3 μg of respective antibody overnight at 4°C under constant rotation. After 
12 hr, 30 μl of protein G-coupled agarose beads (Cell Signaling Technology) were added and 
incubated for 3 hr at 4°C under constant rotation. Antibody-bait complexes were then washed 
and the bound chromatin eluted and reverse-crosslinked overnight. Samples were digested with 
RNase A for 2 hr at 37°C and DNA purified. 
 
Xenograft and syngeneic models. 
All animal experiments were approved by the University of Chicago Institutional Animal Care 
and Use Committee. Animals were not randomized and were not excluded. Sample size was 
based on pilot experiments and previous experience with the models. For the xenograft model, 
female nude mice (6-week old; Harlan) were subcutaneously injected in the left and right flanks 
with 100,000 HeyA8-Luciferase cells mixed with 200,000 CAFs expressing shCtrl or shNNMT 
constructs in 50% Matrigel (BD Biosciences) diluted with serum-free DMEM. Tumor burden 
was assessed 7 and 14 days after injection using a Xenogen IVIS 200. Luciferase imaging was 
performed via intraperitoneal injection of 100 μl D-luciferin (30 mg/ml in PBS; 0.22 μm sterile 
filtered) 10 min prior to imaging. Images were analyzed with Living Image 4.4 software. Mice 
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were sacrificed with isoflurane and tumors dissected to assess total tumor burden under blinded 
conditions. 
 
For the syngeneic model, ID8-luciferase/GFP cells were pre-treated with conditioned media 
(72 hr) from 3T3 cells overexpressing NNMT or a control construct for 48 hr. Animals were 
not randomized and were not excluded. 4 million pre-treated ID8 cells were injected 
intraperitoneally in 7 female C57BL/6 mice (6 weeks old; Harlan) and allowed to implant for 
14 hr before mice were sacrificed and the omentums harvested. Following imaging of the 
omentums (GFP), tissues were lysed with luciferase assay lysis buffer (Promega) and luciferase 
signal detected using a Lumat LB 9507 luminometer (Berthold Technologies). Analysis of 
tumor burden was conducted under blinded conditions. 
 
Statistical analyses. 
Statistical analyses were carried out using Perseus, Excel, R, and GraphPad Prism 7.01. Data 
are reported as mean ± standard error of mean (SEM), unless otherwise noted in figure legends. 
Number and type of replicates are indicated in the legends of the corresponding figures. Sample 
size was based on pilot experiments or previous experience with the models. P values are 
reported in the figure legends and were calculated with unpaired Student’s t-test for two groups 
or analysis of variation (ANOVA) with Tukey correction for experiments with more than two 
groups. For survival analyses, significance was assessed with log-rank (Mantel-Cox) test and 
hazard ratios calculated with log-rank test. P values less than 0.05 were considered significant 
(95% confidence interval).   
 
Data availability. 
Proteomic data is available online at 
 http://maxqb.biochem.mpg.de/mxdb/project/show/9373012627500 (username: review2; 
password: 5kcGES) and have been deposited to the ProteomeXchange Consortium 
(http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD006396) via the PRIDE 
partner repository with the dataset identifier PXD006396 (username: 
reviewer40116@ebi.ac.uk; password: XsCmGwHJ). Microarray data is available in the Gene 
Expression Omnibus (GEO) database (series GSE98267) and can be accessed at 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=wfuvgwkejtqdjol&acc=GSE98267. 
The MaxQuant quantitative proteomics software package and Perseus data analysis software 
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environment are freely available: http://www.biochem.mpg.de/5111733/software. 
Supplementary data is available online.  
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3 Discussion and Outlook 
 
3.1 The modern proteomic toolbox for the study of ovarian cancer   
 
The poor clinical outcome of HGSOC is linked to a variety of factors such as a scarce 
understanding of HGSOC origin and pathogenesis, late diagnosis at an advanced 
metastatic stage and frequently acquired chemotherapy resistance. Furthermore, a 
substantial amount of pre-clinical research has been performed on inadequate cellular 
models.  
 
Modern expression proteomics is powerful, comprehensive and comprised of a 
multitude of techniques to study protein expression, function, regulation, spatio-
temporal dynamics or interactions. Remarkably, each of these can be achieved today 
in single shotgun proteomics runs. Even global proteome studies that aim at 
quantifying ideally the entirety of all expressed proteins in a single cellular system have 
reached a nearly complete detection of all expressed proteins (92, 112). This greatly 
impacts on systems biology-based projects that aim at obtaining a global proteomic 
portrait of the sample of interest. 
 
In manuscript 1 of this thesis, I addressed proteomic similarities and differences 
across 30 frequently used ovarian cancer cell lines. I showed that a single-run (4h) 
workflow can be used to detect and quantify roughly 8,000 proteins across the 
measured cell lines. These numbers could only be achieved previously by extensive 
protein or peptide pre-fractionation, which inevitably increases the analysis time and 
decreases the throughput. This was the first study to apply the single-run workflow to 
a large number of cell lines related to a single disease context. Our data revealed that 
state-of-the-art proteomics can be used to identify distinct cell line groups resembling 
HGSOC tissue at the proteomic level. This is of great relevance for the OvCa 
community as it allows selecting the most appropriate cell lines for any pre-clinical 
investigation. Especially in conjunction with the previous genomic characterization of 
ovarian cancer cell lines (12), the data will be useful for finding the most accurate 
cellular models for a variety of research questions. As a proof of concept, we used the 
proteomic resource to predict the treatment response to all-trans-retinoic acid (ATRA). 
Two receptors have been linked to differential cellular ATRA responses, CRABP2, 
which mediates the anti-oncogenic signaling of ATRA, and FABP5, which induces pro-
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oncogenic signaling (169). The presence of a high CRABP2/FABP5 ratio was 
previously shown to promote apoptosis in cancer cells following treatment with ATRA, 
whereas higher FABP5 levels caused an opposing effect by mediating cell survival 
(169).  Our data indeed revealed that the group of cell lines with high expression levels 
of CRABP2, compared to FABP5, decreased proliferation or changed morphology to 
a more differentiated phenotype. This clearly indicated the beneficial, anti-oncogenic 
ATRA response. Conversely, we observed ATRA-induced proliferation in cell lines that 
showed low CRABP2 expression, clearly reflecting the reported FABP5-mediated pro-
oncogenic signaling pathway. With respect to future clinical trials, these observations 
may help to select patients potentially benefiting from ATRA-based therapy. 
 
The identified cell line groups further revealed a potential cell-of-origin based 
classification into OSE-derived and FTEC-derived. This is of particular importance for 
HGSOC as currently there is no clear consensus on the cellular origin of HGSOC. This 
is largely due to the fact that both hypotheses, the OSE origin and FTEC origin, have 
been supported by animal models or clinico-pathological observations (23, 27, 28, 38, 
40, 257, 258). Consequently, both hypotheses may be correct thus leading to a 
proposed third dualistic precursor model (13). Of note, the gene expression profile of 
normal ovarian tissue was found to be similar to the mesenchymal HGSOC subtype 
(259). This supports our new proteomics-based classification, into predominantly 
mesenchymal (potentially OSE-derived) and epithelial (potentially FTEC-derived). 
Interestingly, the differential expression of EMT markers in the ‘good’ HGSOC cell lines 
has already been reported recently (81), however, it remained unclear what these 
observations actually reflected. Based on our findings, the expression differences of 
the EMT markers may potentially represent two different cellular origins of serous 
OvCa (OSE and FTEC). Consistent with my results, a recent miRNA study likewise 
identified two distinct HGSOC subtypes, an integrated epithelial subtype and an 
integrated mesenchymal subtype (220). The study further identified that a specific 
miRNA, miR-506, promoted CDH1 (E-cadherin) expression, prevented TGFβ-induced 
epithelial-mesenchymal transition and correlated with good clinical prognosis. Indeed, 
our data clearly showed higher expression of CDH1 in the likely FTEC-derived cell 
lines, suggesting that, at least to some extent, miRNA regulatory networks led to the 
differential protein expression in the two identified HGSOC subtypes. Moreover, we 
likewise observed that the epithelial HGSOC subtype correlated with better prognosis 
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as assessed by the comparison of our results to two additional proteomic and genomic 
datasets.  
In summary, manuscript 1 sheds new light onto HGSOC origin and provides a useful 
database for the selection of bona-fide HGSOC cell lines, as well as candidate marker 
proteins to stratify patients into a mesenchymal or epithelial subtype. This might be of 
prognostic relevance as the mesenchymal subtype is linked to unfavorable clinical 
outcome (16, 221). The manuscript was published in the August issue of Nature 
Communications with me as first author. 
 
Manuscript 2 illustrates the power of modern discovery-based proteomics to 
investigate proteins under various biological aspects. We initially employed a single-
run shotgun proteomics workflow to discover proteins associated with chemotherapy 
efficacy in late-stage HGSOC. In this retrospective study, our near-comprehensive 
proteomic dataset (a 9,000 quantified proteins) identified the cancer-testis antigen 45 
(CT45) as significantly up-regulated in the group of patients with favorable response 
to carboplatin/paclitaxel chemotherapy. Due to the strong correlation between CT45 
expression and disease-free survival (Pearson r = 0.75), this suggested an active role 
of CT45 in mediating chemotherapy sensitivity.  
 
CT45 belongs to the group of cancer-testis antigens that are considered as attractive 
cancer immunotherapy targets due to their tumor specificity and broad applicability 
(see section 1.4.4). We used an immunopeptidomics approach to identify CT45 
derived HLA class I specific peptides presented on the surface of CT45+ ovarian 
cancer cells. Our follow-up work showed that these antigens were indeed in vivo T-cell 
targets that promoted proliferation and activation of patient-derived CD8+ T-cells, and 
ultimately mediated cancer cell killing. However, we did not observe an overall 
correlation between the number of CD8+ T-cells and CT45 expression in our discovery 
cohort of 25 patients. Assuming an effective T-cell response against CT45+ tumors in 
vivo, this stands in contrast to the observed correlation between intratumoral T-cells 
and clinical outcome of advanced ovarian carcinoma after surgical debulking and 
chemotherapy (56). However, there are several possible explanations for this finding.  
Firstly, we did not identify CT45-derived HLA-I peptides of HLA alleles other than 
A*03:01, A*11:01 or A*68:01. For example, two HLA-A*02:01 CT45+ cell lines were 
also screened, which did not result in an identification of additional CT45-derived HLA-
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I peptides. The best in silico predicted A*02:01 specific peptides did not result in T-cell 
activation. Therefore, CT45+ tumors without the HLA-A*03:01, A*11:01 or A*68:01 
alleles may not induce a T-cell response against CT45, potentially due to the lack of 
presented peptides. One of the patients with the best clinical outcome in our cohort 
(DFS > 7 years, patient is alive) was positive for allele A*11:01, which was predicted 
to have the highest affinity to our identified CT45 peptides. Additionally, this patient 
had high CT45 protein expression in the tumor. It is tempting to speculate that the 
observed long-term protection from tumor recurrence was facilitated by a strong T-cell 
memory response in addition to the observed chemotherapy sensitivity, and that this 
is mediated by CT45.  
Secondly, in contrast to previous studies, we analyzed metastatic omental tumor 
tissues, which may be associated with a strong immunosuppressive environment 
inhibiting T-cell activation and expansion. In support of this, the number of 
immunosuppressive FOXP3+ intratumoral T-cells was recently found to be predictive 
of good neoadjuvant chemotherapy (NACT) outcome, whereas the number of CD8+ 
T-cells remained unchanged (59). This finding is of relevance for future studies 
addressing the link between CT45 expression, chemotherapy efficacy and the role of 
the immune system. 
 
An interaction proteomics approach helped to discover the function of CT45 by 
identifying the protein phosphatase 4 (PP4) complex as strongly interacting with CT45. 
PP4 is critical for the repair of DNA lesions after exogenous DNA damage (183, 185, 
187, 189, 260). Our subsequent work consequently focused on the role of PP4 and its 
related targets such as KAP1/TRIM28, in the context of DNA damage signaling. Briefly, 
we found that, similar to the PP4 members, CT45 was chromatin associated and 
perturbed PP4 mediated DNA signaling during heterochromatic DNA damage repair. 
CT45 expression inhibited PP4 mediated chromatin re-condensation via KAP1-S824 
de-phosphorylation after DNA damage repair. This may prolong the DNA damage 
signal and ultimately lead to apoptosis (Fig. 13). Interestingly, knockdown of 
heterochromatic proteins, for example KAP1, or induced chromatin de-condensation 
have been linked to DNA damage sensitivity (192, 261). Our model now suggests that 
the selective inhibition of KAP1 de-phosphorylation after DNA damage might be a 
promising therapeutic strategy to pursue in combination with conventional 
chemotherapy. In such a scenario, ATM induced global chromatin relaxation, which is 
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required for the repair of heterochromatic DNA damage foci (202), would be prolonged. 
This may further sensitize cancer cells to more DNA damage due to the vulnerability 
of open chromatin to form carboplatin-DNA crosslinks. Furthermore, CT45-derived 
peptides binding to and perturbing PP4/KAP1 signaling during the DNA damage 
response could be designed. An interaction screen could be used to map the exact 
PP4 interaction site of CT45. These peptides could be further selected for their ability 
to mediate chemotherapy sensitivity. This might be especially advantageous in the 
context of a CT45 negative tumor, ideally in combination with neoadjuvant 
chemotherapy.  
 
 
 
 
 
 
 
 
 
Based on our results and those of other studies, an attractive treatment strategy for 
HGSOC may be the combination of conventional chemotherapy, immune checkpoint 
blockage and personalized cancer immunotherapy (Fig. 14).  This concept can be 
illustrated based on the results of manuscript 2.  
Figure 13: Model of CT45 mediated chemotherapy sensitivity.  
a. Following DNA damage in heterochromatin (HCR), ATM induced chromatin 
relaxation occurs to facilitate DNA damage repair. PP4 restores heterochromatin to 
end the DDR. b. CT45 perturbs PP4 from restoring heterochromatin, leading to a 
maintained DNA damage signal and increased signal amplification in case DNA 
damaging drugs are still present. This may ultimately result in apoptosis and tumor 
shrinkage. 
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Before first-line chemotherapy, tumor tissue taken from the initial debulking surgery 
could be used to evaluate CT45 expression, expression of immune checkpoint 
molecules such as PD-L1 or CTLA-4, and the presence of intratumoral T-cells. In 
parallel, blood and ascitic fluid would be collected to isolate PBMCs and CD8+ T-cells, 
respectively. Following conventional chemotherapy, checkpoint immunotherapy may 
be used to eliminate the remaining tumor cells via T-cell mediated killing. The reported 
up-regulation of PD-L1 on T-cells through chemotherapy may provide a rational to start 
checkpoint blockage directly after chemotherapy (59). Chemotherapy induced 
apoptosis may further lead to T-cell activation through the presentation of tumor 
derived antigens on HLA-I complexes of antigen presenting cells (APCs). To account 
for immune cell depletion through chemotherapy, T-cells isolated form ascites may be 
expanded in vitro and infused back to the patient. Finally, CD8+ T-cells derived from 
PBMC differentiation could also be used to generate CAR T-cells (262) for adoptive T-
cell transfer targeting CT45-derived HLA-I peptides. The continuous administration 
and monitoring of CAR T-cells may promote long-term protection against any tumor 
recurrence. With respect to CT45 negative tumors, drugs like decitabine (5-aza-2'-
deoxycytidine) could be evaluated in combination with standard chemotherapy to 
activate CT45 antigen expression and presentation (152, 179). Interestingly, 
decitabine treatment was shown to result in up-regulation PD-L1 expression in cancer 
cells further indicating its combination with checkpoint blockage therapies (263). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 14: Beyond chemotherapy: advanced possibilities for ovarian cancer treatment 
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Despite the uncertainties with regards to HGSOC origin, there is little doubt about the 
fact that advanced-stage HGSOC almost inevitably includes metastasis to the 
omentum, an adipocyte-rich tissue located in the peritoneal cavity (42). Roughly 75% 
of HGSOC patients present at an advanced disease stage when the cancer has 
already spread from the primary fallopian tube or ovarian sites to the omentum. 
Consequently, research dedicated to understanding HGSOC progression and 
metastasis at the molecular level is of great clinical importance. The goal of 
manuscript 3 was therefore to analyze the complete proteomic progression of 
HGSOC in a discovery cohort of eleven patients with late-stage disease. I established 
a novel, sensitive workflow to analyze proteins derived from minute amounts of laser-
microdissected clinical biobank material (FFPE). We extended the scope of this study 
by separately analyzing changes in the tumor and its associated microenvironment. 
Such a study could not be conducted so far due to great challenges in sample 
collection, processing and proteomic analysis. Interestingly and surprisingly, we found 
that the tumor proteomes did not substantially change during progression to 
metastasis, indicating that the large genomic alterations frequently observed in 
HGSOC are already present at the pre-neoplastic level of STICs. In contrast to the 
tumor compartment, our data showed a distinct metastatic protein signature derived 
from the omental tumor microenvironment. Follow-up work by my collaborators 
confirmed the proteomic findings and discovered the functional importance of the 
proteins associated with omental metastasis. Out of these, we identified together 
Nicotinamide N-Methyltransferase (NNMT) as a major regulator of cancer-associated-
fibroblasts by metabolically reprogramming normal fibroblasts. This knowledge might 
be useful for the design of specific inhibitors against metastatic HGSOC. Furthermore, 
it sheds additional light on the tumor microenvironment as a promising target for 
HGSOC treatment. 
 
The proteomic findings described in manuscript 3 might further have general 
implications for the current understanding of HGSOC and its related subtypes. Based 
on whole-tissue gene-expression analysis, HGSOC can be grouped into four subtypes 
termed differentiated, immunoreactive, proliferative, and mesenchymal (220, 221). 
However, it is a well-known that these subtypes are primarily a reflection of discrete 
microenvironmental features present in the analyzed whole-tumor tissues. Due to the 
absence of spatio-temporally resolution of previous analyses, proteomic changes 
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during progression had not be addressed so far. Consequently, existing subtype 
assignment may be imprecise since it is based on assessment of single samples. Our 
data revealed a conserved stromal signature of HGSOC in the omentum, however, in 
addition we found that the signature was not unique to metastasis and but also 
presented in some HGSOC tissues isolated from the fallopian tube or ovary. A 
comparison to previous datasets showed that the identified stromal proteins clearly 
represented markers of the known mesenchymal HGSOC subtype, which is 
associated with poor survival. This strongly highlights the importance of compartment-
resolved protein analysis to obtain a more refined molecular profile. To put this in 
perspective, had the study be limited to solely omental tumors for subtype definition 
instead of ovarian tumors, one would have found predominantly one mesenchymal 
HGSOC subtype. Alternatively, the analysis of tumors from the FT or ovary of the same 
patient may have resulted in a different subtype assignment. This possibility is 
supported by the highly dynamic nature of the tumor microenvironment (264), e.g. by 
the continuously changing population of different cell types and restructuring of the 
extracellular matrix. In contrast to the stroma, our analysis clearly showed a remarkably 
stable tumor proteome throughout HGSOC progression. Interestingly, similar results 
were obtained for colorectal (124) and luminal breast cancer (125), pointing to a 
general proteomic feature across cancers. This knowledge may provide a rationale for 
the search for distinct HGSOC subtypes based on tumor cell derived protein signatures 
in addition to the known microenvironmental subtypes. Indeed, a recent large-scale 
characterization of 169 HGSOC cases stratified patients into different survival groups 
based on proteogenomic features, derived from DNA copy number alterations (5). Due 
to the known genomic stability of the tumor microenvironment, these features were in 
all likelihood tumor cell derived. Based on our results, tumor cell derived signatures 
might be more conserved across tumor sites than stroma derived signatures. This 
suggests alternative definitions of HGSOC subtypes. 
 
The fact that the identified stromal protein signature, linked to omental metastasis, was 
conserved across all analyzed patients highlights the unique metastatic niche of the 
omentum. Mesothelial cells for example, covering omental tissues as a single cell 
layer, have been implicated in OvCa metastasis because they secrete large amounts 
of fibronectin, which in turn promotes tumor cell adhesion, invasion and proliferation 
(49). Indeed, fibronectin (FN1) was among the proteins highly expressed in all stromal 
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samples of omental metastasis, indicating a strong contribution of mesothelial cells to 
the protein signature. In regard of the observed stromal signature in invasive tumors 
of the fallopian-tube and ovary, it is tempting to speculate that these may represent a 
transformation of the ovarian surface epithelium (OSE) - a mesothelium - which can 
ultimately give rise to a mesenchymal-type tumor resembling tumors of omental 
metastasis.  Consequently, the absence of the mesenchymal protein signature in FT 
or ovarian tumors may indicate an FT origin with primary metastasis from the FT to the 
ovary. This raises the question about the origin of tumors, which show a mesenchymal-
type FT tumor but no mesenchymal signature in the ovarian tumor site. Our data 
revealed that two of eleven patients may belong to this group (Fig. 15). One possibility 
is that some mesenchymal-like FT cancers are linked to a potential stromal origin as 
previously described in a mouse model (40). Alternatively, the original FT derived 
tumor spread to the ovary in these cases, involving an additional epithelial-to-
mesenchymal transition exclusively in the original FT tumor, but not in the ovarian site. 
These site-specific differences may be due to divergent clonal propagation of tumor 
cells as recently reported for HGSOC (265, 266). Our results in manuscript 1 indeed 
showed that a minority of the likely FT-derived cell lines such as KURAMOCHI and 
COV318 showed mesenchymal characteristics (COL3A1high, CDH1low), similar to the 
likely OSE-derived cell lines,  despite their clear proteomic assignment to the group of 
likely FT-derived, PAX8+ cell lines. Interestingly, both cell lines were originally derived 
from ascites which may explain their mesenchymal features due to EMT during 
omental metastasis (46). However, our patient derived proteomic data did not reveal 
significant changes in the tumor compartment during progression raising the question 
about whether an EMT program in the tumor cells indeed occurred. We instead found 
strong pro-metastatic changes in the tumor-associated stroma (e.g. high FN1, TNC, 
VCAN, NNMT, COL11A1 and THBS2). This is in support by a recent study in colorectal 
cancer, which linked the expression of a poor-prognosis, mesenchymal gene signature 
to cancer-associated fibroblasts, as opposed to tumor cells (55). Of note, these 
observations do not exclude that tumor cells undergo EMT. The fact that we did not 
find a clear EMT related proteomic signature in the tumor compartment throughout 
progression simply argues for an apparently small proportion of tumor cells undergoing 
EMT, for example at the invasion front.  
In conclusion, mesenchymal-type of cancers should not be inherently linked to tumor 
cell features, but instead considered to be strongly influenced by stromal contributions. 
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The distinct proteomic signature of mesenchymal-type HGSOC may help to better 
understand the origin for these cancers and to understand the important role of CAFs 
during disease progression.  
  
b 
 
Figure 15: A simplified model for HGSOC progression based on the stromal 
appearance of the mesenchymal protein signature.  
a. A conserved mesenchymal protein signature of HGSOC omental metastasis. 
Proteins are shown on the x-axis. Patients are plotted on the y-axis. Colors from 
blue to red indicate protein levels from low to high expression. Bar plots on the right 
show disease-free survival times. The two highlighted patients who showed early 
stromal changes in the FT and ovary had the worst clinical outcomes likely 
representing the known mesenchymal HGSOC subtype. b. Proposed model for the 
different scenarios in a. Fallopian-tube (FT) derived tumors (blue) or ovarian-derived 
(OV) tumors (red) both metastasize to the omentum. The appearance of the 
mesenchymal protein signature in FT or OV tumors may help to stratify tumors with 
different cellular origins. 
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3.2 The age of large-scale proteomics: implications for biomedicine 
 
The possibility to analyze the entirety of all expressed proteins in a given cellular 
context, the proteome, has been a source of fascination for a considerable time.  
Today, 28 years after the development of Matrix-assisted laser desorption / ionization 
(MALDI) (87, 88) and electrospray ionization (ESI) (89), the two techniques that are 
the cornerstones of modern MS-based proteomics, the field of proteomics has reached 
a remarkable level of maturation. It is now possible to routinely decode nearly complete 
cellular proteomes such as those from yeast (267) or to quantify 10,000 distinct protein 
phosphorylation events in a single 4h measurement without any upfront protein or 
peptide separation (104). For more complex proteomes such as those of mammalian 
cells, 10,000 proteins have already been reported (112, 268). Comparison to 
transcriptomic data revealed that roughly 10,000 – 12,000 different protein coding loci 
are likely expressed in an average mammalian cell line, demonstrating that state-of-
the-art proteomic technology can detect and quantify nearly complete mammalian 
proteomes (defined by at least one protein from every genomic locus (92). From a 
biomedical point-of-view, this strongly aids our current efforts at dealing with a variety 
of diseases by the identification of novel disease driver proteins or drug targets. For 
example, a single-run phospho-proteomics workflow recently allowed the 
quantification of 9,000 phosphorylation sites per sample in Parkinson’s disease cellular 
models. This led to the discovery of novel bona-fide substrates for LRKK2, a kinase 
which is frequently mutated in a subset of Parkinson patients. These findings may 
directly aid the clinical application of specific LRRK2 kinase inhibitors and they already 
shed new light on the biology of Parkinson’s disease. One of the largest challenges in 
the future will be to take full advantage of the spectacular journey MS-based 
proteomics has already made, specifically by demonstrating its uniqueness and 
versatility in important clinical settings. Additional technological advances such as 
improving mass spectrometric acquisition speed, dynamic range of detection, mass 
accuracy, sensitivity and mass resolution are already in development. The routine, fast, 
and accurate analysis of complete proteomes may be realistic in the near future. 
Specifically ion-mobility-separation (IMS) techniques show great promise due to the 
additional orthogonal nature of the separation based on the analyte size, shape, and 
charge (269). Fully integrated into the data dependent acquisition (DDA) workflow of 
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shotgun proteomics approaches, this combination might be especially advantageous 
for the rapid analysis of complete proteomes, e.g. in a discovery-based clinical context. 
It is already certain that MS-based proteomics will make a central contribution to all 
aspects of translational research and clinical practice.   
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Abbreviations 
 
 
APC:    Antigen presenting cell 
ATRA:   All-trans retinoic acid 
AUC:   Area under the curve  
CAF:    Cancer-associated fibroblast 
CCLE:   The Cancer Cell Line Encyclopedia 
CID:    Collision-induced dissociation 
CPTAC:  Clinical Proteomic Tumor Analysis Consortium 
CSF:    Cerebrospinal fluid 
CT45:    Cancer-testis antigen 45 
CTA:    Cancer-testis antigen 
CTA-X:   X chromosome coded class of cancer-testis antigens 
DDA:    Data dependent acquisition 
ESI:    Electrospray ionization 
FDA:   Federal drug administration 
FFPE:    Formalin-fixed and paraffin-embedded 
FTEC:   Fallopian-tube epithelial cells 
HCD:    Higher-energy collisional-dissociation 
HGSOC:   High-grade serous ovarian cancer 
HHMT:   Helene Harris Memorial Trust 
HLA:   Human leukocyte antigen 
HLAp:    HLA peptide 
IMS:    Ion-mobility separation 
IOSE:    Immortalized ovarian surface epithelial cells 
ITRAQ:   Isobaric Tag for Relative and Absolute Quantitation 
LCM:    Laser-capture microdissection 
LC:   Liquid chromatography 
LFQ:   Label-free quantification 
MALDI:   Matrix-assisted laser desorption / ionization 
MRN:    Multiple reaction monitoring 
mRNA:   Messenger RNA 
MS:    Mass spectrometry 
NACT:   Neoadjuvant chemotherapy 
NextGenSeq:  Next generation sequencing 
NNMT:   Nicotinamide N-Methyltransferase 
non-CTA-X:   Non-X chromosome coded class of cancer-testis antigens 
OvCa:    Ovarian cancer 
PP4:    Protein phosphatase 4 
ppb:    Parts-per-billion 
PSM:    Peptide spectral match 
PTM:   Post-translational modification 
SELDI:  Surface-enhanced laser desorption and ionization 
SILAC:   Stable isotope labeling with amino acids in cell culture 
STIC:    Serous tubal intraepithelial carcinoma 
TAA:    Tumor-associated antigen 
TCGA:   The Cancer Genome Atlas 
TIL:   Tumor-infiltrating lymphocyte 
TMA:    Tissue microarray 
TMT:    Tandem mass tag 
Treg:    Regulatory T-cell 
TSA:    Tumor-specific antigen 
XIC:   Extracted ion chromatogram (XIC) 
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